

THE NATIONAL INSTITUTE FOR OCCUPATIONAL
SAFETY AND HEALTH/NATIONAL PERSONAL PROTECTIVE
TECHNOLOGY LABORATORY (NIOSH/NPPTL) PUBLIC MEETING

Thursday, October 12, 2006

ONGOING STANDARDS AND RESEARCH DEVELOPMENT

Commencing at 8:32 a.m. at the Crowne
Plaza Pittsburgh South, Pittsburgh, Pennsylvania.

| | | |
|----|--|----|
| 1 | INDEX | |
| 2 | OPENING REMARKS | 3 |
| 3 | ADDRESS BY FRANK HEARL | 13 |
| 4 | FIVE-MINUTE PRESENTATIONS ON CURRENT NPPTL RESEARCH PROJECTS | |
| 5 | INTRODUCTION BY RON SHAFFER | 36 |
| 6 | END-OF-SERVICE-LIFE SENSORS AND MODELS | 46 |
| 7 | RESPIRATOR FILTER PERFORMANCE AGAINST | |
| 8 | BIOLOGICAL AEROSOLS | 54 |
| 9 | RESPIRATORY PROTECTION RESEARCH FOR | |
| 10 | INFECTION CONTROL | 57 |
| 11 | DEVELOPMENT OF COMPUTER-AIDED FACE-FIT | |
| 12 | EVALUATION METHODS | 65 |
| 13 | IMPROVED CRITERIA FOR EMERGENCY MEDICAL | |
| 14 | PROTECTIVE CLOTHING | 69 |
| 15 | DECONTAMINATION STRATEGIES AND REUSABILITY | |
| 16 | OF CHEMICAL PROTECTIVE CLOTHING | 74 |
| 17 | NANOTECHNOLOGY: PERFORMANCE OF PERSONAL | |
| 18 | PROTECTIVE EQUIPMENT | 76 |
| 19 | PHYSIOLOGICAL MODELS AND COUNTERMEASURES | 81 |
| 20 | NEXT GENERATION STRUCTURAL FIREFIGHTING | |
| 21 | PPE ENSEMBLE (PROJECT HEROES) | 85 |
| 22 | | |

| | | |
|----|--|-----|
| 1 | INDUSTRIAL PAPR - CBRN PAPR STEP 2 | 91 |
| 2 | POLICY AND STANDARDS DEVELOPMENT TOPICS | |
| 3 | MULTIFUNCTION POWERED AIR PURIFYING RESPIRATOR | 148 |
| 4 | CHEMICAL WARFARE AGENT SIMULANT PROJECT | 159 |
| 5 | IDENTIFYING ALTERNATE LIVE AGENT TESTING | |
| 6 | LABORATORIES | 168 |
| 7 | CBRN HAZARD ASSESSMENT OF FIRST RECEIVERS IN | |
| 8 | MEDICAL FACILITIES | 177 |
| 9 | CBRN RESPIRATOR STANDARDS DEVELOPMENT | |
| 10 | - CLOSED-CIRCUIT SCBA | 192 |
| 11 | - COMBINATION UNITS | 198 |
| 12 | - SUPPLIED AIR RESPIRATOR | 214 |
| 13 | TOTAL INWARD LEAKAGE PROGRAM | 221 |
| 14 | TIL CRITERIA DEVELOPMENT | 229 |
| 15 | QUALITY ASSURANCE MODULE | 254 |
| 16 | ADMINISTRATIVE MODULE | 261 |
| 17 | SCIENTIFIC EXCELLENCE FOCUS | 264 |
| 18 | | |
| 19 | | |
| 20 | | |
| 21 | | |
| 22 | | |

1 P R O C E E D I N G S

2 O P E N I N G R E M A R K S

3 MR. BOORD: Good morning. My name is Les
4 Boord, and I would like to welcome all of you to
5 this NIOSH/NPPTL public meeting.

6 It is certainly good to see all of you
7 here today, and I hope that over the course of
8 today's discussions and tomorrow's discussions that
9 you gain a good understanding for the types of
10 things and work that is performed at the NIOSH/NPPTL
11 laboratory.

12 Most of you, I would assume, already have
13 registered and have your information packet. And in
14 the information packet, you have a copy of the
15 agenda. And there are a few things I would like to
16 note on the agenda a little bit later.

17 That's my next slide.

18 Before we get to that, I would like to
19 point out that all of the presentations and posters
20 that are discussed and presented today are being
21 presented by staff, NIOSH staff. So it's people
22 from NPPTL and NIOSH.

1 So for these presentations, there are no
2 guest speakers or outside speakers, not that we
3 don't want any, but the content of the presentations
4 are strictly from NPPTL.

5 During the course of the presentations,
6 what we will do is have the presentations at the
7 conclusion of the discussion. Then we will have a
8 question and answer session.

9 And for the question part of the program,
10 we would appreciate it if the person who has a
11 question would go to the microphone in the center of
12 the room, announce your name, who you represent and
13 then the question.

14 That way, I think everybody can get a --
15 will be able to hear and understand what's being
16 asked and then certainly what the responses are.

17 I think at the manufacturers meeting we
18 had yesterday, there was a little bit of difficulty
19 with some of the questions because we didn't have
20 that microphone.

21 So it would be appreciated if you could do
22 that.

1 I would also point out that the meeting
2 today is being recorded and transcribed. So there
3 will be a recorded document for all the contents of
4 the meeting today, including the questions and any
5 discussions.

6 I will also point out that the meeting is
7 being videotaped. And the purpose for videotaping
8 the meeting is for NPPTL to look at the videotape as
9 one of our outreach mechanisms.

10 So we want to capture some of the segments
11 for the meeting and perhaps use it in future
12 outreach activities.

13 I just wanted to point that out. The
14 video recorder is in the back of the room.

15 Now to the agenda. Basically, the way the
16 agenda is laid out, we have several categories of
17 topics. The first session that we have this morning
18 will be a research oriented poster session.

19 So during that presentation, or that
20 series of presentations, the various researchers
21 will be presenting a short discussion about their
22 research activities and a poster that supports their

1 project.

2 And as you can see, the posters are
3 located around the room. So first session will be
4 the poster session.

5 Following that, we will have discussions
6 on our standards development activities.

7 That begins at the 10:30 session this
8 morning, and will actually extend throughout the
9 afternoon, I think concluding at 3:30.

10 So our policy and standards development
11 activities will be focused on, and there we will
12 have presentations on the various projects that are
13 occurring within our standards development.

14 To round out the day then, we will have a
15 discussion on our quality performance initiatives,
16 some of the things that the laboratory is doing to
17 instill quality into our programs and processes.

18 Looking into the content of today's
19 discussions, I think there are a few changes to the
20 agenda that you have that I would like to point out.

21 The first one is on the poster sessions.
22 The University of Maryland multifunction PAPER poster

1 will not be part of that presentation. The content
2 of that information and project will be addressed in
3 the policy and standards development discussions for
4 the PAPR -- discussions later in the day.

5 The second change is the 1:15 sessions,
6 policies and standards development sessions
7 addressing the CWA live agent testing, CBRN and CBRN
8 topics, that entire session will be switched for the
9 2:30 session, which is a policy and development
10 standards topic on our Total Inward Leakage program,
11 our quality assurance module and the administrative
12 module.

13 And both of those have an allotment of
14 about one hour for the presentation, so I think it's
15 an even switch. And the reason for making that
16 switch is we have a guest participant who has a --
17 is interested in the TIL program and the QA program
18 and would like to see those, but he also has an
19 early flight, so we are going to make that slight
20 modification.

21 Then finishing out today, as I said, would
22 be the quality performance discussions.

1 Tomorrow, we will resume the meeting with
2 the discussions on research projects, and these
3 research discussions will be presentations,
4 presentations followed by the questions and
5 discussions that -- parts of these presentations as
6 well.

7 And then, we will also have a quality of
8 science discussion at the end of the day tomorrow.

9 The meeting should wrap up on schedule, so
10 I would anticipate that tomorrow early afternoon we
11 should be wrapping up the meeting.

12 And, again, the objective of the meeting
13 today for NIOSH/NPPTL is to provide program
14 information to our customers and stakeholders.

15 We thought that this would be a good
16 opportunity for us to share with you the types of
17 things that we are doing, the projects that we are
18 working on, and to create dialogue and hear
19 different discussions and different points of view
20 relative to those programs and projects.

21 And before we get into the technical
22 discussion today, I would like to give you a brief

1 overview of NIOSH and NPPTL. I would like to give
2 you a little information relative to the operational
3 strategies that we have at the laboratory and then a
4 brief discussion relative to the organizational
5 structure, and more importantly, to set the stage
6 for the different topics and activities within the
7 laboratory and how they are -- which branches they
8 occur in to give you a better understanding for the
9 laboratory in general.

10 And I think most of you in the room are
11 probably familiar the current paradigm for
12 Occupational Safety and Health in the United States.
13 And probably many of you have been working with it
14 since the beginning.

15 But the current paradigm that we have was
16 established with the Occupational Safety and Health
17 Act of 1970. And that act was to assure safe and
18 healthful working conditions for working men and
19 women in the United States.

20 As part of that act, the Occupational
21 Safety and Health agenda was really set up to be
22 addressed with two arms within the federal

1 government.

2 And the first of those was the regulation
3 and enforcement arm, which is the Department of
4 Labor. And then within the Department of Labor, we
5 have the Mine Safety and Health Administration,
6 MSHA, and we have the Occupational Safety and Health
7 Administration, OSHA.

8 And I think we have participants in the
9 audience today, certainly from the OSHA side of that
10 regulation and enforcement activity.

11 The parallel arm addressing occupational
12 safety and health issues is the Research, Training,
13 Prevention, and Recommendations arm. And that is
14 located in the Department of Health and Human
15 Services within the Center for Disease Control and
16 operated by the National Institute for Occupational
17 Safety and Health, NIOSH.

18 So when you look at NIOSH and the
19 laboratory, our agency structure, as I have
20 illustrated here, we are part of the Health and
21 Human Services agency within the Center for Disease
22 Control, National Institute for Occupational Safety

1 and Health. And we have the various divisions and
2 laboratories that comprise the Institute.

3 And those divisions and laboratories are
4 many, as you can see on this illustration. I
5 believe there are 16 different laboratories and
6 offices that comprise the Institute.

7 Some of them I'm sure you are familiar
8 with. The Division of Respiratory Disease Studies,
9 DRDS; Division of Safety Research, DSR; Health
10 Effects Laboratory are located in Morgantown, West
11 Virginia.

12 We have the Education and Information
13 Division, EID; the Division of Applied Research,
14 DART; Division of Surveillance Hazard Evaluation and
15 Field Studies, DSHEFS; Office of Compensation
16 Analysis and Support; Research to Practice --
17 Research to Practice, r2p. That's a theme that you
18 will hear more and more throughout the day.

19 And those offices and laboratories for the
20 Institute are located in Cincinnati.

21 Then we have the Spokane Research
22 Laboratory on the right side of the column. We have

1 the Pittsburgh Research Laboratory with whom we
2 share the campus in Bruceton, and we have the Office
3 of Extramural Programs, which is located in Atlanta.

4 And then, of course, we have the Office of
5 the Director for the Institute, which is located in
6 Washington DC.

7 And at the meeting this morning, we are
8 honored to have a representative, Mr. Frank Hearl,
9 who is the Chief of Staff for the NIOSH Office of
10 the Director. And I need to say that we are really
11 pleased to have Frank at the meeting today.

12 So while he is the esteemed Chief of Staff
13 for the Institute, Frank is really, I think for the
14 laboratory, represents a little bit more. He helps
15 us on many occasions to navigate through the systems
16 and the processes that we need to deal with in order
17 to accomplish the many things that we like to do.

18 So Frank is certainly a welcome guest for
19 the public meeting today, and with that I would like
20 to introduce Frank.

21 ADDRESS BY FRANK HEARL

22 MR. HEARL: Thank you, Les. You made me

1 sound a little bit like an expert, but I did stay at
2 a Holiday Inn Express, so I guess that works.

3 I would like to bring you all greetings
4 from our institute director, Dr. John Howard, who
5 I'm sure would love to be here today but has some
6 conflicting appointments.

7 And I want to give thanks to Les and the
8 leadership team at NPPTL for putting together this
9 stakeholder meeting and also to the speakers and
10 poster presenters who you will be hearing from soon
11 today who will be telling you a little bit about the
12 research going on at the laboratory here and also
13 the activities going on in the certification
14 programs.

15 And also I would like to thank all
16 those -- everyone else who helped organize the
17 meeting here today.

18 I would like to kind of touch on three
19 things in the few minutes that Les has given me to
20 chat about NIOSH in general and to talk a little bit
21 about one, NPPTL's important role it plays within
22 NIOSH.

1 Second, I want to give you a little bit of
2 insight into what NIOSH is doing to help improve our
3 quality and relevance of our programs overall and
4 our emphasis to improve and increase the impact that
5 we actually have in the workplace.

6 First, talk about NPPTL. NPPTL is -- and
7 its forerunner components -- have been critically
8 important to NIOSH and to the American workers.

9 For over 35 years, they have helped to
10 assure that U.S. workers receive quality, reliable
11 protection from exposure to industrial toxic gases,
12 vapors, and dust.

13 And recently, of course, the programs have
14 expanded to include some new agents that we have had
15 to deal with, the chemical warfare agents, through
16 our CBRN program. And this is all very important to
17 first responders and those involved in homeland
18 security.

19 We have also been expanding our research
20 here at the lab at NPPTL for dealing with emerging
21 hazards that we are facing in these current days,
22 things such as dealing with the unknowns of dealing

1 with things like nanomaterials and also the
2 particular problem with dealing with infectious
3 agents that we face from either natural or not so
4 natural sources.

5 So NPPTL plays a critical and vital role
6 within NIOSH, and it really does cut across all
7 sectors of research that NIOSH has in its program
8 portfolio, and so we really very much value the work
9 done here.

10 In terms of overall NIOSH directions, one
11 of the things that Dr. Howard, through his
12 leadership, has done is to help us to direct our
13 programs to try to improve our quality and relevance
14 of our programs.

15 And what we recognize is that it's through
16 outside independent external peer review that we
17 really get the kind of feedback that we need to be
18 able to better focus our programs, to redirect
19 things and to give us some guidance for the future.

20 And in order to do that, what we have done
21 is we have entered into a five-year agreement with
22 the National Academies, through the National Academy

1 of Sciences and Institute of Occupational Medicine
2 to review all of the various NIOSH program
3 activities.

4 And we are doing this in basically
5 reviewing 15 different program areas over five years
6 through this agreement with the Academies.

7 The Academies have set up a framework
8 committee that has established rules and procedures
9 and are setting up independent committees that will
10 look at each of the program areas, committees that
11 have the particular expertise to be able to evaluate
12 our programs for impact, relevance, quality, and
13 future directions.

14 Now, you out there as stakeholders of
15 NIOSH and NPPTL is one of the program areas -- or
16 personal protective technology, which is
17 predominately located here at NPPTL, is one of the
18 areas that will be undergoing review by the National
19 Academies.

20 And you may well be contacted by some
21 staffers from the Academy or maybe even asked to
22 come and present to them and let them know how the

1 programs from NIOSH have impacted you and the
2 effects you have had and asking your opinions. So
3 you may all be actually involved in this process.

4 The other thing that we have done is we
5 have established an Office of Technology Transfer in
6 Cincinnati and staffed it up over the last year to
7 implement our research to practice, r2p, initiative.

8 One of things we recognize that NIOSH
9 research -- if we just put it out as a journal
10 article or as a NIOSH numbered publication, well,
11 that's not a good enough end point.

12 What we really need to do is develop
13 partnerships, formal and informal, to help diffuse
14 the information that we have learned from our
15 research, to make it effective and actually put to
16 use in the workplace for the protection of U.S.
17 workers.

18 And as part of this, we also recognize the
19 need to involve our stakeholders on an up-front
20 basis, that is, as we get into the program planning.

21 As each project is developed, we need to
22 get input from you. And that's where meetings like

1 this really come in handy, to be able to get
2 feedback to make sure that the things we are
3 researching are going to be things that you will be
4 able to put to use to help protect U.S. workers.

5 You can see this, and we have done this in
6 a couple of ways. One, you know, this is the
7 beginning of our second year of the National
8 Occupational Research Agenda, NORA.

9 We completed the first ten years of the
10 program, and the new ten years of the program just
11 launched this year.

12 We held stakeholder meetings in 12
13 different cities in the last nine months or so, and
14 we have taken input from over 1,500 people at those
15 meetings, as well as we have created a website so
16 that we can collect feedback through the web on all
17 of the NIOSH program areas.

18 So we are looking for input, and we're
19 listening.

20 So stakeholder meetings like this focused
21 on a particular topic are also very useful to us.

22 And I want to conclude by thanking all of

1 you for taking your time to come to this meeting to
2 learn about what is going on at the NPPTL and to
3 maybe look for opportunities for partnership, to
4 look for things that you can offer to us as helpful
5 guidance and suggestions as you, stakeholders, give
6 us feedback and input.

7 We very much want to hear from you, and we
8 value your input a great deal. So it is very
9 important that you come forward and speak, or give
10 us the feedback at a later time through the email or
11 through our website.

12 So thanks again, and I hope you have an
13 enjoyable two-day meeting here and that you find it
14 both interesting and productive.

15 Les.

16 CONTINUATION OF OPENING REMARKS

17 MR. BOORD: Thank you, Frank.

18 Just to touch bases a little bit on some
19 of the things that Frank had mentioned in his words
20 to you is relative to the NIOSH research program
21 portfolio.

22 As Frank had mentioned, this year launched

1 the new leg of the NORA program, and that program is
2 being designed around industry sectors and is really
3 the leading edge of the entire NIOSH research
4 portfolio.

5 So, as you can see in this illustration,
6 we have the eight different industry sectors,
7 agriculture, construction, healthcare, mining,
8 manufacturing, services, transportation, and
9 wholesale trade as the primary industry sectors
10 geared for the NORA NIOSH research program
11 portfolio.

12 In the second column on the slide, you see
13 additional cross-sector programs. And these
14 cross-sector programs are the types of initiatives
15 and programs that the Institute has that really cut
16 through the various industry sectors indicated on
17 the left-hand column.

18 And it is interesting to note that about
19 three-quarters of the way down the cross-sector
20 programs, you see the personal protective technology
21 cross-sector.

22 That cross-sector for the Institute is

1 being managed from the laboratory in Pittsburgh.
2 And at tomorrow's discussions, the first discussion
3 in the morning, we will tell you more about the work
4 that's being done to develop that PPT cross-sector
5 research program and portfolio.

6 Then in the far right column, we have the
7 major emphasis areas for the Institute. The
8 economic exposure assessment, engineering controls,
9 and so on.

10 So with these three areas of focus, we
11 have the entry sectors, the cross-sectors, and the
12 emphasis areas. Those will be the road map from
13 which the NIOSH research agenda is designed and
14 implemented as we go forward.

15 And with that, what I would like to do now
16 is talk a little bit more about some of the aspects
17 for the laboratory, and the laboratory being NPPTL,
18 which is located at the Bruceton research center.

19 Approximately 18 months ago in the
20 laboratory, we introduced a program that we refer to
21 as our APEX program, which is Achieving Performance
22 Excellence.

1 And that initiative is basically what it
2 implies. It is our program and our process to
3 instill continuous improvement into the processes
4 and operational aspects for the laboratory.

5 Our APEX program is patterned after the
6 Malcolm Baldrige (phonetic) criteria comprising
7 seven different categories. And those categories
8 are leadership, strategic planning, customer market
9 focus, measurement analysis, knowledge management,
10 human resource focus, process management, and
11 business results.

12 Within the laboratory, we have identified
13 seven category teams with a leader for each of those
14 teams to direct the activities and lead the
15 activities in those specific areas.

16 One of the true benefits of this program
17 is that it enables the laboratory to provide a
18 focused strategic direction for the priorities for
19 the laboratory.

20 And in that aspect, we have identified
21 seven priorities for the laboratory. These are
22 standards focus, personal protective technology

1 evaluations, science center of excellence, outreach,
2 partnerships, human resource excellence, and
3 achieving performance excellence in our APEX
4 program.

5 A little bit of the detail behind each of
6 these for the standards focus, the priority is to
7 increase our focus and enhance the Laboratory's
8 leadership role in the development of standards
9 pertinent to work-related personal protective
10 equipment.

11 Personal protective technology
12 evaluations. Improve our technology evaluation and
13 respirator certification processes.

14 Science Center of Excellence. Improve the
15 quality, consistency, and dependability of the
16 science delivered to our customers and stakeholders
17 through a program of rigorous evaluation.

18 Outreach. Improve our communications with
19 stakeholders and customers.

20 Partnerships. Increase quality and
21 improve the effectiveness of partnerships with
22 organizations in NIOSH-defined sectors, industry,

1 government, and academia.

2 Human resource excellence. Improve the
3 management of our human resources.

4 And then, finally, achieving performance
5 excellence to demonstrate performance excellence in
6 all we do.

7 So I think within the content of those
8 seven priorities, I think you are going to hear and
9 see many themes that are going to be recurring over
10 the next couple of days of presentations and
11 activities within the laboratory.

12 Outreach. The meeting today is part of
13 our outreach initiative. So it's very important to
14 us that we stay focused on these seven priorities as
15 we go forward to carry out our programs and
16 projects.

17 What we have done within the laboratory is
18 identify a value creation system. And this is a
19 little bit of a complex illustration, but there are
20 several key things I would like to point out.

21 As Frank mentioned, the outputs of any
22 research program or activity are certainly

1 important, but that's not the end of the story. We
2 need to have relevance and quality with those
3 outputs.

4 So as we progress from the outputs
5 delivered by the laboratory, we get into the world
6 of intermediate outcomes, and the ultimate public
7 benefit of those outcomes is to people who use
8 personal protective equipment.

9 So we have this process of outputs and
10 intermediate outcomes to achieve the public benefit.

11 In achieving that and in accomplishing
12 that, we have many partners that we need to work
13 with, our technology developers, the users, all the
14 stakeholders in this room, regulators, our
15 Congressional representatives, administrations, and
16 state organizations.

17 And all of those stakeholders and other
18 partnerships are helpful to us in achieving the
19 outcomes and benefits that we ultimately want to
20 achieve.

21 But they are also important aspects to
22 provide input to this little -- this item here,

1 which is basically our surveillance and
2 environmental assessment.

3 So while we are producing outputs, we are
4 making them available to our stakeholders and
5 customers and users, and we also have our receptors
6 open because we want to have dialogue with the users
7 and the stakeholders to learn more about the outputs
8 that we have delivered and feed those into our
9 assessment and surveillance activities.

10 It is also interesting to note that the
11 intermediate outcomes aspect of our value creation
12 system is also a key component because we recognize
13 that a standard, a personal protective technology
14 standard is recognized as an intermediate outcome.

15 So by identifying a standards focus for
16 the laboratory, we are jump starting any of the
17 programs that we undertake in the laboratory with a
18 targeted intermediate outcome.

19 So at the inception of our programs, we
20 like to have that intermediate outcome identified.

21 And I think as we go through the
22 discussions in the poster sessions today and

1 tomorrow, you will see more and more of that
2 connection towards standards.

3 The other thing that I would like to point
4 out is the flow of this value creation system is
5 pretty obvious if you follow the arrows.

6 The real challenge is then taking this
7 information and factoring it and processing it
8 through the inputs into new programs that the
9 laboratory undertakes.

10 And for that, we have identified a
11 strategic planning process. I think it is time that
12 we talk about this process today because, as most of
13 you know, the federal government operates on a
14 fiscal calendar that ends September 30, begins
15 October 1.

16 So today, being October, we are in the
17 first month of the fiscal calendar year for 2007.

18 The process that we have identified here
19 actually takes that surveillance and environmental
20 assessment activity and addresses that in the early
21 stages of this strategic planning process.

22 So, as you see on the flowchart here, we

1 have the environmental assessment occurring in the
2 first fiscal quarter of the year.

3 So what we are in the process of doing
4 with this, as one of our research activities and
5 other activities identified here, is we are starting
6 to build the input data that we will take into a
7 summit meeting in the laboratory, occurring the
8 beginning of next year, which will then be used to
9 identify new programs, continuing programs,
10 allocations of resources, and to eventually hone
11 that down to an operating strategy for the next
12 fiscal year.

13 So the process that we follow and will
14 follow as we continue to develop the laboratory is
15 as illustrated here.

16 So within the laboratory, how are we
17 organized and structured?

18 Basically we have Office of the Director
19 and three operating branches for the laboratory and
20 various support activities for the branches that are
21 housed in the Office of the Director.

22 We have a program manager component that

1 is -- crosses the boundaries of the individual
2 branches, and we have several program manager
3 positions that are aligned with the technologies of
4 the laboratory, but also aligned with the industry
5 sectors of the NIOSH NORA program.

6 We have technical support aspects,
7 including our IT functions, our statistical analysis
8 that are housed in the OD, but then provide support
9 services to the various branches.

10 We have the Associate Director for
11 Science, which is the driver for the quality
12 initiatives for the laboratory.

13 The peer review and the review aspects
14 that Frank mentioned, and the importance of those
15 review processes for building quality into our
16 program and building in the relevance are led
17 through the Associate Director for Science.

18 Then we have the three operating branches
19 for the laboratory, Technology Evaluation Branch,
20 which is the home for respirator certification.

21 We have the Policy and Standards
22 Development Branch, which is obviously the area

1 where we focus our standards development activities.

2 And then the third branch is our
3 Technology Research Branch.

4 Over the course of today and tomorrow, you
5 will hear about many of the programs, particularly
6 in the Policy and Standards Branch and the
7 Technology Research Branch.

8 The topics of respirator certification are
9 fed by these other branches and were topics
10 discussed at a manufacturers meeting yesterday.

11 I would like to talk a little bit about
12 some of these major areas of operation for the
13 laboratory.

14 The first is our quality performance
15 initiatives. And, as I mentioned, this is led by
16 the Associate Director for Science, Maryann
17 D'Alessandro.

18 And during the course of the discussions
19 at the end of today and tomorrow morning, we will
20 hear more about some of our quality performance
21 programs, our National Academy of Science
22 involvement, which really ties into the programs

1 that Frank mentioned, but also expands that
2 initiative very specifically for programs at the
3 laboratory.

4 Our customer surveys. It is a very
5 important part of our quality process to hear from
6 our customers and know how what we are doing is
7 being received and perceived.

8 And then the various committees and
9 conferences that the laboratory participates in.

10 So as we go through the discussions today
11 and tomorrow, we will learn more about that.

12 For the technology research, the branch
13 chief for that is Ron Shaffer, who will be actually
14 leading the discussions for the poster session and
15 the research activities for the laboratory.

16 And the focus, the technological focus for
17 our research activities is embodied in four
18 different PPT areas. The first is sensor
19 technologies, respiratory protection, ensembles, and
20 then human performance.

21 And as we talk about our research
22 programs, we will learn more about our activities in

1 each of those areas.

2 The Technology Evaluation Branch is led by
3 Heinz Ahlers, the branch chief for that activity.

4 As I mentioned, this is the home for
5 respirator certification and the audit. They are
6 postcertification activities that take place.

7 Many of you are already familiar with our
8 respirator certification program. Since the
9 inception of the NIOSH respirator certification
10 program, which goes back to the Occupational Safety
11 and Health Act of 1970, there have been more than
12 8,500, probably closer to 9,000 approvals,
13 respirator approvals that have been issued.

14 Those approvals had been issued to
15 approximately 90 different manufacturers with more
16 than 100 manufacturing sites located around the
17 world.

18 So the respirator certification program
19 has really been the cornerstone for the laboratory
20 when NPPTL was established.

21 Some of the audit or postcertification
22 programs that we conduct on a routine basis in the

1 branch is our certified product audits whereby we
2 obtain and test and audit product, off-the-shelf
3 commercial product.

4 We have a component for manufacturing site
5 audits to audit the program quality for the various
6 respirator manufacturers.

7 We have a certified product investigation
8 program which conducts investigations into reported
9 issues and occurrences with the use of a certified
10 product.

11 We have our Firefighter Self-contained
12 Breathing Apparatus Evaluation Program, which looks
13 at evaluations of SCBA used within the fire service
14 industry.

15 Then we finally have our long-term field
16 evaluation program which primarily addresses
17 self-contained self-rescuers, and this program goes
18 back to the early days of the establishment with the
19 U.S. Bureau of Mines.

20 Within our Policy and Standards
21 Development Branch, Bill Hoffman is the branch
22 chief. And many of the topics and projects that are

1 housed within that branch are CBRN respirator
2 standards, our powered air purifying respirators,
3 closed-circuit escape respirators, quality assurance
4 provisions, and Total Inward Leakage. And most of
5 those you will hear presentations on during the next
6 two days.

7 So finally, the mission for the laboratory
8 is to prevent work-related illness and injury by
9 ensuring the development, certification, deployment,
10 and use of personal protective equipment and fully
11 integrated, intelligent ensembles. And the
12 corollary to that mission is that we intend to
13 accomplish this through the advancement and
14 application of personal protective standards.

15 So that's a brief overview of the
16 laboratory.

17 And since I am running over time, I will
18 expeditiously try to get to the next part of our
19 program.

20 And for that, I would like to introduce
21 Dr. Ron Shaffer, who is the branch chief for our
22 research branch. And Ron will direct and moderate

1 through the next part of the program, which is a
2 poster session.

3 And he will key you in to the process of
4 how we are going to conduct that part of the
5 program.

6 Thank you.

7 FIVE-MINUTE PRESENTATIONS ON CURRENT NPPTL RESEARCH
8 PROJECTS

9 INTRODUCTION BY RON SHAFFER

10 MR. SHAFFER: Thank you, Les.

11 Some of you that were here yesterday,
12 there was a talk by Maryann D'Alessandro about the
13 Customer and Market Focus Team and a survey that
14 they did last year in conjunction with the Office of
15 Personnel Management, where they contacted
16 stakeholders, end users, and asked about -- various
17 questions about NPPTL and its performance.

18 I think Maryann will have a talk about
19 that actually at the end of the day today.

20 One of the questions on that survey was
21 people were asked about their awareness of NPPTL
22 research programs.

1 And it was surprising to me, we didn't get
2 the kind of response that we thought we might get.
3 Only 38 percent of manufacturers gave us a favorable
4 response, and 56 percent of end users gave us a
5 favorable response.

6 So as part of our outreach efforts to sort
7 of improve the awareness of what we are doing in our
8 research -- in terms of our research projects,
9 trying to increase the transparency of the projects
10 that we are doing, how we select the projects, and
11 how we execute them and how we can get you involved,
12 we are increasing our awareness in these areas.

13 And so, as part of that outreach effort,
14 we are focusing on the research projects today.
15 This is -- having this poster session this morning
16 is just one step in that process. We are trying to
17 improve our performance in that area.

18 So before I go into detail about the
19 poster session itself, I wanted to give you a broad,
20 you know, review from 10,000 feet of what we do in
21 the research branch, and that will help set the
22 stage for the research posters that we are going to

1 talk about next.

2 And I'll actually expand on this. I have
3 another presentation tomorrow morning where I will
4 expand on what we are doing in the branch a little
5 bit more, so this is just a one-slide snapshot.

6 The branch, as the name implies, Research
7 Branch, we are out on the leading edge of
8 technology, so we are the ones that are assessing
9 new technology and how it can affect personal
10 protective equipment. We are developing new test
11 methods where appropriate, and also helping to set
12 performance criteria and assess new and emerging
13 hazards.

14 And all of this is done within the context
15 of supporting various standards, whether that be 42
16 CFR or an ASTM, and NFPA and ISO standard. And you
17 will hear that through the various talks today, that
18 every one of our projects, at least in one way or
19 another, is involved or is -- the goal is to impact
20 a standard or a guidance that NIOSH or CDC would put
21 out.

22 The four research areas that the lab

1 focuses on are shown on this slide. Obviously
2 respiratory protection is the bread and butter of
3 the laboratory.

4 We also have a program in sensors and
5 electronics. Primarily that's how they integrate
6 with personal protective equipment and personal
7 protective technologies.

8 To date, our sensor effort has really
9 focused on end-of-service-life indicators.

10 The other areas are protective clothing
11 and ensembles and human performance.

12 We strive to keep a diverse mix of
13 projects in the branch. And so if you look at it
14 from a budgetary standpoint, about 50 percent of our
15 funds go in the area of respiratory protection, and
16 50 percent in clothing and ensembles.

17 And the way we do that is essentially
18 since the sensor projects right now support
19 primarily respiratory protection and our human
20 performance, which is sort of measuring or assessing
21 the burden imposed upon the wearer of personal
22 protective clothing, all of those today are focused

1 primarily on clothing and ensembles.

2 So we try to maintain a 50/50 split of our
3 research funds and our portfolio projects.

4 So within our portfolio, at any given
5 time, we will range between 10 to 15 projects in the
6 branch.

7 And, of course, those will be at various
8 stages. Some of will be at the end of their
9 lifetime where we are getting a significant number
10 of outputs and impacting outcomes to new projects
11 that are just in the sort of the brainstorming mode
12 and getting input from stakeholders.

13 And so you will see today, we have got
14 projects that are just starting this fiscal year as
15 the ones that just finished in the last fiscal year.

16 And today -- within the research branch, I
17 should say, we have 10 to 15 projects. That's only
18 within this branch.

19 Obviously the policy and standards groups,
20 on occasion where there's a specific need, they may
21 delve into something may look a lot like research
22 where it impacts a specific standard they are

1 working on, maybe because they have the right set of
2 skills to do that project or there is some other
3 reasons for doing it.

4 So today we are mostly focusing on just
5 the -- at least this morning, just the projects in
6 the research branch.

7 For a staff, we have about 20 people in
8 the branch, and that includes the federal employees,
9 senior research fellows that we get from the
10 National Academy of Sciences, as well as contract
11 staff in the laboratory.

12 With the summer students, you know, that
13 may range up to 25 or so in the summer.

14 Our budget typically is in 2 to 4 million
15 dollar range. Occasionally we will get some
16 supplemental funds CDC or other organizations to
17 conduct specific projects.

18 And in terms of the way we conduct our
19 work, it's a mix of in-house work. We have research
20 capabilities. We have got a brand new aerosol
21 research lab that just came aboard last summer, and
22 as well as sensor labs, physiology labs.

1 So we do the bulk of the work now
2 in-house, but on occasion we go extramural and fund
3 a contract with a university or an organization,
4 another research organization as needed.

5 So that's a little bit about the lab -- or
6 the branch itself.

7 I want to get into the poster session.
8 Actually, we have 11 posters, not 10, and that
9 actually covers about 12 projects. So for
10 simplicity, we have actually -- where it makes
11 sense, two projects may be on a single poster where
12 they are closely aligned or related.

13 And one project actually has two posters
14 because it has such interesting -- some new
15 interesting results that we wanted to update. It
16 didn't all fit conveniently on one poster board. So
17 that's on two projects -- or two posters.

18 So these are a mix of ongoing projects:
19 One new-start project for FY '07 as well as -- that
20 had some significant interest, and we wanted to make
21 sure it was presented today; and also one recently
22 completed project is on the -- in the agenda here

1 this morning.

2 So the plan is to basically have each --
3 one of the authors, usually the primary or the lead
4 author, is going to come up to the podium here, give
5 a five-minute or less overview of their project,
6 tell you where it is in the room. And they will
7 give you a little bit of information about the
8 purpose of the project and maybe some impact that
9 they have had.

10 We are going to hold -- I'm going to ask
11 that all questions be held until the end so that
12 they can actually be part of the poster session.

13 Because after everybody has a chance to
14 give you an introduction to their project and excite
15 you about what they are doing, draw you back to
16 their poster; the plan is for you to go there,
17 mingle a little bit, and ask your questions one on
18 one with them right at the poster where they may
19 have some data that they can show you or additional
20 discussion can follow up.

21 The posters will be on display until noon
22 tomorrow, but the primary discussion points will be

1 during the breaks and maybe a little bit during
2 lunchtime when people can get back from lunch and so
3 on.

4 So, again, the poster session will go this
5 morning until 10:30 or so when I think that the
6 policy and standards discussion kicks off.

7 And I should mention that four of the
8 projects will be discussed in more detail tomorrow,
9 and I will mention those as we go through the poster
10 session this morning.

11 And what I will be doing is I will be
12 introducing each speaker. And as I am introducing
13 them, they will come up to the front.

14 And I thought it was important that I give
15 each person a nice bio because I think it would help
16 as part of the exchanges, you have some discussions
17 with people if you understood maybe their background
18 and the types of projects they work on, what other
19 standards committees they may support. So you will
20 hear a little bit of a background for each person
21 and sort of a -- to get to know us a little better
22 on the research side.

1 Certainly the policy and standards guys,
2 the certification branch have conducted, you know,
3 numerous public meetings, and you may know them a
4 lot better than you know the researchers. So this
5 is sort of out there to get the awareness of what we
6 are doing improved a little bit.

7 So with that, I will turn it over to the
8 first poster that we are going to discuss this
9 morning. And that is going -- the first speaker
10 will be Jay Snyder.

11 Jay is an engineer at NPPTL. He has been
12 here for five years now. He has been the primary
13 person that's developed our sensor research program
14 to where it is today.

15 Previously, Jay worked for MSHA for 30
16 years. He has a bachelor's degree in chemical
17 engineering from WVU, a master's degree in
18 occupational health from Pitt.

19 Obviously Jay is going to be very busy
20 today. He has got three posters and a talk
21 tomorrow. Very -- his projects have been very
22 productive in getting a lot of information out, so

1 he has got a lot of things to mention to you today.

2 So with that, I will turn it over to Jay.

3 END-OF-SERVICE-LIFE SENSORS AND MODELS (POSTER)

4 MR. SNYDER: Well, I'm Jay Snyder, and I
5 approved the content of that message.

6 Good morning, everyone.

7 I want to talk to you about NPPTL's
8 end-of-service-life program today, and I have got
9 three posters that cover that topic.

10 Early in NPPTL's history, a survey was
11 commissioned, one in which the Bureau of Labor
12 Statistics contacted users of personal protective
13 equipment in the industrial sector and asked a
14 variety of questions about how they use them.

15 And one of the interesting facts that came
16 out of that survey was the fact that approximately
17 20 percent of the respondents said they left it up
18 to the discretion of the employee as to when to
19 change their respirator cartridge.

20 More recently, one of the organizations
21 that we partnered with, the Organizational Resource
22 Counselors, which represents a large segment of the

1 manufacturing companies in the U.S., posted some
2 questions on their website.

3 And one of them which they asked their
4 members to respond to was what improvements would
5 you like to see in personal protective equipment.
6 And you might guess that the answer would be reduced
7 cost, more comfortable equipment, et cetera.

8 But, in fact, the by far largest response
9 was end-of-service-life be associated with personal
10 protective equipment.

11 So a couple of reasons why we have a
12 personal protective program at NPPTL. We do think
13 it's an important issue based on what our customers
14 think.

15 It's been a two-pronged approach, a
16 short-term and a long-term approach. The longer
17 term approach, which we think is the ultimate
18 solution, would be a sensor, an electronic sensor
19 system be associated with personal protective
20 equipment.

21 And our very first effort in this area
22 would be to place sensors in respirators to provide

1 end-of-service-life information to the user.

2 Our initial effort involved getting
3 involved with a manufacturer of sensors, Cyrano
4 Sciences in Pasadena, California, which has now
5 become part of Smiths Detection, a major DOD sensor
6 contractor.

7 We tried to modify one of their
8 off-the-shelf sensor systems to utilize it in the
9 respirator cartridge system. It involved quite a
10 bit of modification.

11 The picture you see on the screen on the
12 left is their standard sensor system, which had 27
13 individual sensors on a chip on a rigid format.

14 And the conclusion from that work was the
15 fact that there are a major number of problems to be
16 addressed in this application.

17 For example, we found that temperature and
18 humidity were significant barriers to implementing
19 this device in the system.

20 The other interesting thing that came out
21 of that was when they transferred their basic sensor
22 system on a rigid format, which is what is shown

1 here, to a flexible format, which is what you need
2 in a respirator cartridge, the amount of noise went
3 up significantly.

4 So the bottom line was that we felt that
5 that was not going to work as a final solution.

6 So we began a research program with
7 Carnegie Mellon University here in Pittsburgh on
8 developing a polythiophene-based chemical system.
9 And we have been doing this jointly with the U.S.
10 Air Force.

11 They have also been contributing this
12 function under their multiuniversity research
13 initiative work for Muriam (phonetic), which they
14 have been providing funds for the basis research,
15 and NIOSH has been providing support for the
16 transfer and engineering aspects, moving that
17 research into practice.

18 In support of that, we developed a
19 cartridge simulator, which you see in the center of
20 the picture. It's a diagram.

21 Up near the top, there's a red line. You
22 will see that's a means of doing remote sampling

1 within the cartridge bed.

2 This entire area contains 50 milligrams of
3 carbon, which, at the end of the red line, you can
4 see a sensor that we would be placing inside the
5 carbon bed.

6 This has given us an opportunity to
7 collect and evaluate interesting, and in some cases
8 unique, data from actual carbon bed applications.

9 The latest version of the sensor system,
10 which is Generation 4, shown on the right, consists
11 of a two and a half millimeter by two and a half
12 millimeter silicone chip, which we have six spiral
13 electrode sensors on polythiophene polymers
14 inkjetted onto those sensors.

15 And this entire thing is then contained in
16 a T-05 package, which is about a quarter of an inch
17 in diameter. The T-05 package is a common
18 electronics package that you would find in the
19 electronics industry.

20 That entire thing will then be placed
21 inside the cartridge bed. And it would then provide
22 information feedback to the user about the condition

1 of the respirator cartridge.

2 So that's the summary of my two posters
3 covering the sensor work. They are located on your
4 right in the back of the room.

5 The first poster I described is a
6 historical review of our sensor work. And the
7 second one is a more in-depth, detailed look at our
8 current efforts at Carnegie Mellon University.

9 The other area that we have been
10 addressing end of service life through is our
11 mathematical modeling systems.

12 And today we have developed three models
13 to predict the service time for organic and
14 inorganic respirator cartridges, purifying
15 respirator cartridges.

16 The first model was Breakthrough you see
17 on the screen. It was introduced in December of
18 2004, placed on the OSHA website. It's a
19 downloadable program that you would download to your
20 machine, run locally.

21 In its history, it has been downloaded
22 over 5,000 times. There have been 10,000 visits to

1 the OSHA website to either ask questions or view a
2 tutorial that also accompanies that program.

3 It is capable of calculating the service
4 time for a single vapor with the effects of relative
5 humidity.

6 A second model was produced, which we call
7 GasRemove. It is for inorganic gases and vapors.

8 It has been completed. However, we did
9 not release it to the public because we determined
10 at about the time that we were ready to release it
11 that data probably didn't exist with manufacturers
12 that would need to be plugged into this model in
13 order to make it useful.

14 So rather than cause irritation among
15 users and manufacturers, we decided to refrain from
16 releasing that.

17 In the meantime, we have been looking for
18 some alternate forms of funding to actually do the
19 work necessary to generate the data. If and when
20 that happens, why, we will be releasing that model.

21 Finally, a model we are just about to
22 release called MULTIVAPOR. It will replace

1 Breakthrough because it's capable of calculating a
2 service time for organic vapor respirator cartridges
3 based on five vapors as well as the effects of
4 relative humidity.

5 And it will be somewhat different from
6 Breakthrough in that it will be available in five
7 versions. And the most significant difference there
8 will be one Java-based version, which will permit it
9 to run on any machine, not just a Windows-based
10 machine, as Breakthrough was limited.

11 The other feature that that will provide
12 will be a web-based version of this that you can go
13 to the website and work with it interactively.

14 Any data that you would store or put into
15 the system would stored locally in your system. So
16 no need to worry about that information going
17 somewhere that you can't control.

18 We expect to release this by the end of
19 the year, and I hope that it will receive as good of
20 a review as Breakthrough has.

21 So I'll be available at breaks throughout
22 the day to talk in more detail about any of these

1 projects. If you would like to, please stop by.

2 MR. SHAFFER: Our next speaker is Sammy
3 Rengasamy. Sammy has a Ph.D. in biochemistry. He
4 has been with NPPTL five years now. Previous to
5 that, he worked for five years with NIOSH down in
6 Morgantown.

7 Sammy is a member of the ASTM E-56
8 committee on nanotechnology and the ISO TC-229
9 committee on nanotechnology, and is also a member of
10 the American Industrial Hygiene Association.

11 So I will let -- Sammy is going to talk
12 about a project. Actually, two of the collaborators
13 from this project, which was just completed this
14 past summer from Edgewood and Battelle are actually
15 here. It's nice to see you.

16 Sammy.

17 RESPIRATOR FILTER PERFORMANCE AGAINST BIOLOGICAL
18 AEROSOLS (POSTER)

19 MR. RENGASAMY: Thank you for your
20 introduction.

21 I welcome you all. My name is Sammy
22 Rengasamy, and I am going to talk to you on my

1 project, respirator protection against bioaerosols
2 under high flow rate conditions.

3 Workers are expected to breathe at high
4 flow rates under heavy workload conditions. And it
5 is well known that high flow rates increase the
6 penetration of particles through respirators.

7 So what happens to biological aerosols
8 under heavy workload conditions? To address this
9 question, we collaborated with the U.S. Army RDECOM
10 laboratory and Battelle laboratory.

11 The experiments that are conducted are
12 high flow rates ranging from 85 to 360 liters per
13 minute under constant and cyclic flow conditions.

14 The bacterium called bacillus globigii, or
15 BG, and the virus called MS2 were used in this
16 study.

17 Aerosols of BG and MS2 were prepared, and
18 penetration through NIOSH approved N95 and P100
19 filtering facepieces cartridges were measured.

20 And the sensors showed that the
21 penetration of BG and the MS2 biological aerosols
22 did not exceed the NIOSH approved levels, even at

1 the high flow rates at 360 liters per minute.

2 And, as you can see, we have gotten the
3 report from the RDECOM and Battelle. And you can
4 see the front page of the report in the corner of
5 the poster.

6 If anyone needs the information, it is
7 available to the public. And I will be happy to
8 answer your questions during the break time.

9 Thank you.

10 MR. SNYDER: The next poster is entitled
11 Respiratory Protection Research for Infection
12 Control. It has a lot of authors involved in this
13 one. It is going to be discussed today by Jon
14 Szalajda.

15 Jon joined NPPTL NIOSH in 2001. Before
16 that, he has 16 years experience with the U.S. Army
17 where he was a team leader and system manager in
18 respiratory protection devices.

19 Jon -- since he has been at NPPTL, Jon led
20 the development of the CBRN standards. He has won a
21 number of FEB, HHS, and NIOSH awards for that work
22 on the CBRN standards.

1 He has a bachelor's degree in chemical
2 engineering from Penn State, and a Master's degree
3 from Pitt in systems engineering.

4 Today, Jon is the program manager for
5 respiratory protection at the laboratory and is
6 responsible for coordinating the respiratory
7 protection work across all of the branches leading
8 from research all the way through certification.

9 Jon.

10 RESPIRATOR PROTECTION RESEARCH FOR INFECTION CONTROL

11 (POSTER)

12 MR. SZALAJDA: Thank you, Ron.

13 It's always a challenge when you have the
14 opportunity to talk at sessions like this to try to
15 come up and think about what you want to say.

16 And one of the things that struck me this
17 morning in listening to Les's and Frank Hearl's
18 comments was the subject of the relevance, the
19 relevance of the research that we are conducting.

20 And I thought that's a really good focus
21 for this project that is currently being conducted
22 in the technology research branch.

1 Because, when you think about it and you
2 think about dealing with things such as an influenza
3 pandemic, this is something that could theoretically
4 touch everyone in this room, and not necessarily if
5 you are a manufacturer.

6 But when you look at the things like a
7 pandemic and how -- what we know about how these
8 types of diseases are transmitted, you know, things
9 that we can do from a public health standpoint to
10 prevent those occurrences from happening I think are
11 very important.

12 I think one of the nice things with my
13 involvement with this project is the fact that we do
14 have a multitalented, multifaceted team working on
15 the project, between Sammy, who you just heard;
16 Dr. Roberge; Ron, who will be the project officer
17 for this effort; Evanly Vo; Dennis Viscusi; and
18 Dr. Zhuang.

19 And everyone has brought different skills,
20 different aspects to this project, which I think
21 will ultimately make it a successful undertaking.

22 And this is one of the areas that we are

1 going to address in a little bit more detail
2 tomorrow.

3 The poster is in the center of this -- of
4 the room here on my left. And I welcome to have
5 discussions with you regarding the contents of our
6 research during the breaks today or at any time when
7 you see me around the facility.

8 One of the things that is interesting with
9 how -- the genesis of the project is that really the
10 foundations and the seeds for ideas as far as what
11 needed to be done began in a workshop that was
12 conducted at CDC back in the early days of Fiscal
13 Year 2005, which looked at respiratory protection
14 needs for dealing with infectious aerosol
15 substances.

16 And following that, you know, the
17 incubation period starts, which is probably a bad
18 term to use when you are thinking about flu.

19 But, you know, we started some internal
20 brainstorming within the laboratory as far as what
21 could be done, you know, with regard to projects
22 that we could execute within our capabilities and

1 with our facilities to address some of these issues.

2 And around the beginning part of the
3 calendar year, the early part of the Fiscal Year
4 '06, CDC came out with an internal request for
5 proposals to look at items where elements within CDC
6 could conduct internal research to address different
7 concerns regarding the influenza pandemic.

8 Ron led an effort to develop a proposal.
9 We submitted it, and we received supplemental
10 funding to conduct the program.

11 Along with this, or parallel with this --
12 and I think a lot of you are aware of it, this
13 little -- the Department of Homeland -- or not
14 Homeland. That's happens when you work in CBRN too
15 long.

16 The Department of Health and Human
17 Services issued a -- or consulted with the National
18 Academies, and in particular the Institute of
19 Medicine, to do an assessment. And that assessment
20 was supposed to look at measures that would permit
21 the reusability of filtering facepiece respirators.

22 I think, as most of the people involved in

1 the healthcare community and in the respirator
2 manufacturing community know that CDC recommends the
3 use of N95 filtering facepieces or higher as
4 respiratory protection for influenza viruses and
5 also other infectious aerosols.

6 The concern being that during a pandemic,
7 there is going to be an increased reliance within
8 the healthcare community as well as potentially by
9 the general public to use the N95 filtering
10 facepiece respirator.

11 One of the things that the IOM identified,
12 which I thought was fairly significant, was the fact
13 that during a pandemic, at least 90 million N95 type
14 respirator -- filtering facepiece respirators could
15 be used within the healthcare community. And that
16 is independent of any requirements that may be used
17 in other areas.

18 That's a significant number of systems.

19 But what our project is focusing on is
20 it's addressing some of the recommendations that
21 came out of the IOM report.

22 And if you are familiar with the IOM

1 report, one of the things that they identified as
2 part of their evaluation was the fact that there
3 really are no decon measures currently available
4 that could be used on filtering facepiece
5 respirators.

6 However, having said that, you know, their
7 recommendation was -- and I know people will say,
8 well, researchers always recommend additional
9 research.

10 But in this area, one of the things that
11 we felt was important to pick up and carry on was to
12 look at this topic of decontamination, in
13 potential -- in particular looking at the simple
14 type methods that could be done in a healthcare
15 setting that could potentially be used to
16 decontaminate respirators and allow their reuse
17 without compromising the respirator's integrity.

18 Another aspect of the work is
19 understanding risks associated with the handling of
20 respirators that may have been exposed to a viral
21 type agent. And those two things I'm going to talk
22 about in a little more detail during the

1 presentations tomorrow morning.

2 The other portion of our research
3 addresses the -- that addresses the IOM
4 recommendations relates to the quantified benefit of
5 annual fit testing.

6 And this is a proposed project which is
7 currently not funded, but on our books for
8 consideration, which would look at determining
9 whether or not changes in anthropometrics result in
10 changes of the fit of the respirator to the
11 individual.

12 And also, this in conjunction with the
13 benefits of annual fit testing.

14 You know, like anyone else, you know, as
15 you get older, your facial dimensions change. You
16 may get heavier. You may get thinner.

17 You know, those types of physical factors
18 that address your anthropometrics as far as your --
19 your face could potentially impact the fit of the
20 respirator to the individual. And that is another
21 aspect of our program.

22 Again, I would encourage you to come and

1 discuss this with me at any point during the day
2 today. There is -- various members of the group are
3 present in the audience today, and we would be happy
4 to discuss the project with you.

5 Thank you.

6 MR. SHAFFER: Our next poster that will be
7 discussed is the Development of Computer-Aided
8 Face-Fit Evaluation Methods. Sometimes we call this
9 our anthropometrics program. And discussing that
10 today will be Ziqing Zhuang.

11 And Ziqing has a very long bio. I will
12 give you the shortened version of that. Ziqing
13 joined NIOSH in 1996, and has been at NPPTL since
14 2001. He has a Ph.D. in industrial engineering,
15 specializing in ergonomics from WVU.

16 Previously he was chairman of the AIHA
17 Respiratory Protection Committee and is currently
18 the past chairman of the committee.

19 He is on various ISO TC-94 SE15
20 respiratory protection committees. He is also the
21 editor of the Journal of the International Society
22 for Respiratory Protection.

1 His research papers have won a number of
2 awards. I'm not going to go through all of them,
3 but he has been nominated by NIOSH for -- twice for
4 CDC Charles Shepard Science Awards and also has won
5 three AIHA John White Best Paper awards.

6 So I'll turn it over to Ziqing.

7 DEVELOPMENT OF COMPUTER-AIDED FACE-FIT EVALUATION
8 METHODS (POSTER)

9 MR. ZHUANG: Thank you, Ron.

10 Well, yeah, when we initiated this
11 project, at that time, the military data was the
12 only data available. And then when you look at
13 military data, the data were collected on people
14 they covered young. And then also back in the 60 as
15 well.

16 And then when new personnel were
17 recruited, they cover -- need to go through some
18 restrictive criteria that, yeah, they may not
19 represent the, yeah, the diversity that you see in
20 the civilian population.

21 So -- and then also, over the last 30
22 years, the population demographics have changed a

1 lot.

2 And then also, over the years, I think,
3 yeah, the earlier '70s, the Los Alamos Fit Test
4 Panel was developed. There are a few scientific
5 studies that look at the panel, and they found that
6 the panel was, however not representative of the
7 population and most of the people. I decide by then
8 we have a significant portion of the subjects are
9 outside the panel.

10 And so, you know, which we -- so we
11 initiated the project. And in the words of our
12 NPPTL former director, Rich Metzler, in the audience
13 today, at that point he told me that like this kind
14 of project is important. And it's like -- it's so
15 important that like when you build a building on the
16 sand versus you build a solid foundation and build a
17 building on top of that.

18 So whatever NIOSH is doing or
19 manufacturers are doing, like this have like
20 information, very critical and very important.

21 So at that time, we set our goal to
22 develop a database to collect data on respirator

1 user, their facial dimension. And then, yeah, use
2 the information to develop fit test panels. And
3 then also headforms for testing respirator and eye
4 and face, like, protective device.

5 So what we need was, we created a database
6 with like 3,397 subjects, and we also scanned
7 one-fourth of the subjects.

8 And then at this point, we have developed
9 two fit test panels. One is based on face length
10 and face width, and the other one is based on ten
11 facial dimensions, and we used principal component
12 analysis approach.

13 And we also have laboratory study look at
14 correlation between fit test and dimension and also
15 did some review on those subjects as well.

16 And I also, yeah, was able to get seven of
17 US manufacturer to fund a study in China to collect
18 data from, yeah, Chinese worker. And that study has
19 been completed, and we are doing data analysis right
20 now.

21 And with the three-dimensional data, we
22 were able to create our first generation of

1 headform, and now we are working on the second
2 generation.

3 And as I am on various committee, and I
4 was able to get input from the committee to help
5 with the research.

6 So we expect the product to be used by the
7 committee. And as we get a lot of people from them,
8 and hopefully there will be, yeah, have good -- a
9 lot of input on the standard. Thank you.

10 MR. SHAFFER: I forgot to mention that
11 Ziqing will have a talk tomorrow where he will focus
12 on one aspect of the project development of mid fit
13 test panels.

14 Our next speaker is Angie Shepherd. Angie
15 is the newest member of the research branch at
16 NPPTL. She has been with us for about a year and a
17 half now.

18 Her focus is protective clothing. She
19 previously worked for Underwriters Laboratory, also
20 in protective clothing. She has a bachelor's degree
21 in chemical engineering and a bachelor's degree in
22 textile chemistry from North Carolina State.

1 Recently, she won a number of -- two
2 awards with the Pittsburgh Federal Executive Board.
3 She was the rookie of the year and also -- the gold
4 award for that one, and I think she got a bronze for
5 the woman of the year the professional
6 nonsupervisory category.

7 She's a member of five different NFPA
8 Technical Committees and has been a task group
9 leader or a task chairperson for CBRN issues in
10 particular.

11 She is also member of the ASTM F23
12 committee on protective clothing and equipment.

13 And Angie is going to talk about her
14 project, Improved Criteria for Emergency Medical
15 Protective Clothing.

16 Her poster is over there with the nice
17 display items.

18 IMPROVED CRITERIA FOR EMERGENCY MEDICAL PROTECTIVE
19 CLOTHING (POSTER)

20 MS. SHEPERD: Thank you, Ron.

21 As Ron mentioned earlier, and you will
22 actually hear over the next two days, we are doing a

1 lot of internal work on standards.

2 But this particular project actually is
3 looking at helping an outside standards activity for
4 the National Fire Protection Association.

5 As, Ron said, NFPA is the standard on
6 protective clothing for emergency medical
7 operations. It's currently in its 2003 edition.

8 And the standard is little different from
9 some of the other standards. It actually has more
10 of a menu approach. You can pick just a garment,
11 just a single-use garment, just a glove, just a face
12 protector. So it's not an ensemble standard.

13 The problem with that is, although it has
14 had very, very good industry response, it has only
15 been in certain categories, just as reusable
16 garments. And there are a couple of certifications
17 that exist currently for footwear.

18 But there are other areas, such as face
19 protection and cleaning gloves, which actually have
20 had little to no industry participation.

21 Why is this? A couple of different
22 reasons.

1 Such items as cleaning gloves actually had
2 mutually exclusive criteria in the standard, meaning
3 nothing can be certified. You have tests that
4 overlap one another. So if it passes one test, it
5 automatically fails the other.

6 You also have other items that, once it
7 passes a standard, the products that are a result of
8 the standard actually don't meet the first
9 responders' needs.

10 So even though you have certified products
11 out there, nobody is wearing them, and nobody is
12 buying them. So that does not make for a good
13 standard either.

14 There are other categories, such as head
15 protection and flammability as well as
16 retroreflectivity that aren't currently covered by
17 the standard, so it is something else we are looking
18 to try to fill the gaps with.

19 And how we are doing this, we have
20 partnered and actually have a contract with Mr. Jeff
21 Stull with International Personnel Protection.

22 And we are looking -- the first thing we

1 did was we did a series of interviews with nine
2 different departments ranging from your large
3 metropolitan EMS departments, such as New York City,
4 down to small ambulance services in Texas.

5 And what we learned from those interviews
6 is which products were acceptable, which products
7 were unacceptable, what they were using, what they
8 weren't using, and why they were using the products
9 they were using.

10 Gained a lot of good information from
11 that. We selected the products that were going to
12 be moved -- that we are going to move forward and
13 test, both acceptable and unacceptable products.

14 And based on the test results that we get,
15 we will be able to determine acceptable criteria and
16 actually hand those over to the NFPA as
17 recommendations and look to impact the 2008 edition
18 of the standard.

19 So this is a really, really good example
20 of how the work that we do at NPPTL actually can
21 have a direct impact to the -- like the research
22 practice that they mentioned earlier.

1 So -- and the other to mention with the
2 standard, the NFPA 1999 is also one of the standards
3 that's on the list for federal funding. So this
4 is -- we have to see very, very good results from
5 this project.

6 As well as my poster is over there on your
7 left, and I have a significant number of samples.
8 So please feel free to come and take a look at -- I
9 have single-use garments. We will use different
10 types of cleaning gloves. So I would love to hear
11 your input on some of those.

12 Thank you.

13 MR. SHAFFER: Our next poster will be
14 discussed by Pengfei Gao. Pengfei joined NIOSH in
15 1996 and worked in Morgantown down there, and in
16 2001 joined NPPTL.

17 Pengfei's background is in aerosol science
18 and in protective clothing. He has a Ph.D. in
19 environmental health science. He is a member of the
20 AIHA Aerosol Technology and the Protective Clothing
21 and Equipment Committees.

22 He is also a voting member for the ASTM

1 F-23 committee. He has been a certified industrial
2 hygienist since 1999.

3 He has also won a number of awards, and
4 most recently was awarded by the Pittsburgh Federal
5 Executive Board the Outstanding Contribution to
6 Science Gold Award.

7 Pengfei.

8 DECONTAMINATION STRATEGIES AND REUSABILITY OF
9 CHEMICAL PROTECTIVE CLOTHING (POSTER)

10 MR. GAO: Thank you, Ron, for a wonderful
11 introduction.

12 The title of my poster is the detox
13 strategy and the reusability of CPC.

14 As we know, detox is a very important
15 issue for the use of CPC. OSHA has the -- this is
16 requirement for CPC decon, and it is a number of
17 spindle (phonetic) and regulation. However, they
18 don't tell you how the decon should be done.

19 So this project was to develop a -- test a
20 method for CPC decon and to develop a methodology
21 how you can evaluate decon efficacy, and then to
22 provide you with a guideline for CPC requirement.

1 We selected seven most commonly used CPC
2 material and the 12 of liquid chemical. The
3 chemical was selected under the ASTM for a total of
4 26 materials and chemical combinations.

5 We used two decon method. One use heat,
6 and the other one is water and detergent for
7 comparison.

8 The exposure and the decon was repeat up
9 to ten cycles, or until material fails. After that,
10 we look for a change of chemical resistance and the
11 degradation.

12 What we find, reuse -- multiple reuse of a
13 CPC could be set for certain chemical/material
14 combinations.

15 We also find that if you wanted to
16 evaluate a CPC decon efficacy, not only the change
17 of chemical resistance should be investigated, but
18 also the change in physical properties needed to
19 investigate.

20 Some other outcomes of this project
21 include the development of a computer program we
22 call Permeation Calculator. It is only -- this is

1 the first screen of the program.

2 This program calculated all the permeation
3 combination for ASTM standards F-739 and ISO
4 standard 7529. And also, we develop a decon
5 guideline. We -- a letter was published by AIHA
6 last December.

7 My poster is located at the corner there.
8 Please stop by, and I will be able to discuss with
9 you for -- any questions you might have regarding
10 this project.

11 Thank you.

12 MR. SHAFFER: The next poster will be
13 discussed by Sammy Rengasamy, who I introduced
14 previously.

15 While he is coming up, I will just mention
16 that this is will be the subject of a longer
17 presentation tomorrow that I will actually be
18 giving, but Sammy is going to tell you a little bit
19 about the poster that we have here today.

20 NANOTECHNOLOGY: PERFORMANCE OF PERSONAL PROTECTIVE
21 EQUIPMENT (POSTER)

22 MR. RENGASAMY: Thank you, Ron.

1 This talk is going to be on the
2 nanotechnology performance of personal protective
3 equipment. And the co-authors are Dr. Pengfei Gao
4 and Ron Shaffer.

5 I want to say we are living in a small
6 world, but the nanotechnology is growing at a faster
7 rate. Nanotechnology brings a lot of good things,
8 but there are several concerns that have to be
9 addressed.

10 And NIOSH, if you look at the center of
11 the slide, NIOSH addresses these concerns. NIOSH
12 addresses ten areas of nanotechnology issues by
13 conducting research. One of them, you can see on
14 the left, it is controls. These controls include
15 engineering as well as personal protective
16 equipment. That improves respirators, protective
17 clothing, and other materials.

18 And Dr. Pengfei Gao, he is working on the
19 protective clothing to look at the penetration of
20 nanoparticles through the material, and I am looking
21 at the penetration of nanoparticles through
22 respirators.

1 Let me tell my story first.

2 There are lot of studies that look at the
3 penetration of particles greater than 20 nanometers
4 in size through respirators, but there is no
5 information on the penetration of particles smaller
6 than 20 nanometers through respirators.

7 So we wanted to look at the penetration of
8 the smaller of these particles through respirators.

9 The contract was awarded to the University
10 of Minnesota, and they did the work for us. And
11 they -- the results from their study showed that the
12 particles smaller than 20 nanometers, down to the
13 size of 3 nanometers, they are captured well by the
14 filter media. They used a filter media in this
15 study.

16 Then we wanted to continue this study to
17 look at the penetration of particles ranging from
18 three to 400 nanometer size through NIOSH approved
19 respirators.

20 So now we are doing this study in our
21 laboratory at NPPTL, and we also want to look at the
22 penetration of particles under a tight-fitting --

1 and also the leakage conditions using a mannequin
2 head model.

3 And this we hope will give us a better
4 information on the nanoparticle penetration through
5 respirators and respirator protection for workers.

6 And I will be -- as you can see, some of
7 our research has been incorporated in the NIOSH
8 document entitled Approaches to Safe Nanotechnology,
9 An Information Exchange with NIOSH. And this, you
10 can get it from the web.

11 I would be happy to answer your questions
12 at the poster session, and my poster is the second
13 one from there.

14 Thank you.

15 MR. SHAFFER: I should mention that this
16 was one of the posters, this has two projects on it.
17 Also, there is a number of bullets and some
18 discussion of the penetration through protective
19 clothing that Pengfei Gao has led.

20 Both of those projects and some the
21 preliminary results are discussed in the safe
22 working practices document.

1 Like I said, I'll talk about this in more
2 detail tomorrow, and I'll have a link to the website
3 where you can download the report yourself.

4 The last speaker this morning is going to
5 talk about two different projects, Dr. Jon Williams.

6 Jon joined NPPTL in 2003. Previously he
7 worked at NASA where he directed one of the
8 physiology labs there. He has a Ph.D. in
9 physiology. He is currently the chair of the U.S.
10 Tag (phonetic) PG-5 Human Factors Committee. And in
11 2004, Jon was the Pittsburgh Federal Executive Board
12 Rookie of the Year.

13 So Jon will talk about two projects,
14 physiological models and countermeasures, as well as
15 the Project Heroes.

16 While Jon is getting untangled there, I
17 will mention that Ray Roberge, who is our new
18 medical doctor, who has been with the lab for about
19 a year, was unable to attend today and tomorrow
20 because they are actively doing testing in the lab,
21 so I send his regards today.

22

1 PHYSIOLOGICAL MODELS AND COUNTERMEASURES (POSTER)

2 MR. WILLIAMS: Thanks, Ron.

3 One of the things that our laboratory is
4 interested in is the physiological impact of wearing
5 personal protective ensembles.

6 And you wear personal protective equipment
7 and ensembles primarily because you are engaged in
8 activity that exposes you to some external threat to
9 your life or your health.

10 And unfortunately, those personal
11 protective ensembles tend to be encapsulating. They
12 are hot. They are heavy. Therefore, they impose a
13 physiological burden on the wearer.

14 And our interest is how much of that
15 burden is -- can be characterized, and what can we
16 do about it.

17 And we also are interested in developing a
18 model of that physiological burden that is
19 predictive so that we don't necessarily always have
20 to do testing. We can apply a model and get some
21 idea of what the physiological burden will be when
22 the person wears that particular ensemble.

1 We are also interested in how we can we
2 alleviate that burden because a person has to
3 wear -- if they are in a certain occupation, they
4 have to wear their personal protective gear. That's
5 not an option for them. They need the protection.

6 But in the case of, for instance,
7 firefighters -- and I will show you another slide in
8 a minute -- one of the biggest incidents of
9 morbidity and mortality in firefighters is
10 cardiovascular disease.

11 And thermal stress has been implicated as
12 one of cluster of risk factors for the development
13 of cardiovascular disease in firefighters, repeated
14 high thermal stress.

15 And it isn't just coming from the
16 incident -- high incident heat that you are exposed
17 to when you go into a burning building, but it comes
18 from the metabolic heat that a person generates
19 because they are very active, and their muscles
20 generate a lot of heat, but it cannot be transferred
21 to the external environment as it normally is
22 because they are encapsulated in this garment.

1 And so they tend to start getting a high
2 thermal stress. And that, repeated over many years,
3 can contribute to cardiovascular disease.

4 So one of the things we are interested in
5 is the countermeasure to that. Well, the obvious
6 thing is cooling them down, if possible.

7 And so my postdoctoral fellow, Dr. Itor
8 Coca (phonetic), has a project that has been
9 approved to look at cooling garments which take
10 advantage of certain areas of the body where optimal
11 cooling can take place.

12 You don't necessarily have to completely
13 cover somebody's body with a cooling garment to get
14 the appropriate amount of heat transfer out of their
15 body. You need to take advantage of certain areas
16 of the body where this optimal heat transfer can
17 take place.

18 And that's why this cooling garment isn't
19 completely encapsulating. It is simply taking
20 advantage of head, forearms, chest, which are
21 regions where a lot of heat transfer can take place.

22 The other thing is that you don't need to

1 cool somebody down maximally. You need to cool them
2 down optimally.

3 The difference is is that if you cool them
4 down maximally, then they tend to show warm blood,
5 which tends to remain in their core, is not
6 transferred to their peripheral vasculature in their
7 skin. So that heat transfer, that warm blood does
8 not transfer heat to the external garment.

9 One of the things that we are also
10 interested in is providing -- in our models,
11 providing a information to the ASTM standards, which
12 will provide a guidance as to what type of
13 physiological testing you need to do when you
14 actually put somebody in a garment. What are the
15 type of tests that you run?

16 So we supplied information to Angie
17 Shepherd, who you heard speak a little bit ago, and
18 she has been involved in developing this
19 physiological test methodology for the ASTM groups.
20 She has been pushing that through for the last year
21 or so.

22

1 NEXT GENERATION STRUCTURAL FIREFIGHTING PPE ENSEMBLE

2 (PROJECT HEROES)

3 MR. WILLIAMS: The next project that I'm
4 working on with everyone here is Project HEROES.
5 And we are applying a lot of the physiological test
6 methodology that I spoke of earlier to a project
7 which involves looking at how a new firefighter
8 prototype ensemble with some level of chemical and
9 biological hazard protection affects a person when
10 they wear it.

11 And I don't know if you can see from the
12 picture, but if you look in this area here, you can
13 see a little hose which takes -- is attached both to
14 the mask, and then reroutes the exhaust air from the
15 SCBA facepiece back into the garment.

16 And that does a couple of things. Number
17 one, it presumably provides a certain amount of air
18 flow through the upper part of the garment, which we
19 are hoping will provide some level of cooling
20 without the addition of a new garment or extra
21 garment like the cooling garments I showed you
22 earlier.

1 The other thing it does is that it can
2 provide some degree of positive pressure, which
3 limits total inward leakage, we think. So that
4 that's another barrier to bad stuff getting into the
5 garment and giving them a little more protection
6 than they would have had before.

7 The other thing is that the company,
8 Morning Pride, which manufactures the suit, has
9 created novel seals between the wrist sleeve/glove
10 interface and the pant leg and boot interface, along
11 with some zippers and sealing -- a hood that
12 actually seals around the facepiece. And all of
13 these different -- right around here, kind of a
14 baffle that goes around.

15 And all of these strategies are there to
16 limit the firefighter's exposure to whatever is out
17 there in the environment, whether it is a chemical
18 or biological hazard.

19 The downside of that is that the more
20 seals you put on somebody, the less you are able to
21 transfer heat to the environment, and your core
22 temperature goes up.

1 And so we are applying a lot of the
2 physiological testing methodology that we have
3 developed to studying how much that garment will
4 actually either cool you through this novel hose
5 arrangement by using the exhaust gases from the SCBA
6 and blowing it back into the garment, how much that
7 actually cools you, if it does at all, and what the
8 heat stresses really are.

9 And so we are in the middle of this
10 project right now. We conduct this particular
11 project in an environmental chamber to control the
12 environment. And we are comparing it to a standard
13 ensemble which -- upon which this prototype has been
14 built up.

15 This is a standard ensemble which serves
16 as the platform that has been modified up to create
17 this prototype.

18 So that's our big project that we are
19 conducting right now, and I would be more than happy
20 to discuss any of these projects or any aspect of
21 them.

22 Our posters are located behind the screen

1 there to your right. Don't worry. I'll hand out
2 money to convince you to come to these posters. Not
3 really. I'm getting behind it.

4 But, in any case, I will be more than
5 happy to discuss any of the aspects of the project
6 at another point in the presentations here.

7 So thank you very much, and I hope to see
8 you at the posters.

9 MR. SHAFFER: Okay. So that's the
10 five-minute overviews of the various projects. Just
11 a few closing remarks.

12 About the Project HEROES, obviously, if
13 you have got physiology questions, Jon can tackle
14 those.

15 Angie Shepherd has also been heavily
16 involved in the project with a standards focus of
17 various changes to some NFPA standards 1971, 1994.
18 And she has been heavily involved in that aspect of
19 HEROES, so that is part of the reason why those
20 posters are back there, so they are close to Angie's
21 poster as well. And Angie is going to discuss those
22 topics if anyone is interested.

1 So if you haven't been to the laboratory
2 in a couple of years, you will see some changes. We
3 have got some new facilities in place. We have got
4 a new aerosol research lab. Our anthropometrics lab
5 is moved out of those tiny little buildings. We
6 have got an entire -- Building 13, we have got the
7 entire second floor which houses all of our
8 respiratory protection research.

9 We have state-of-the-art physiology labs.
10 We have got environmental chambers that we use for
11 testing, in addition to the sensor labs and the labs
12 that were there previously.

13 A protective clothing lab as well.

14 So if you haven't been to the labs, I
15 encourage you. Give us a call. We will be happy to
16 show you around and talk a little bit more about the
17 projects.

18 So we are going to go on break now, which
19 is open, obviously, for refreshments, restrooms, as
20 well as for discussions at the various poster
21 sessions. And we will reconvene at 10:30 with the
22 discussion of the CBRN PAPR Step 2, Industrial PAPR.

1 (A recess was taken.)

2 MR. BOORD: I would like to start off by
3 reversing an agenda adjustment that I announced
4 earlier. And the adjustment is that there will be
5 no changes to the afternoon sessions.

6 The original schedule for the CBRN PAPR
7 standards development activities, the CWA live agent
8 testing, CBRN hazard for first receivers, and the
9 respirator standards will occur at 1:15. And the
10 2:30 session for Total Inward Leakage quality
11 assurance module and administrative module will
12 occur at 2:30.

13 So the agenda as you have it in your
14 program is what we will adhere to. And sorry for
15 any inconveniences that may have -- or confusion
16 that may have caused.

17 To continue with our program today, I
18 would like to introduce Bill Hoffman, who is the
19 branch chief for our policy and standards
20 development activities.

21 The next sessions, the industrial PAPR,
22 the chemical warfare CBRN discussions, and the TIL

1 discussions later this afternoon are all part of the
2 Policies and Standards Branch.

3 So I will turn it over to Bill.

4 INDUSTRIAL PAPR - CBRN PAPR STEP 2

5 MR. HOFFMAN: Okay. As all of you
6 probably know, the CBRN Step 1 PAPR standard which
7 was implemented by policy has gone into place. So
8 we do now have a mechanism to approve CBRN PAPRs.

9 From this point forward, though, as Terry
10 Thornton is going to discuss, all future changes to
11 regulations or implementations will go through the
12 rulemaking process. So it will be a lengthier but,
13 I guess, more conclusive process in that everything
14 will go through the proper steps to do that.

15 Terry is going to give the full
16 presentation on the CBRN industrial PAPR standard,
17 which we are going to be changing it from industrial
18 PAPR to PAPR. Because when it goes through
19 rulemaking, it will cover everything when we do
20 that.

21 It's a rather lengthy presentation, but we
22 are going to try -- we have tried to cover all of

1 the details.

2 So at this point in time, I'm going to
3 turn it over the Terry. And following his
4 presentation, we will go to lunch.

5 MR. THORNTON: All right. The quicker I
6 can get done with this, the quicker we go eat. Wow.
7 It did go pretty quick. We seem to be well into it
8 by now.

9 Let me see if I can find the beginning of
10 this. I hope there is no timer on this. I'm not
11 sure why it has jumped over there.

12 As Bill said, my name is Terry Thornton.
13 I'm a chemist. I work in the policy and standards.
14 Many of you know me out there. I have been talking
15 about CBRN for quite a while, especially the PAPR
16 CBRN.

17 So today we are going to really kind of --
18 I've changed my focus a little bit. We are going to
19 talk about the industrial PAPR.

20 As Bill pointed out, this may be a lengthy
21 presentation because, you can imagine, industrial
22 PAPR, or PAPR, covers a quite a bit, a little bit

1 more detail than we thought when we first jumped
2 into it.

3 If you didn't get all of that...

4 I'm going to try to back that up somehow
5 and slow that down. It would be nice to go through
6 that presentation that fast.

7 But does somebody have a timer set up on
8 this? We will try again.

9 This is a lot of fun, isn't it? Does
10 anybody know how to stop this from taking place?

11 If we have any suggestions, please come
12 forward now because I'm going to have to -- Jon to
13 the rescue. If we can't fix it here in a minute, we
14 will go through it a slide at a time.

15 All right. This makes it more exciting
16 when things like this take place. Hopefully it
17 won't do this anymore.

18 We also -- we have one thing that we have
19 put out, that after this, we would go to lunch. I
20 think that's incorrect. What we are going to do
21 after this is Tim Rehak is going to stand up and
22 talk to us about multifunction PAPER.

1 Once I get going here, this shouldn't take
2 very long. I know that's hard to believe, but that
3 may have taken my concentration away a little bit.

4 So I think I was introducing the
5 industrial PAPR. Let me see if I can get back on
6 track now.

7 The industrial PAPR concept is an actual
8 project now, this year, in '07 for NPPTL. Before,
9 it was something we were working on. Now it's an
10 actual project. It has a can (phonetic) number. It
11 has money to be involved to complete the project.

12 As you can see, this is what the project
13 requires. It's really to put together everything
14 for a PAPR to incorporate that into the 42 CFR.

15 We are going to look at it. Hopefully, we
16 are going to pull in new technology and new
17 requirements and put that all together.

18 Yes, it will go through formal rulemaking.
19 That is one of the parts that will probably make it
20 take a little longer than we have done prior. The
21 formal rulemaking should be a very good thing for
22 this.

1 I'll let you know that we are still using
2 a concept process, and that's a process that we have
3 used so far. We are going to continue that, even
4 though we are going to do formal rulemaking. So the
5 concept papers will go out. We will have public
6 meetings. We will have manufacturer meetings.
7 Maybe possibly 101 meetings. We will talk to user
8 communities.

9 So we are still going to use that same
10 process, and we'll use it to its fullest extent
11 before we start the formal rulemaking.

12 So one of the things I want to bring out
13 is we have a concept paper out there right now on
14 the internet. It is dated September 19, and
15 probably quite a few of you have already seen it,
16 pulled it off, looked at it.

17 That concept paper is very fluid, and it
18 keeps changing all the time. We have meetings in
19 NPPTL between ourselves. Other manufacturers
20 come -- or manufacturers come in, user communities.

21 So what you see there right on that date
22 for September 19 is kind of like a snapshot of what

1 took place to that point.

2 So some of the things I will discuss in
3 here are different from what's in that concept
4 paper. And I'll try to point those out before I
5 bring those up.

6 The docket comments, please use the docket
7 comments and submit to the docket. You can see the
8 number, 008. Put that on there whenever you are
9 talking about the PAPR concept. It makes it get to
10 the right place, and it's easier to find.

11 The computer is just not working for me
12 today very well.

13 One of things I wanted to hit, kind of
14 like Bill had spoken about, there was a little bit
15 of confusion. I want to make sure we try to clear
16 that up before we get started.

17 There has been a lot of talk about CBRN
18 PAPR. We have done the CBRN PAPR Step 1. That's a
19 statement of standard that's out there right now.

20 Some of the other terminology a lot of you
21 have heard and may be confusing is CBRN PAPR Step 2
22 PAPR module, or PAPR standard, or PAPR concept. All

1 of those terminologies kind of get thrown in
2 together.

3 This is what we are discussing here, and
4 it will encompass all of the PAPR standard. When we
5 are done, it will be a standard. For now, we are
6 going to talk about it as a concept.

7 You also -- I slip up sometimes. I may
8 use the word PAPR module or PAPR concept. We use
9 those interchangeably. Once it is completed, it
10 will be a PAPR standard.

11 So what we have presented in the past
12 was -- this is kind of what we are looking at, how
13 to redo this standard. We want it flexible enough
14 to cover a potential wide range of applications.

15 We also wanted to have the flexibility to
16 have specific tests associated specific
17 applications. CBRN comes into mind, mining process.

18 One size fits all, the 42 CFR, is kind of
19 quite old. But for the PAPR, it was a
20 one-size-fits-all. We're not sure if that's really
21 the best way to do it. So we think we have come up
22 with a better way to have the standard laid out so

1 it's easier to look at, easier to understand.

2 All right. So for this PAPR concept
3 consideration, we are going to cut it into two
4 categories. The first will be a base requirement.
5 This is just like it sounds. Base requirement would
6 have -- all PAPRs would pass these base
7 requirements.

8 That can be broken into the two subgroups,
9 respiratory and nonrespiratory. The differences
10 between respiratory and nonrespiratory, there is not
11 a clear-cut line here. But that seems to be a very
12 good way to distinguish some tests so that it's
13 easier to look at the standard and read the standard
14 once it is in place.

15 Use and application specific. Now, this
16 is a little bit new to 42 CFR or to the way that
17 NIOSH NPPTL has been doing testing. Usually we have
18 had a standard.

19 This use and application specific gives us
20 an area where we can have specific tests based on
21 needs or a type of respirator.

22 So right now, what we have come up with

1 is -- that's a little out of place there. This is
2 the listing that we have that would be under use or
3 application specific.

4 Where it says CBRN responder, right
5 underneath that, assesses new technology, that
6 assesses new technology should be -- it got out of
7 place. It's right here. It should be right under
8 here. So it should read additional requirements to
9 assess new technology. One of the confusions, I
10 guess, when you transfer these things.

11 So the areas we have are CBRN responder,
12 which we have been working one quite a bit.

13 You will see the law enforcement, clean
14 room, hospital. Those are some of the areas, the
15 specific-use applications. And then some of the
16 others we will see on this slide are some of the
17 additional tests that not all PAPRs would need to
18 pass, but some PAPRs would be able to use that. So
19 it would be almost like an option that you could
20 have these additional tests performed.

21 We will kind of jump right into the meat
22 of the story here. For the PAPR concept -- this has

1 been a big question that has come about. We have
2 discussed it many times in NPPTL. Do all PAPRs need
3 to be considered a positive pressure device?

4 Different opinions out there, but for
5 right now, NPPTL is going to look at that. The
6 answer to this is yes. We are going to look at them
7 as a positive pressure device.

8 Now, exactly what does that mean? Kind of
9 depends on who you are speaking to.

10 For a positive pressure device, we are
11 going to have positive pressure inside the facepiece
12 or inside the breathing zone while tested under
13 NIOSH requirements.

14 So we can't -- we will look at it with a
15 NIOSH test on a breathing headform with a breathing
16 machine, specific tests, and see that it maintains
17 positive pressure in there.

18 That's not to say that when a human puts
19 the respirator on that he's going to be able to
20 maintain positive pressure at all times while using
21 a respirator.

22 And I think if anybody has used a

1 loose-fitting respirators, manufacturers, you know
2 that as the user gets in there and starts moving his
3 head and starts talking or doing hard work, extra
4 hard work, that the positive pressure may not be
5 there.

6 So when we say positive pressure device,
7 that is going to be for NIOSH testing.

8 A couple of areas in here that you will
9 see under the concept paper that talk about positive
10 pressure test, and that's the low flow pressure
11 indicator, power requirements, air flow
12 determination, which is going to be some things we
13 talk about, and then Total Inward Leakage. Those
14 are areas where positive pressure will come into
15 play.

16 As I said, we talk about air flow
17 determination. Traditionally, under 42 CFR, we have
18 two air flows, tight-fitting and loose-fitting.

19 Tight-fitting has 115 liters per minute.
20 Loose-fitting has 170 liters per minute.

21 With new technology, we would like to be
22 able to incorporate a little bit more expanse on the

1 PAPR and how they operate.

2 So if we look here, there is kind of three
3 ways you can look at a PAPR operating. The first
4 one is a single power blower unit. And a single
5 power blower unit is kind of traditionally what's
6 out there right now for a PAPR.

7 It has a blower. You turn it on. It goes
8 up to an constant speed. You breathe in it. You
9 use that flow.

10 Another thing that we have suggested by
11 manufacturers and the user community is to have
12 multiple blower speeds. All right. This would be a
13 PAPR that is not just one setting. You could turn
14 it to low. You could turn it to moderate. You
15 could turn it high. So you would have the ability
16 to change that setting, manually change that
17 setting.

18 So some flows in there may be different
19 for that.

20 The last way that we know that these types
21 of units are out there is a breath response unit.
22 And this is -- you can kind of look at it. It is

1 the same as a variable power blower unit, except
2 it's not a manual switch that goes back and forth.
3 It responds to the user and his breathing pattern.

4 So those are three kind of ways we can
5 look at the PAPR that we are discussing here.

6 So the question is, what do we do with the
7 flows? What type of flows are needed for these type
8 of units?

9 It's also, we would like to do some
10 performance type testing. So we would like to test
11 these respirators as they are performing on a
12 breathing machine, on a headform, actually breathing
13 at some type of work rate.

14 So that's what we would like to do. Now,
15 how are we going to establish what the minimum flows
16 would be for those different work rates?

17 There are some questions there. And
18 comments at end of the docket are going to be needed
19 so that we can clarify this.

20 What we have right now, if we look at the
21 tight-fitting, the three. We have low, moderate,
22 and high. For a low tight-fitting, we would --

1 right now, it looks like there is no need for that.

2 We wouldn't allow that.

3 If you had something that would be a
4 low-flow tight-fitting, that would be probably an
5 APR, not breath response, but breath assisted. So
6 it would fall under an APR.

7 Now, this is a -- like I say, this is a
8 concept. It's not completely finished. If there is
9 docket comments that come in that suggest that we do
10 have that, we can look at that.

11 For tight-fitting, look at the moderate,
12 115 liters a minute. That's an average air flow at
13 40 liters per minute breathing.

14 High looks like we would need somewhere
15 around 250 liters per minute on an 86 liter a minute
16 breathing machine.

17 If we look at loose, we have three flows
18 there, also. We have 100, 170, and 370. Everybody
19 is familiar with the 170. This 250 right here and
20 this 370, those are numbers that are really under
21 consideration. And we would like more docket
22 comments on what those flows need to be, whether

1 those flows are too high or those flows are too low.

2 So that's some docket consideration that
3 we would really like to see.

4 The other thing we have to keep in mind is
5 the breath response units that we are looking at
6 now, the ones that are currently on the market.
7 They are very difficult to just measure the air
8 flow.

9 All right. That doesn't mean all of them
10 will be that way, but for right now, they are
11 difficult to just turn them on and measure an air
12 flow because they respond to the breathing pattern.

13 So what we have in the concept paper today
14 is for a tight or loose-fitting or breath response
15 unit, we would maintain positive pressure inside the
16 facepiece.

17 And that would be inconsiderate of -- we
18 would not consider needing a minimum air flow for
19 that. We would just look to see on the breathing
20 machine it maintains positive pressure inside the
21 facepiece.

22 We can measure that average flow -- and I

1 think I have talked about that in prior meetings
2 about how we can measure that average flow on that
3 breathing machine. And we could use it in later
4 testing if needed.

5 Another way that we have looked at this --
6 and this is not in your concept paper right now.
7 This isn't -- what I'm going to talk about here is
8 not discussed in the concept paper, the flows I had
9 just mentioned, the minimum air flows are what is
10 talked about in there.

11 The other way we can do this is to take
12 all of the PAPRs and not require a minimum air flow,
13 whether it be low, moderate, or high. We just would
14 not require a specific minimum air flow.

15 We would hook it up and set it up just
16 like we were looking for the breath response unit,
17 put it on a headform, turn on the breathing machine,
18 and see that it maintains positive pressure at that
19 specified breathing rate.

20 These specified breathing rates, the 40 is
21 traditional NIOSH. We have used that prior -- or we
22 have used that in the past. You will remember that

1 as a Silverman Cam at 40 liters per minute minute
2 volume. And that's 1.67 liters at 24 respirations
3 per minute.

4 We have come up with a couple of more, and
5 these go along with ISO, not directly with ISO, but
6 we are more in line with ISO, looking at a low of 21
7 liters per minute minute volume and a high of 86
8 liters a minute.

9 Again, this is something that docket
10 comments can come in, if you agree, disagree with
11 these actual minute volumes or how we are setting up
12 the liters and respirations per minute, we would
13 like comments on that.

14 I covered two concepts there that we are
15 looking at.

16 One of them is what's in that 19 September
17 concept paper right now where we could actually
18 measure flows for a constant flow type unit. We
19 would measure, and there would be a minimum flow
20 that it needed to pass.

21 Also with that, the breath response units
22 would be tested differently, and they would just be

1 put on a headform and maintain positive pressure.

2 The other concept that I talked about, it
3 is not requiring minimum air flows for any of the
4 PAPRs and doing everything by positive pressure
5 inside the facepiece.

6 Hopefully when the next concept paper
7 comes out, both of those will be in there. Maybe
8 they will be listed as an alternative. But we hope
9 to get both of them in there so you will have more
10 opportunity to read specifically on what we are
11 looking at.

12 Jump to some of the other details of the
13 concept, the PAPR concept. We will talk a little
14 bit about battery life here and power requirements,
15 specifically to battery life.

16 I think we have talked about this in past
17 sessions, so we are looking at battery life at a
18 minimum of two hours. Right now there is really no
19 specified battery life except that you must pass the
20 silica dust test, and that's a four-hour test.

21 Now we are looking at requiring a minimum
22 of two hours, and you could advertise that in

1 increments of one hour at a time. So two, three,
2 four hours.

3| Again, how are we going to measure this
4 battery life? We are going to put it on a breathing
5 machine on a headform. We are going to let it run
6 at that breathing rate, or work rate, and see that
7 during that time you have said that the battery will
8 last, you maintain positive pressure inside the
9 facepiece.

10 We have had a lot of comments and
11 questions about alternative power sources besides a
12 PAPR battery. Traditionally there is a battery
13 there somewhere. You can plug into it, or it is
14 internal into the system. You have rechargeable or
15 nonrechargeable.

16 A lot of people have asked and said, why
17 do you force us to use a battery when we are in a
18 cab of a tractor, spraying pesticides. We have 24
19 volts or 48 volts, a 12-volt system right there.
20 Why can't we plug into that?

21 So in this new PAPR concept, we are trying
22 to incorporate an alternative or external power

1 supply, and you would be able to use that for
2 tight-fitting or loose-fitting.

3 You see in red here some of the questions
4 that we are asking. What type of power limitations
5 should we have? Should we restrict it to a certain
6 type of power, or should we leave that open for the
7 market and let the market drive that power
8 requirement?

9 Type of connections is something a lot of
10 people have worried about. Will a connection that
11 we authorize actually fit into cigarette lighters or
12 other things like that.

13 So one of things we want some comments on
14 is the type of connection.

15 In the PAPR, as we look at tight-fitting
16 PAPRs, they always have -- should have, may have an
17 escape capacity to them.

18 If you have an external power supply, but
19 you have to have an escape capacity, you are going
20 to be required some type of battery. Probably a
21 15-minute emergency battery to be added on there.
22 And that would need to be something that

1 automatically converts over, switches over to that
2 battery so that you would not lose any kind of
3 protection in there.

4 Another area that we have had a lot of
5 comment on. I think we have tried to work on this
6 in the past a little bit. And some units out there
7 right now already have this type of indicator. It's
8 a power indicator.

9 The user needs to know, as he looks down,
10 he needs to know what his status is of his battery
11 or his external power supply, if that's what he has
12 on there. He needs to know how much he has
13 approximately.

14 Now, I believe this needs to be a
15 real-time measurement that specifically monitors and
16 predicts information to that indicator, kind of like
17 your cell phone.

18 When everybody opens up their cell phone,
19 they see that little battery display up there. You
20 can see it go up and down. And you know, when you
21 open it up, you have a certain battery.

22 But then as you start using it, punching a

1 bunch of numbers, sending some emails, you start to
2 use that battery a little quicker.

3 Well, that's what should be on a PAPER, I
4 think. There should be some kind of indicator there
5 that tells that user how much battery life he has
6 left.

7 It also should alert him at the point
8 where there's about 15 minutes left. Now, is 15
9 minutes the right number? Maybe. Maybe not.

10 We should be able to get some docket
11 comments on that to see if that's a good number.

12 But there should be something that alerts them that
13 their battery is getting low and it is about to go
14 away.

15 That should be able to take care of it,
16 whether it's the lowest temperature or the highest
17 temperature resistance.

18 If it's a feedback mechanism, it should be
19 able to monitor that and predict that.

20 Now, again, when we do the test, we would
21 do it specific to a breathing rate or work rate on a
22 headform with a breathing machine. So in the test,

1 it would be very consistent. And we would be able
2 to measure that 15 minutes or 30 minutes, whatever
3 it comes out to be, to see that that alarm does go
4 off, it does alert the user.

5 Low flow pressure indicator, we have had
6 quite a few meetings on this. We went back and
7 forth. The main thing you will see from the concept
8 paper that you have right now, what is up here, is
9 at all times, we use flow/pressure.

10 That indicator is just like I have said up
11 here. It needs to be able to alert the user when
12 this particular PAPR has insufficient power, whether
13 that be flow or pressure, to maintain that
14 protection inside the facepiece.

15 And so a low pressure alarm is what we
16 look at in the laboratory because we can measure
17 pressure much, much easier than I can measure flow
18 inside of a PAPR, whether that be inside the
19 facepiece.

20 If I'm measuring flow, you can measure
21 that flow in the tube, in the facepiece. It just
22 kind of gets convoluted on how exactly you would

1 measure that flow.

2 So measuring a pressure is much easier.

3 You can put a pressure transducer in the breathing
4 zone or anywhere else on the headform, and I can
5 measure that pressure.

6 So an indicator needs to be there on the
7 PAPR. It needs to be on all PAPRs. This would be
8 another part of the base requirements. And it would
9 measure and alert the user when the positive
10 pressure is no longer there.

11 Now, the manufacturer can do that by flow
12 if that's the way you want to do it. That's why it
13 always says flow and pressure, flow/pressure.

14 We will go over a little bit to the
15 respiratory inlet covering.

16 The main thing we are kind of bringing out
17 here, which is new, would be lens must meet the ANSI
18 standard for high impact. If they do not -- and
19 this would be for all types of facepieces, whether
20 it be loose-fitting or a tight-fitting, whether it
21 be a permanent solid facepiece or eye lense
22 covering, or whether it be a semiflexible or

1 completely flexible one.

2 It should either pass the high impact test
3 or be prominently marked, Not Impact Resistant.
4 This way the users could look at PAPRs and know that
5 they have the impact resistance unless they
6 specifically read that it does not have impact
7 resistance. So that's something we are going to
8 require.

9 A second here to catch up on my notes.

10 Service life testing. Here's another area
11 that you can have a lot of fun when you go into
12 meetings.

13 Not everyone agrees perfectly why service
14 life testing is done in a certain way. So I'm going
15 to kind of talk about a little bit what's in the
16 concept paper first and the way it's laid out. And
17 then I'm going to put in another concept that we
18 were looking at as far as doing.

19 Service life, capacity testing, you are
20 probably going to hear me use those interchangeably.

21 So the main thing for service life
22 testing, when have you figured out what that

1 concentration is that we are going to test against
2 and the time and the breakthrough, everybody is
3 concerned about flow. This seems to be the point
4 that we really need to look at a little bit with a
5 little bit more detail, I think, is the best way to
6 put that.

7 Again, if we look at these new types of
8 PAPRs that are coming out, we have tight-fitting.
9 We have loose-fitting. We are going to have
10 different flow or breathing rates that they can
11 have, a low, a moderate, and a high. We have breath
12 response units. They all work a little bit
13 different.

14 One of the things that I keep hearing is
15 that a constant flow PAPR really responds to the
16 breath of an individual user. All right.

17 And we have seen -- and I have showed this
18 data -- if you put it on a breathing machine, even
19 though it's constant flow, you turn it on. Yes, you
20 do see a breathing pattern, all right. And it is
21 consistent to what the breathing machine is doing.

22 But that works -- a constant flow usually

1 has a higher flow, even though it alternates up and
2 down with the breathing, different from a
3 breath-response unit. Remember, a breath-response
4 unit is a unit that electronically controls that
5 blower to slow it down and speed it up based on that
6 user's breath, based on the response.

7 So they have a lower -- normally, they
8 have a lower average flow based on a specific
9 breathing rate, whether that be low, moderate, or
10 high.

11 So for right now you can see that we would
12 perform service life testing for a system based on
13 this chart. Tight-fitting, moderate, traditional
14 115 liters per minute. Constant high flow, 270
15 liters a minute.

16 Again, this 270 and 325 is some numbers
17 that we really need to look at and investigate.
18 Docket comments would be very useful to see are they
19 too high, too low. What do we need to do with them?

20 And this concept for breath response unit
21 would be measured at a breathing rate, whatever the
22 breathing rate is the manufacturer comes in with,

1 whether it is moderate, whether it is high.

2 If he says it can do high, then we would
3 put it on at 86 liters a minute, and we would
4 measure that breathing rate.

5 And for that system, we would use that
6 average air flow that goes through there, that
7 average minute volume, use that for testing of the
8 canisters.

9 So in this, the breath response being a
10 new type of unit, does work -- usually works more
11 efficiently. I'm not going to say all of them are
12 because I don't know what else is out there that
13 somebody may be able to manufacture.

14 They usually work more efficiently with
15 their air flow, and so we will probably be able to
16 test those lower.

17 Go through this PAPR -- these are two --
18 actually, this slide and the next slide behind it,
19 pretty busy slides, but I think everybody has seen
20 these before.

21 I specifically marked these as nonCBRN.
22 And the reason I wanted to do that is so you could

1 not get those confused with the ten TRAs that we use
2 for CBRN.

3 CBRN still is that special application,
4 and it will always continue to use the ten TRAs. We
5 don't want to get that confused with this slide,
6 which is for cartridges, and the slide for
7 canisters.

8 Out of this PAPR concept, you will be able
9 to come in, as you have done right now, and ask for
10 ammonia protection and get just specifically ammonia
11 protection, or any of the other gases that are
12 listed on these charts.

13 For right now, these are the test
14 concentrations, the breakthroughs, and those service
15 times. All right? Don't get these confused with
16 the CBRN, which has a service time of -- set up in
17 capacities of 15-minute increments.

18 One of the things we are looking for here
19 on this PAPR concept is an understanding if these
20 chemicals are the right chemicals to have. Those
21 are the protections that are really needed.

22 We are looking for docket comments, are

1 there additional gases that you would like to see
2 that we run, that we have on this table so they are
3 always there, people will be able to ask for.

4 You can see a lot of those have come from
5 the TRAs used in CBRN, nitrogen dioxide. I think
6 for there, we used the same type of breakthrough
7 that we did for CBRN.

8 One of the things I want to point out,
9 under the PAPR concept, we see organic vapor.
10 Traditionally, organic vapor has been done with
11 carbon tetrachloride. That was the organic vapor.

12 For this PAPR concept, we would like to
13 step away from carbon tet -- many different reasons
14 for that -- and go to cyclohexane. Now, we have
15 already done that for CBRN, but for the PAPR
16 concept, this industrial type PAPR also, we would
17 like to go with cyclohexane.

18 I'm not sure what type of studies we are
19 going to need to be able to go over there. I know
20 there is some work being done in NPPTL about that.
21 If you have specific comments, please send those
22 into the docket.

1 PAPR concept, we are really looking at
2 following along with what we did with CBRN and
3 getting rid of the temperature and humidity
4 equilibration for canisters and cartridges. And we
5 would go to service life testing at high humidity
6 and low humidity.

7 I'll go over this pretty quickly because,
8 really, we haven't put it out yet in any kind of
9 documentation where you could really see what we are
10 looking at and see kind of how we have come up with
11 this.

12 But an alternative concept to service life
13 testing is to step away from kind of the traditional
14 look that we have now, which is either a canister or
15 a cartridge, and we would go to strictly a capacity
16 testing.

17 And for this -- this is just a concept we
18 are bringing out. We would like comments on it.

19 We would use one concentration for a
20 chemical. We will take ammonia, for instance. We
21 would use one concentration and one flow and test
22 the capacity of that canister or cartridge, whatever

1 it is. And we would label those as some type of
2 differentiation between them, whether it be a high
3 capacity, low capacity, whether we keep it the
4 terminology of canister or cartridge.

5 One thing we are concerned about is
6 getting that -- if we go with this route, getting
7 that confused with a Cap 1. So it would have to
8 have some other type of terminology.

9 But this is an example of what we could
10 come up with.

11 For ammonia, you would test everything at
12 2,500 PPM. We will say, for an air flow, 170 liters
13 a minute. For a lower capacity, you would do that
14 for 15 minutes. For a higher capacity, you would do
15 that for 60 minutes.

16 Now, these times are just examples right
17 now, 15 to 60 minutes. We could have more
18 capacities, less capacities -- I guess you couldn't
19 have less capacities, but you could have more
20 capacities than that. You could work it in
21 30-minute increments.

22 So with some docket comments on these

1 times, that's something we would like to see.

2 Now, this is not laid out in the September
3 19 concept right now. Hopefully, in our next
4 iteration of the concept paper, we will have this
5 alternative out there. I'm hoping to write some
6 other type of document, like a white paper, so we
7 can show some calculations on what we have looked
8 at.

9 Some other areas of the research that we
10 are continuing in, as I mentioned, the organic vapor
11 going to cyclohexane. Want to make sure we have the
12 correct research done for that to prove that we can
13 do that.

14 Acid gas, right now we do an acid gas for
15 canisters only. We would like to see if those
16 families of acid gas can be used with cartridges and
17 canisters. We would like to expand that a little
18 bit.

19 If you look at our CBRN and what we did
20 with that for the APR, we really developed a lot of
21 families there. So some other research needs to
22 continue to see if we can carry on those families

1 from that CBRN and move that into PAPRs so that you
2 wouldn't have to come in and do ammonia and
3 methylamine. You would just do ammonia, and it
4 would represent that base family.

5 So that's some research that we would like
6 to continue to do. We are thinking about that.
7 It's not in a concept right now.

8 Approval for tear gas. Quite a few people
9 have asked for this. If you have a full-face
10 tight-fitting respirator, would you need to perform
11 the CS test and the CN test?

12 We think that we should be able to have it
13 meet the cyclohexane, which would be the organic
14 vapor and the P100 requirement, and that would be an
15 approval for tear gas.

16 Carbon monoxide is listed in the concept
17 paper. I'm not sure if there is really a demand for
18 carbon monoxide testing against a PAPR. There
19 doesn't seem to be a demand out there. We could
20 take that out.

21 Any kind of comments you would like,
22 please send those in.

1 Additional gases and vapors, you will see
2 a large list of how that can be done, more detailed.
3 The main thing to remember there is NIOSH still has
4 a final authority when you come in and ask for an
5 additional gas.

6 Failure mode and effects analysis is
7 something that will be required. We will be
8 covering this later on, probably not in this public
9 meeting, but later public meetings. We are still
10 developing that.

11 But it looks like for now, a PAPR
12 submitted for certification will need an FMEA.
13 These are the minimum requirements right now. Now
14 those could change very much, and we really haven't
15 decided exactly how we are going to require that.

16 I will go through some additional
17 applications specific areas pretty quick.

18 The first one CBRN, everybody likes to
19 talk about that. Tight-fitting 14G. It is going to
20 really follow along with what we have done prior.
21 The 10 TRAs with the DOP, LRPL, live agent testing,
22 and durability conditioning for live agent.

1 Loose-fitting is going to follow the same
2 thing. Now, remember, they are going to have to
3 follow the base requirement, all of the power
4 indicators, the air flow indicators or pressure
5 indicators. They have to have all of that, and then
6 this additional testing to get them a -- an LCBRN
7 would be a loose-fitting CBRN responder. That would
8 be the loose-fitting 23C.

9 Again, as you can see, it follows along
10 with what we have done right, which is the 10 TRAs,
11 the LRPL, the live agent testing.

12 LRPL, we are going to cover that a little
13 bit later. Really, we should be able to drop LRPL
14 and move towards TIL in the future. That concept is
15 out there and is going to be discussed later on
16 today. It does go through formal rulemaking.

17 We hope that also as we develop the TIL,
18 we may be able to get rid of the isoamyl acetate
19 testing. But that's still a concept out there.

20 Multifunction PAPER, Tim is going to get up
21 and speak about that.

22 These are other application-specific

1 requirements that, if you look on that -- concept
2 papers out there right now, there is no information
3 about that. It says to be determined or to be
4 written later on.

5 So what we would like is some more
6 comments on what we could have underneath hospitals,
7 clean rooms, for law enforcement, what kind of
8 specific tests they would need for that.

9 Again, this is the docket comment number,
10 008. I hate to say it, but I would gladly answer
11 any questions that you have.

12 No questions, even better.

13 Please turn that microphone on.

14 MR. METZLER: In a formal rulemaking
15 process, the agency is required to provide an
16 explanation, rationale for why comments were
17 accepted or rejected for leading to the final
18 standard.

19 How do you intend to handle comments that
20 are being placed on the docket during this
21 conceptual phase? Will they actually be accumulated
22 and then just handled under the formal docket for

1 the rulemaking process?

2 MR. THORNTON: That's a very good
3 question.

4 Can you tell us your name, when you come
5 up to the mic, name and -- we want to make sure we
6 know who was asking.

7 MR. METZLER: Rich Metzler with the SEA
8 Group. It's a little more nervous on this side of
9 microphone than up there.

10 MR. THORNTON: I'm sure it is.

11 That really wasn't for me. That was for
12 our -- a person over here that's recording
13 everything, so they know who it is.

14 I'm not sure how we intend to handle that,
15 just don't know at this point either.

16 So we will address all comments -- really,
17 I don't think we have come up with that question
18 yet. How we are going to do that, I'm not sure, but
19 all comments would be looked at for formal
20 rulemaking.

21 MR. METZLER: I think the comments he
22 presented today are an improvement over the

1 September 19 document that is posted. So, you know,
2 I would encourage the update to be published as soon
3 as possible.

4 And the last question is, do you intend to
5 use the ISO work rates so that when some of your
6 testing, where the manufacturer can submit an
7 application where you define what work rate you want
8 your respirator tested at, are you considering to
9 use the new ISO work rates that are being developed
10 under the physiology committee?

11 MR. THORNTON: I think -- we have three
12 work rates, and ISO has eight or nine. So they have
13 more detailed work rates than we do.

14 I think if we look at ours -- too close or
15 too far away, the 21 for the low, the 40 for the
16 moderate, and the 86 for the high is very similar to
17 what ISO -- three of the standards ISO has right
18 now.

19 But, you know, exactly how they match up,
20 I'm not sure yet.

21 So, especially with the 21 and the 86, we
22 would like comment on that. The 40 is kind of

1 locked in. NIOSH has used that traditionally for
2 quite a while.

3 But the 21 and 86, we would be willing to
4 look at ISO to see if we could match up with those.

5 MR. METZLER: All right. Thank you.

6 Terry, you did a great job.

7 MR. THORNTON: Thank you.

8 MR. SZALAJDA: I wanted to add something
9 on Rich's original question.

10 One of the things I think that we have
11 tried to be sensitive to when you -- with the
12 docket, dockets have been set up for CBRN primarily,
13 at least as far as going through and assessing them
14 as part of our process for making decisions on the
15 performance requirements for the respirators.

16 I think the one thing that is advantageous
17 that will come out with the rulemaking that,
18 depending on how we resolve comments that are
19 developed in the concept phase, that the user, the
20 stakeholder community will still have the
21 opportunity during the rulemaking phase, if there
22 are elements of performance that you think we should

1 consider or did not consider as part of the process,
2 that at that point in time, if you feel a comment
3 that wasn't made or a comment that was made during
4 the concept phase wasn't adequately addressed, you
5 know, that type of issue could be resurrected and
6 reissued as part of the formal comment phase.

7 MR. HEINS: It is Bodo Heins speaking from
8 Draeger Safety in Germany.

9 I have problems in understanding your
10 service life when it is tested against gases and
11 vapors.

12 First thing you say that minimum
13 requirement for PAPR is two hours. I think it is
14 much too low because a PAPR will be used for a
15 long-term usage, and two hours is nothing.

16 But even if you say then, at least the
17 service time has to be two hours, how can the
18 minimum requirement then be 24 minutes when the
19 test -- the canister is tested?

20 MR. THORNTON: I think there is two
21 different things that we are talking about, a
22 battery life. And in that 19 September concept

1 paper, it may -- it is kind of confusing when you
2 talk about service life.

3 What I would like to do is distinguish
4 service life testing. That's for the canister
5 specifically and how we do a minimum service life
6 for that, distinguish that from the battery.

7 The battery would have a minimum two-hour
8 battery life, and that would be two hours that would
9 operate the PAPR.

10 And then separate from that is the
11 canisters. And they are tested dependent upon the
12 chemical, whether it is a canister or a cartridge.
13 Some are 24, 12, 50 minutes, 60 minutes, so they
14 have many variations. But that's chemical
15 dependent.

16 I think switching out batteries is
17 something that the user should be able to do
18 regardless of what kind of service life there is for
19 a canister. I think it would be very difficult to
20 try to match up service life of canisters or
21 cartridges specific to the operational life of the
22 battery.

1 MR. HEINS: Two hours are nothing for
2 batteries -- in our opinion, our opinion, the PAPR
3 should last at least one shift, which is probably
4 eight hours.

5 So, okay. My next question is if you are
6 testing the breath control units with an average of
7 the highest work flow rate, then I think it is a
8 disadvantage for these units. Because these units
9 are breath controlled to reduce the flow through the
10 filter to increase the service lifetime.

11 And if you test some with a maximum
12 average air flow, then it's not testing in
13 accordance of the technique of this unit.

14 MR. THORNTON: That's a good comment. We
15 will take that into consideration.

16 That is something that we need to look at.

17 MR. HEINS: Okay. That's it. Thank you.

18 MR. PFRIEM: There is nobody behind me, so
19 that means I have all the time in the world; right?

20 MR. THORNTON: Well, we are going to get
21 hungry soon.

22 MR. PFRIEM: The first question is, a lot

1 of the things that you presented weren't in the PAPER
2 concept paper.

3 And if we want to comment on those
4 alternatives, and slides weren't provided in the
5 handouts, could we get a copy of your presentation
6 so we can comment on your alternatives as well?

7 MR. THORNTON: Yeah. I'm not sure how
8 quick we are going to be able to get that out.

9 MR. HOFFMAN: Yeah, we can do that. But
10 they are also going to be on the web as well, the
11 presentations. Because of the length of them and
12 the number of slides, printing them out became --

13 MR. PFRIEM: So they will be posted on the
14 web?

15 MR. HOFFMAN: Yes.

16 MR. PFRIEM: When?

17 MR. THORNTON: As soon as we can. I don't
18 know how long it actually takes to do that.

19 We think within a week. Is that a fair
20 assumption, Jon, within a week?

21 MR. HOFFMAN: Oh, yeah. It will probably
22 be before that, but a week is --

1 MR. THORNTON: So they should be out there
2 within a week. That's normally when they come in.

3 If we don't make it in a week, ten days,
4 give us a little time to get it out there.

5 MR. HOFFMAN: Dale, while you're there, I
6 want to point out, just in addressing that question,
7 in your handout is a yellow sheet of paper that has
8 all of the docket numbers on it.

9 And it is important that you get the
10 correct docket number with the comment. Because
11 what sometimes happens is the people that are
12 categorizing look at the docket number rather than
13 the text of the material, and your comment could get
14 placed in the wrong docket. If that is the case, we
15 may not see it. We may not know that it goes to
16 ours.

17 Because if you look at the sheet, there is
18 a whole lot of things going on, not all with NPPTL.

19 MR. PFRIEM: And most of the time I will
20 run out of time, and you won't see it, so that's why
21 I come up here and blab.

22 And then I guess there's a typo in a lot

1 of different places in the concept paper because I
2 can't get past the fact that you guys want to allow
3 a loose-fitter at a hundred liters per minute, but
4 you are not allowing tight-fitter.

5 So I asked the question yesterday, why we
6 are not preconditioning cans or units for
7 loose-fitting hoods and helmets, and I didn't get a
8 substantial answer.

9 So I ask this question. Why in the world
10 would you guys put that out there?

11 MR. THORNTON: You mean to allow for a
12 loose-fitting --

13 MR. PFRIEM: You are going to allow a
14 loose-fitting helmet at a hundred liters per minute,
15 but you are going to disallow a tight-fitter.

16 MR. THORNTON: You know, the
17 tight-fitting -- there is kind of that minimum
18 requirement for tight-fitting we looked at, which is
19 the 115 liters per minute. That's what we have
20 right now, and that seems to be a pretty good basis
21 to put that on.

22 So allowing a low flow, or a low unit for

1 tight-fitting just does not seem to fit what we have
2 right now.

3 Now, we are doing that for a loose-fitting
4 yes, but we think that there is a need for that and
5 a demand for that.

6 People who use a loose-fitting, users and
7 manufacturers have come up and said that they use
8 these in a setting where there is not strenuous work
9 going on, not a large activity. They could be
10 sitting still. They could be in some type of chair
11 where they are in the cab of a vehicle.

12 So we thought that we could allow that and
13 be able to do that.

14 Now, if the comments come in that says
15 that's too low of a flow, should not be allowed, we
16 will take that into consideration.

17 So we will have to look at that.

18 MR. HOFFMAN: There has been a lot of
19 interest in the medical community to have a small
20 battery, short-term filter, particulate filter only
21 unit in loose-fitting, and we are trying to address
22 those needs so that they don't have to carry a big

1 battery for something that may be a 15-minute
2 procedure.

3 And like Terry pointed out, we are still
4 looking into all of those things. And I don't think
5 that we have actually said that we will not consider
6 a tight-fitting, low flow, but there doesn't seem to
7 be any need for it or any interest in it at this
8 point. So we don't want to put things in there that
9 will -- like a type A or type B supplied air
10 respirator where nobody cares about them anymore,
11 nobody will ever do anything with them.

12 MR. PFRIEM: Understand. And I can
13 support the thought process, that it's -- it could
14 be feasible as long as we have good fit testing
15 protocols to allow for a hundred liter per minute
16 unit on a loose-fitting.

17 But on the reverse side of that, I don't
18 agree in the thought process, like you guys don't
19 think that PAPRs, loose-fitting, are going to be
20 handled delicately in the CBRN world where you don't
21 think it is going to be needed on a tight-fitter.

22 So that's my thoughts.

1 MR. HOFFMAN: Why the conditioning for one
2 versus the other.

3 MR. PFRIEM: He addressed that yesterday.
4 I just don't happen to agree.

5 MR. THORNTON: I think we got that one.

6 MR. PFRIEM: Okay. And the maximum
7 average flow rate, when you guys put this out to the
8 next version, if you could define that a little bit
9 more clearly as far as -- because it's maximum
10 average flow rate as specified by the manufacturer.
11 All right.

12 So then the manufacturer is going to have
13 to, at least in my opinion, provide some data on how
14 that maximum average flow rate was derived.

15 And then I'm thinking NIOSH should set
16 some kind of protocol boundaries on how that -- how
17 these things should be derived.

18 MR. THORNTON: Yeah, I think there may be
19 a little confusion there.

20 I think when we are saying, let
21 manufacturer specify that, they would specify one of
22 those breathing rates, a low, a moderate, or a high.

1 And we would measure that average flow using that
2 breathing --

3 MR. PFRIEM: Using the notated values?

4 MR. THORNTON: Yes.

5 MR. PFRIEM: So the terminology maximum
6 average flow rate as specified by the manufacturer,
7 I can ignore that?

8 MR. THORNTON: Whether it specifies the
9 high or the low or the moderate.

10 MR. PFRIEM: Got it. Excellent.

11 MR. THORNTON: And then we would measure
12 that.

13 That information, the next concept paper
14 that comes out, I will try to get that information
15 out there of how that measurement will be made.

16 MR. PFRIEM: Okay. And then, you know.
17 You had two. You had an alternate in the way it is
18 presented here, but I can't wrap my head around how
19 you guys are normalizing pressure when you're
20 shoving 250 liters a minute, you have got an 86
21 liter per minute breathing rate, quote unquote,
22 okay, and you are trying to measure that flow.

1 MR. THORNTON: We are not going to measure
2 flow. We are going to measure pressure.

3 MR. PFRIEM: But you said you are
4 measuring flow in the concept paper.

5 MR. THORNTON: Yes. I tried to clarify
6 that, that we are -- I'm not sure where it says we
7 are going to measure -- we are going to measure
8 pressure. That's going to be our measurement that
9 we --

10 MR. PFRIEM: The alternate scheme, you
11 were going to ensure that there was always positive
12 pressure maintained.

13 But in the concept paper, the principal,
14 you had positive pressure only for a variable for --
15 only for breath responsive PAPRs, but not for -- for
16 nonbreath-responsive PAPRs, at least the protocol as
17 I read it, is flow based.

18 MR. THORNTON: Yes. And we would measure
19 average flow while it was on a breathing machine,
20 whatever that was that the manufacturer came up
21 with, whether they wanted a high, low, or moderate.

22 MR. PFRIEM: So you have got a breathing

1 machine working at 86. You have got a PAPR trying
2 to push at 250. How are you normalizing?

3 MR. THORNTON: That's kind of a detailed
4 answer, and we have talked about that in prior -- I
5 can sit down with you and go over that, how we have
6 done that and how we -- in fact, I think there is a
7 draft standard test procedure out there that I could
8 direct you to that shows how we have done those
9 tests and how we take those measurements.

10 That should help us out quite a bit.

11 MR. PFRIEM: And we are getting to the end
12 here.

13 MR. THORNTON: Good. Because we have got
14 one more presentation before lunch.

15 MR. PFRIEM: On the LRPL, are you going to
16 keep this same number of subjects, same number of
17 samples as the APR STP protocol, because it's not
18 specified in the paper.

19 MR. THORNTON: For the Step 2, or for the
20 PAPR concept?

21 MR. PFRIEM: Yes.

22 MR. THORNTON: I'm not sure. I believe

1 for right now, yes, we would keep the same number,
2 but we may need to re-evaluate that when we move
3 that into TIL.

4 So right now, we don't have a specific
5 answer for that except yes, that's what we are
6 looking at, keeping the same amount. But that could
7 change.

8 MR. PFRIEM: Okay. And then there was one
9 more, if I can find it.

10 You are specifying two conditions for the
11 end-of-service-life tests.

12 You're testing 25 and 85 percent RH, and
13 then you say at two contamination levels, but you
14 don't say what those contamination levels are.

15 So if I'm testing for a manufacturer
16 ammonia service life, okay, and you have got it down
17 25 and 85 percent, but then you are saying, you
18 know, two contamination levels.

19 What are the contamination levels?

20 MR. THORNTON: I will have to talk with
21 you on that because I'm not sure what -- you will
22 have to show me where that is in there.

1 That doesn't sound familiar.

2 MR. PFRIEM: And then Annex A for the FMEA
3 that's referenced, but not here, is that going to be
4 available? Or at least I couldn't find it.

5 MR. THORNTON: It will be -- I didn't know
6 it wasn't out there, so, you know, we are going to
7 have to get that appendix out there.

8 MR. PFRIEM: That's it. Thanks.

9 MR. THORNTON: Thank you.

10 MR. VANDERWOUDE: Brian VanDerWoude from
11 Stryker Instruments.

12 My question is in regards to the
13 filtration efficiencies that are presented as
14 approvable in the draft standard.

15 You currently offer a P95 and a P100
16 equivalent for the powered -- for the PAPRs.

17 MR. THORNTON: Yes.

18 MR. VANDERWOUDE: I wonder why you don't
19 offer an N95 equivalent.

20 MR. HOFFMAN: I'll comment on that one.

21 Actually, we are using the DOP for what we
22 are calling the PAPR 95, but it's an instantaneous

1 DOP test. And the data we have shows that if you do
2 it -- it's a 30-second test, because the DOP really
3 doesn't have a degrading effect in that short of a
4 time.

5 The 100 series is actually the full test
6 with the full loading. And the interest seems to
7 have been to this point that people only care about
8 one or the other. There doesn't seem to be much
9 need or interest of anything else we have like we do
10 in the non-powered one.

11 That's not to say we won't consider them,
12 but up until this point in time, there hasn't been
13 any interest. We don't want to do the test at high
14 flows with salt because it is just too hard to
15 maintain and control the instrumentation.

16 MR. VANDERWOUDE: The concern is the, in
17 the healthcare environment, the recommendation from
18 CDC is often an N95 or better. And then the
19 filtration media options are greater at that rating.

20 And that's our interest in pursuing the
21 N95 option for a powered air respirator.

22 The other comment is in regards to

1 filtration -- or no, flow rate.

2 MR. THORNTON: I'm sorry. Can you say
3 that again. Into --

4 MR. VANDERWOUDE: In regards to flow
5 rates, our customers typically are asking for more
6 flow rate than what would be covered underneath your
7 standard, so a higher flow rate.

8 What you are saying about possibly not
9 requiring a flow rate but only requiring positive
10 pressure, I would be highly in favor of that so we
11 could offer a higher air flow rate to our customers.

12 Since ultimately what matters is that
13 there is positive pressure in, that their CO2 level
14 is not excessive, and as long as you can keep the
15 noise levels appropriately underneath your other
16 requirements, the air flow rate is not significant.

17 MR. THORNTON: Very good. Thank you.

18 We have time for one more, and then we
19 will to start this next presentation.

20 MR. SOLYNTJES: I hope this will be quick.

21 Alan Solyntjes from 3M.

22 Can you comment on why you have limited

1 single level blowers, the single flow levels, to
2 only the middle flow?

3 Why would there not be -- allow -- why
4 would not allow a low flow single setting blower?

5 MR. THORNTON: Well, for tight-fitting, I
6 think we have already had that discussion, whether
7 we were going to look at that or not.

8 And I -- in the concept, as I think about
9 that concept paper and the way it is written, we may
10 have left out a single flow blower that just
11 establishes a high as opposed to any of the other
12 flows.

13 I think we do -- we are going to allow
14 those. I just don't think it is written.

15 MR. SOLYNTJES: So a single flow, low flow
16 loose-fitting might also be --

17 MR. THORNTON: Yes. Yeah.

18 MR. SOLYNTJES: Okay. Thank you.

19 MR. THORNTON: All right. If there is no
20 other questions, thank you.

21 I'm going to present Tim Rehak. He is
22 going to cover the multifunction PAPER and the

1 research that is going on with that.

2 MULTIFUNCTION POWERED AIR PURIFYING RESPIRATOR

3 MR. REHAK: Okay. Good morning. My name
4 is Tim Rehak. I'm the project officer of the
5 Multifunction Powered Air Purifying Respirator
6 contract.

7 Okay. The goals of the contract are to
8 develop new comprehensive test standards for hearing
9 protection, head protection, eye protection along
10 with respiratory protection for multifunction PAPRs.

11 Okay. This contract is funded by NPPTL.
12 It's a multiyear contract that we have with the
13 University of Maryland's Human Performance
14 Laboratory.

15 The principal investigator for the
16 contract for the University of Maryland is Dr. Art
17 Johnson, and he has a long history of research in
18 all wearability issues of respirators. And I guess
19 the unique thing with his research is he takes a
20 bioengineering approach to his projects.

21 This contract is -- MSHA is collaborating
22 with us and our stakeholders besides the equipment

1 operators, is BCOA, the National Mining Association,
2 along with the unions, the UMWA.

3 Okay, briefly, I'm going to go over a
4 summary, after all of the testing and research that
5 the University of Maryland has conducted for this
6 contract.

7 Okay. First, they did testing on exercise
8 performance while wearing a tight-fitting PAPR with
9 limited air flow. Okay. For this testing, 16
10 subjects were tested at 80 to 85 percent of their
11 VO2 max while wearing a tight-fitting PAPR.

12 And the power supply was changed to
13 produce 100 percent, 94 percent, 66 percent, 30
14 percent and zero percent of a 110 liters per minute
15 flow.

16 The results that they came up with,
17 inadequate blower flow rate decreased performance
18 time, facial cooling, and respirator comfort.

19 If you want more information on this
20 research, it was published in the July 2005 issue of
21 the Journal of Occupational and Environmental
22 Hygiene.

1 The next testing they conducted was
2 overbreathing a loose-fitting PAPR.

3 Here, 16 subjects were tested, again, at
4 80 to 85 percent of VO2 max while wearing a
5 loose-fitting PAPR in a portable breathing chamber
6 that they developed. That's it there.

7 All subjects exceeded the PAPR flow rate.
8 17 percent of the breathing volumes exceeded 1.4
9 liter dead volume that they measured inside the PAPR
10 visor.

11 All instantaneous corrected flow rates
12 were above 38 liters per minute. 30 percent were
13 above 150 to 158 liter per minute range. And a
14 small portion, approximately 1 percent of the flows,
15 were in the 520 to 558 liters per minute range.

16 Again, this research has been published in
17 the ISRP Journal, the spring/summer 2005 edition.

18 Inhalation flow rates during strenuous
19 exercises, the subjects were measured under the
20 following conditions:

21 Twenty-four were tested without a
22 respirator at 80 to 85 percent VO2 max with a peak

1 inhalation flow rate of 379 liters per minute. Nine
2 were tested without respirator at 100 percent VO₂
3 max with a peak inhalation flow rate of 440 liters
4 per minute.

5 Ten were tested while wearing a PAPR at 80
6 to 85 percent VO₂ max with a peak inhalation flow
7 rate of 679 liters per minute.

8 Conclusions they draw. A linear
9 relationship was found between the peak flow rate
10 and the average minute volume, which we began to use
11 to produce peak flow rates expected at any given
12 flow rate.

13 This research was published, again, in the
14 ISRP journal, fall/winter 2005.

15 Okay. They did some testing that
16 determined the effects of helmet weight on volume
17 performance time at 80 to 85 percent of maximal
18 aerobic capacity.

19 Ten subjects were tested with four
20 helmets -- the weights are listed up there -- while
21 walking on a treadmill to produce 80 to 85 percent
22 of their VO₂ max. The results that they came up

1 with show that the performance time in minutes was
2 literally related to the helmet mass.

3 There's the equation right there. I'm not
4 going to have to read it to you. And this research
5 has been submitted to the Journal of Occupational
6 and Environmental Hygiene, currently hasn't been
7 published yet.

8 They also have been in a process -- I
9 think this started well before our contract, but
10 they are looking to develop a model to predict the
11 physiological and performance features of respirator
12 mask wear.

13 Currently, they are looking with the model
14 to predict oxygen consumption, minute volume, and
15 performance time. And right now, they are at the
16 point where they are pretty accurate with the -- in
17 predicting oxygen consumption and minute volume, but
18 they still have some ongoing work that they are
19 doing to improve the accuracy when trying to predict
20 performance time.

21 And the goal, again, is to predict
22 performance time and physiological responses for

1 respirators in the preprototype stage of
2 development.

3 Okay. They have done testing on a
4 correlation between personality type and performance
5 time while wearing a respirator.

6 Here subjects perform at 80 to 85 percent
7 VO2 max while wearing a modified M-40 respirator to
8 create various inhalation resistance at 85 liters
9 per minute, and all 31 subjects were tested using
10 the Myers-Briggs type indicator and the State-Trait
11 Anxiety Inventory.

12 The results that they came up with, when
13 air intake resistant is the highest,
14 sensing-intuition and thinking-knowing (sic) versus
15 performance time was found to be statistically
16 significant.

17 If you need more information on this, this
18 has been published in the June 2006 edition of the
19 Journal of Occupational and Environmental Hygiene.

20 They have been doing work on a flow
21 visualization. First, on the loose-fitting PAPR.
22 Two loose-fitting PAPRs were fitted on a headform

1 and connected to a breathing machine.

2 A modified portable breathing chamber
3 contained all of the fog that was generated. And
4 during the testing, the images were captured just
5 using a basic video recorder.

6 The results that they came up with, about
7 1.4 liters of protective volume was observed to be
8 inhaled before the fog was able to reach the mouth
9 of the headform.

10 Items of interest that they came -- also
11 noticed during the testing included that head tilt
12 affects the protective volume that the PAPR
13 provided. Also the racial fog was present inside the
14 face shield at all times, even when there was no
15 breathing.

16 And third, the fog reached the mouth
17 quicker when you had a PAPR without a scarf. 1.2
18 liters of air was inhaled without a scarf compared
19 to 1.4 liters when the PAPR had a scarf. And this
20 testing has been submitted to the ISRP for
21 publication.

22 Okay. Protective volume inside the

1 loose-fitting hood.

2 This was done in a full body chamber which
3 they developed in their lab there. It was
4 fabricated to test how much air must be inhaled
5 before the fog reached the mouth with the blower
6 off.

7 With the blower at 110 liters a minute,
8 the breathing machine was set at 30 beats per
9 minute, tidal volume, 2.21 liters. Total
10 overbreathed volume was measured at about one liter,
11 and no fog was evidenced.

12 The results they came up with was there
13 was two liters of protective volume.

14 Okay. Also, flow visualization with the
15 tight-fitting PAPRs. Here they tested two different
16 tight-fitting PAPRs in a full body chamber.

17 They used a bronchoscope to observe when
18 the fog was actually entering the mouth. And they
19 broke down their videos, you know, frame by frame so
20 they could tell it down to the second. And also
21 they measured leak volumes.

22 The results showed that no fog was

1 visualized at the mouth, but they did detect leak
2 volumes.

3 With the one unit, it was .26 to .28
4 liters, on or off. And with Unit B, it was .02 to
5 .09 liters on, and .26 to .28 liters when the unit
6 was off.

7 They also detected a possible leak. They
8 weren't sure at the time from the face seal or the
9 exhalation valve. And this research they have
10 submitted to the Journal of Occupational
11 Environmental Hygiene.

12 Since they discovered that there was some
13 leakage here, they did some further testing to see
14 if it was from the face seal or from the exhalation
15 valve.

16 They discovered through testing that both
17 face seals leaked approximately .05 liters.

18 Unit A, the exhalation valve closed within
19 .16 seconds with about a hundredth of a liter of air
20 entering only when the blower is overbreathed on
21 this PAPR.

22 With the other PAPR, Unit B, the

1 exhalation valve open and closed three times
2 throughout the entire breathing cycle.

3 They have conducted human testing of
4 loose-fitting PAPRs in a full body chamber. So far,
5 they tested 12 subjects to date.

6 The preliminary data that they came up
7 with shows that from one to 1.3 liters needs to be
8 inhaled before the fog would reach the mouth. And
9 also that the pathways were similar with human
10 testing as they were with -- while using the
11 headform.

12 And finally the remaining work, they are
13 doing work for us now to check or test on the CO2
14 buildup within the PAPRs, both loose-fitting and
15 tight-fitting PAPRs.

16 They are going to do this work in the full
17 body chamber. And the breathing machine's inhaled
18 air will be instantaneously analyzed for CO2
19 concentration to determine actual overbreathing.

20 And, finally, all of this research and all
21 of the reports, the testing that the University of
22 Maryland did for us, it will be submitted to us in a

1 final report. We will have it peer reviewed, and it
2 will be a NIOSH numbered document.

3 If there is any questions -- if not, we
4 can go to lunch.

5 Okay. Thank you.

6 MR. BOORD: Okay. So we will break for
7 lunch. And I think, according to the agenda, we
8 will resume at 1:15.

9 So that leaves a little over an hour,
10 about an hour and 25 minutes. Thank you.

11 (A luncheon recess was taken.)

12 MR. HOFFMAN: Okay. If we can get
13 started. For the afternoon session, there's a lot
14 of topics that we need to cover. And I did want to
15 mention that for the policy and standards groups,
16 there is a lot of areas we are working on, and some
17 of those include guidance documents.

18 CBRN, we continue to develop and improve
19 the test procedures and tweak things that we need in
20 that area.

21 Combination units are going to be talked
22 about, supplied air respirators, closed-circuit

1 SCBAs, closed-circuit escape respirators a little
2 bit. We have talked about the PAPRs. Total Inward
3 Leakage, QA and administrative module.

4 We are going to stay with the agenda. And
5 the only difference in the agenda is a couple of the
6 presenters are different so that we can give the
7 speakers a rest so that the same person isn't
8 speaking through the whole thing.

9 Without delaying the process any further,
10 I would like to bring Frank Palya up who is going to
11 give the first presentation on the Chemical Warfare
12 Agent Simulant Project.

13 CHEMICAL WARFARE AGENT SIMULANT PROJECT

14 MR. PALYA: Thank you, Bill. And I would
15 like to welcome you all to the NIOSH public meeting.
16 I'm going to be discussing the Chemical Warfare
17 Agent Simulant Project.

18 Back in April of 2001, when NIOSH said
19 that they were going to use actual chemical warfare
20 agents to do certification testing, the stakeholder
21 community requested that we develop simulants so
22 that the manufacturers could go ahead and do a lot

1 of their in-house testing without going -- and
2 testing their products in-house.

3 Because a lot of this testing, the live
4 agent testing is very expensive and requires a lot
5 of lead time.

6 We partnered with NIST and RDECOM on this.

7 Most of the experiments were performed at
8 Natick, and -- mainly the simulants were performed
9 at Natick and Edgewood chemical biological center,
10 and that's where the agent testing was done.

11 The project goals were to identify
12 compounds to simulate the permeation effects of the
13 GB and HD through elastomeric barrier materials.
14 Also, the goal was to develop a standardized method
15 that can be used by the stakeholders to measure
16 simulant permeation times with the identical method
17 that was employed with the HD and GB.

18 This would provide stakeholders with a
19 readily accessible low cost screening method to
20 evaluate their material, how it resisted agent
21 permeation by testing it with simulants.

22 And this would also allow the stakeholders

1 to rank their materials. And then whatever
2 materials performed best, then they could go ahead
3 and perform actual live agent testing.

4 The accomplishments -- Phase 1 has been
5 completed. And I would like to go ahead and discuss
6 some of the accomplishments.

7 The accomplishments were that we obtained
8 test data using the identical method. We tested --
9 gained information on the GB and HD, with the four
10 simulants using three barrier materials. And these
11 three barrier materials were silicon, EPDM, and
12 butyl.

13 We also performed permeation tests and
14 sorption tests. And we did find the four simulants
15 that we felt that worked the best. And we found two
16 for HD. That's the DCH and the CEPS. And for the
17 GB, the DEMP and the DIMP.

18 We also developed a test method capable of
19 testing liquid permeation resistance. It could test
20 materials up to .7 centimeters thick, and it uses
21 the Flooded Cell Technique. It is -- basically,
22 it's not the whole cell is flooded, but it's just

1 the whole surface is covered and is challenged with
2 simulant or agent.

3 This is a schematic of the permeation test
4 system. It is pretty basic. This is the permeation
5 cell that was developed at Natick. We came up with
6 a new permeation cell, but everything else is pretty
7 much standard equipment.

8 Again, that's a side view of the
9 permeation cell.

10 As you can see, it's -- you have the sweep
11 gas flow through there. That's the detector gas.

12 This is the specimen. This is the film, the agent
13 film, or the simulant film. A Teflon gasket, and
14 then this screws on the top. And the agent is
15 applied in this area right here from the top.

16 This is the actual picture of it with the
17 various components.

18 Another accomplishment is that there was a
19 journal article published in the Journal of Membrane
20 Science in 2005. Also we produced a scientific
21 document entitled Estimating Permeation Resistance
22 of Nonporous Barrier Polymers to Sulfur Mustard and

1 Sarin Chemical Warfare Agents Using Liquid
2 Simulants.

3 The document describes the rationale for
4 the simulant and barrier materials selected. It
5 contains 75 pages of detailed requirements needed to
6 perform the test, including a test procedure.
7 There's the test procedure, data analysis
8 techniques, plots. Also a mechanical drawing is
9 included in there, so respirator manufacturers could
10 build it in their machine shop and use it.

11 So it does contain a lot of information in
12 this report. This document will be published as an
13 official NIOSH numbered document.

14 The status of this document is that it's
15 in external review process. It already went through
16 internal NIOSH review. The document was changed,
17 substantially rewritten. And then it went through
18 NIOSH OD review again, and it was rewritten.

19 So this document has come quite a long
20 ways. So one of the last steps is to have it
21 externally peer reviewed, and it's due back from the
22 external peer review by the end of the month.

1 Hopefully it will be published as a NIOSH
2 numbered document in '07, Fiscal Year '07. Then it
3 will be released.

4 And this is another good example of
5 research to application. There was a Phase 2 part
6 of this project as well, and -- because we liked the
7 results of Phase 1. So -- but we wanted to go ahead
8 and expand this information, so we did this.

9 And part of their project, or Phase 2
10 project goals were to broaden the estimation and
11 reliability of the simulant methodology by
12 evaluating additional barrier materials, including
13 thermoplastics.

14 Develop additional simulants if we felt
15 that it needed to. Determine the quantitative
16 relationship between the flooded cell technique and
17 the conventional drop loading.

18 The conventional drop loading is the
19 technique that is used currently by NIOSH when they
20 are performing the agent testing, and that's ten
21 grams per meter squared.

22 And also determine the sorption/desorption

1 characteristics and to correlate those with
2 permeation results.

3 This information would be good for --
4 would assist in understanding the decontamination of
5 PPE materials.

6 Also, we wanted to identify critical
7 properties that control the permeation of G agents
8 and mustard type agents through barrier materials
9 and improve the capability to predict barrier
10 material permeation just based off of certain,
11 chemical and physical characteristics of the
12 material and the agent.

13 So if we got a broader understanding of
14 the materials and what certain characteristics
15 resist agent permeation, just by studying the
16 material, you may have some idea what material would
17 resist chemical agent permeation without going
18 through testing, just from going ahead and doing the
19 research and finding these certain characteristics.

20 The status of the project is that we have
21 gone through a lot of screening. We have screened
22 over ten candidate materials at one or more

1 thicknesses, and we selected these five right here.

2 But the trouble is a lot of these
3 materials have such excellent permeation resistance
4 that you just can't get any of the data from them.
5 Because you want a material that will break in a
6 reasonable amount of time, let's say between one and
7 eight hours, and -- or you don't want it to break
8 too soon, but you don't want it to break too long,
9 because you need to get it in this one to eight-hour
10 time frame.

11 So it has been quite a challenge to get
12 the materials. You can only get them so thin. But
13 these are the Phase 2 materials that we feel that we
14 are going to go with.

15 A lot of the times, you can't get really
16 get a lot of information from them because they are
17 proprietary as well.

18 Also, there's -- some comparison testing
19 has been completed. The flooded cell versus the
20 conventional droplet contamination. We did that
21 with DIMP and DCH on butyl.

22 And what we found, whether it was the

1 flooded cell or the droplet, basically has
2 essentially the same breakthrough times.

3 Right now we have some interlab comparison
4 tests set up to make sure that what work has been
5 done with the simulant, what test results we got
6 with the simulants will yield the same results in
7 another lab. Basically a round robin test to ensure
8 these results.

9 We also have some agent work scheduled for
10 the ASTM neoprene. And also performed was 17 and
11 sorption/desorption experiments completed for the
12 simulants.

13 In summary, we developed a rapid
14 relatively low-cost laboratory procedure that can be
15 used by manufacturers to estimate chemical warfare
16 agent permeation through candidate materials using
17 simulants.

18 We identified the four simulants, and also
19 we contributed to a peer review journal article in
20 the Journal of Membrane Science. And then there's
21 the NIOSH scientific information document developed,
22 which is going through the external peer review

1 process.

2 So, again, we are expecting comments by
3 the end of October, and we anticipate publication in
4 fiscal year '07.

5 Thank you.

6 And I'll address some questions at this
7 time, if there are any.

8 Okay. Thank you.

9 IDENTIFYING ALTERNATE LIVE AGENT TESTING

10 LABORATORIES

11 MR. PALYA: Well, I'm going to continue on
12 here. There is no use for introductions, so -- I'll
13 get a drink of water, though.

14 I would like to discuss the efforts NIOSH
15 NPPTL has been doing into identifying alternate
16 laboratories for qualification to perform NIOSH
17 chemical warfare agent testing for certification of
18 CBRN respirators.

19 There has been some concern that there
20 was -- we only have one lab, NIOSH only has one lab
21 qualified to perform the live agent testing. So,
22 you know, we started this project to go ahead and

1 find out, you know, find a different lab performance
2 work.

3 So the live agent testing that we are
4 performing, we only used two agents, and that's GB
5 and HD.

6 And also the type of testing that these
7 labs do is they test a NIOSH standard and test
8 procedures development testing. They do CBRN
9 certification testing, and then there is a
10 manufacturing R & D testing program in place.

11 So when we go ahead and qualify these
12 additional labs, there will be three types of tests
13 being performed.

14 The benefits for funding another, an
15 alternate lab is to expand the test capacity in case
16 of a national emergency. The capability is needed
17 to accommodate a surge in CBRN respirator
18 applications, and increased lab availability for PPE
19 manufacturers to perform their R & D testing for
20 their product.

21 Again, we started this initiative in
22 February 2006.

1 The goals of the project were to identify
2 and qualify alternate laboratories that were capable
3 of performing NIOSH LAT testing. Select alternate
4 labs based on a stated criteria that we developed,
5 not NPPTL developed.

6 This is to ensure that CBRN certification
7 testing continues without interruption. So that was
8 a high priority for us. And ensure that these labs
9 are capable of performing NIOSH testing in
10 accordance with our standard test procedures.

11 We contracted EG&G Technical Services,
12 Incorporated to perform this work. And they also
13 brought aboard a technical expert in chemical
14 warfare agents from Georgia State University.

15 The work that -- the results of this work
16 is that they identified two government-owned,
17 government-operated labs. And these labs were
18 surveyed. That was Dugway Proving Ground and Pine
19 Bluff Arsenal in Arkansas.

20 And they also found that there is five
21 contractor-owned, contractor-operated labs. And
22 they were also surveyed.

1 EG&G went out and physically visited these
2 laboratories, and they had a series of questions to
3 ask. And they evaluated them based on this criteria
4 that we established.

5 And these are the five contractor labs
6 contractor-owned, contractor-operated labs that were
7 surveyed.

8 The selection criteria for the candidate
9 labs was -- this pertained to the contractor-owned,
10 contractor-operated labs, was if they had a bailment
11 agreement in place. That was a very important
12 aspect of it.

13 This bailment incorporates such documents
14 as Army Reg 50-6, AR 385, AR 190-59 -- most of these
15 documents that I'm reading here pertains to chemical
16 surety, chemical security, chemical safety.

17 In one way or the other, all of these
18 things that are listed below, the training, the PPE,
19 the inspection, accountability, decon, disposal,
20 medical surveillance, storage, you name it. It's
21 all addressed within these documents and then within
22 this bailment agreement.

1 And this bailment agreement is negotiated
2 with the Army. So if they cannot fulfill and meet
3 the Army regs, there is no bailment agreement
4 issued.

5 The selection criteria that we felt, NPPTL
6 felt was important, was that if we went to these
7 contractor-owned, contractor-operated labs, does the
8 bailment agreement allow for NIOSH LAT testing,
9 testing of nonDOD products.

10 And the products that NIOSH gets certified
11 are considered nonDOD products, not directly
12 defense, Department of Defense related.

13 The bailment -- within the bailment
14 agreements, there are limitations on the amount of
15 agents stored on site. Basically, is there an
16 adequate supply of agent for NIOSH testing. Do they
17 have quality assurance to ensure that the agents,
18 this GB and HD, meet the purity requirements that we
19 are currently using of the CASARM agent.

20 Because just agent is not agent. There is
21 a lot of purity in agents, or impurities in agents,
22 depending -- especially if it is weapons grade,

1 depending if it's stored in an artillery round or a
2 rocket or bulk.

3 So as they are stored there and, over
4 time, they get these impurities. And these
5 impurities cause the agents to behave different and
6 therefore affecting the permeation rates.

7 So we have to ensure that we have good
8 agent and there's consistency so there's consistency
9 amongst our tests.

10 Looking at the lifecycle costs, obviously,
11 the convenience of the laboratory. The location for
12 delivery of the agent for NIOSH and PPE
13 manufacturers to visit.

14 So is it convenient for NIOSH and PPE
15 manufacturers to visit, or is it very difficult? So
16 that was a criteria we looked at.

17 And of course, does the laboratory have
18 the capability to meet the demand to develop
19 alternate tests.

20 Because such as these -- the tests that
21 were coming through for -- during policy
22 development. So we are always doing a lot of

1 development tests as we are developing our
2 standards.

3 So just not certification, but additional
4 alternate tests that NIOSH may require of them.

5 The projected milestones, the status of
6 the project is the draft is -- the draft report is
7 being written right now, and it will be sent to
8 NPPTL.

9 We are going to evaluate it, and then we
10 will send this report back out to the laboratories
11 to ensure that they -- what's in the report is
12 accurate and so there is no disagreement.

13 And then the report -- after the comment
14 period, the report will be revised and then provided
15 to NIOSH NPPTL management to make a decision whether
16 to activate the alternate lab. And, if so, which
17 lab.

18 And that concludes my presentation on the
19 alternate lab.

20 And any questions at this time? Okay.
21 thank you.

22 MR. HOFFMAN: You have got one.

1 MR. PALYA: Oh. Oh, geez, Dale.

2 MR. PFRIEM: 17025 wasn't listed. Can I
3 assume it's among one of the criteria?

4 MR. PALYA: Dale, would you stand up to
5 the mic, please?

6 MR. PFRIEM: Dale Pfriem, ICS Labs.

7 MR. POA: Is that on?

8 MR. PFRIEM: Dale Pfriem, ICS Labs.

9 Was 17025 one of the criteria?

10 You didn't note it.

11 MR. PALYA: You mean was it a DA PAN

12 (phonetic)?

13 MR. PFRIEM: No. Accreditation to the ISO
14 model.

15 MR. PALYA: No.

16 MR. PFRIEM: Why not?

17 You guys don't think that's important? I
18 don't know.

19 MR. PALYA: Well --

20 MR. PFRIEM: Is a surety license all that
21 counts?

22 MR. PALYA: No. That's not all that

1 counts.

2 But, I mean, again, we are going to go
3 ahead -- there is quality assurance in there. Okay.
4 I mean, we did have some quality assurance
5 provisions, and that was part of the survey. We are
6 going to go through the survey and see what they
7 have.

8 MR. PFRIEM: Will you require a 17025?

9 MR. PALYA: Not at this time.

10 I would think -- I don't know. We are
11 going to go ahead there and go look at --
12 investigate it further.

13 MR. PFRIEM: All right.

14 MR. PALYA: But thank you for a point well
15 noted on that.

16 MR. SZALAJDA: That's a good comment,
17 Dale.

18 I think the one thing we need to keep in
19 mind is really the intent of the study up front was
20 to look and see if it was even possible to go and
21 use an alternate lab and try to identify the issues
22 associated that.

1 I think any implementation on the way
2 forward, obviously we are going to look at
3 accreditations and things like that, at least as far
4 trying to make sure that when we, if an alternate
5 lab is established, that, you know, we are getting
6 repeatable, reproducible type results independent of
7 which lab the testing they go to.

8 So that's a good comment.

9 MR. PFRIEM: Thanks, Jon.

10 CBRN HAZARD ASSESSMENT OF FIRST RECEIVERS IN MEDICAL
11 FACILITIES

12 MR. PALYA: Okay. This is the last
13 presentation I have, so -- I'm going to present
14 another project we were performing here, and that's
15 the hazard assessment of First Receivers in medical
16 facilities responding to CBRN terrorist events.

17 Some of the issues that came up is what
18 degree of individual protection is required for
19 First Receivers in emergency departments in response
20 to a CBRN terrorist attack.

21 Also, what is the extent of the secondary
22 hazard that it will be in the ED.

1 So we need to find this out before we go
2 ahead and develop our standards or, you know -- so
3 it would assist in our standards development.

4 The definitions of the First Receivers are
5 emergency physicians, emergency nurses, patient care
6 associates, clerical staff, hospital cleaning staff,
7 and security staff.

8 The secondary hazard would be the residual
9 contamination from the chemical or biological agent
10 on the clothing or the bodies of the casualty coming
11 into the ED.

12 This is the definition of the First
13 Receivers in the OSHA best practice document. And
14 it basically says the same as the definition that I
15 used.

16 Some background is that the chemical
17 warfare agents and biological agents are orders of
18 magnitude more toxic than Toxic Industrial
19 Chemicals. First Receivers have suffered in the
20 past in previous CBRN terrorist events, such as in
21 Tokyo and Matsumoto incidents.

22 The potential of contamination hazards

1 that might be encountered by the First Receiver have
2 not been determined yet. So we know that, and
3 that's the whole purpose of this hazard analysis, is
4 to determine what has -- what is the concentration
5 level that can happen inside the emergency
6 department.

7 This effort was performed primarily by
8 OptiMetrics, and this is through a NIOSH
9 collaboration with the U.S. Army Research
10 Development and Engineering Command.

11 The contract was let through the Army
12 because they have a task order contract with
13 OptiMetrics to do this type of work, and it was
14 funded by NIST and the Department of Homeland
15 Security.

16 The object is was to identify potential CB
17 hazards inside a typical emergency medical facility.

18 Estimate the levels of potential vapor
19 concentration to enable development of the standards
20 for NIOSH CBRN nontight-fitting PAPRs and other
21 appropriate standards for clothing, PPE clothing.

22 Also, the objective was to use sound

1 rationale and assumptions based on previous studies,
2 published documents, mathematical modeling, to
3 obtain estimated hazard concentrations within the
4 emergency departments.

5 There is an infinite amount of scenarios
6 that one could have, and, therefore, yielding an
7 infinite amount of concentrations. So, therefore,
8 we had to make some -- what we felt were sound
9 assumptions, and go with those and model with those
10 assumptions.

11 The first one was that the medical
12 facility is not the primary point of attack. It's
13 not ground zero. The contamination source is from
14 the incoming victims.

15 We selected nine chemicals to model, and
16 these nine chemicals were from the NIOSH list of
17 chemicals used to when we developed our CBRN APR
18 standards. And we felt that -- they were from the
19 TICs. Well, seven were TICs. Two were CWAs.

20 But the seven TICs that we developed, we
21 felt that they were going to be the most likely to
22 be encountered. And we also based that on toxicity

1 as well.

2 And the seven TICs were ammonia, chlorine,
3 formaldehyde, nitrogen dioxide, phosgene, phosphine,
4 and sulfuric acid.

5 And the two CWAs are GB and HD.

6 So once we developed what chemicals would
7 probably potentially be used in a terrorist event,
8 we said, Okay, now, first you have to develop a hot
9 zone contamination level.

10 So we looked at the various hot zones, and
11 there was -- one venue would be a meeting room with
12 350 people in it. And we felt one liter of CW
13 chemical. That's reasonable.

14 There's an auditorium venue, a theater
15 with 800 people. One and four liters of chemical
16 warfare agent.

17 Airport concourse, 300 occupants at
18 various amounts of chemical agent.

19 But we decided to use the
20 auditorium/theater and with a -- for the TICs, a 50
21 gallon of initial explosion at Ground Zero.

22 So this contamination would explode,

1 contaminate the people in the room. And then these
2 people would be eventually sent to the hospital.

3 So it would be 50 gallons for a TIC, or
4 one and four liters for a chemical warfare agent.

5 There was many aspects of it. One of them
6 that was characteristic was the agent to explosive
7 ratio. So there was five parts agent, one part
8 explosive.

9 And basically this yielded a very fine
10 aerosol, which meant there was high vapor, and the
11 high vapor would be disseminated or placed on the --
12 deposited on the victims in the room.

13 So there was high vapor deposited on the
14 victim's clothing or on the skin, and another
15 assumption was there was a ten minutes elapsed time
16 from the explosion until when the victims entered
17 the ED.

18 Yeah, that sounds pretty short, but we
19 were -- most of all -- on this study, we tended to
20 overestimate the hazard rather than underestimate
21 the hazard.

22 Also on the hot zone decon device

1 modeling, used to Non-Uniform Simple Surface
2 Evaporation model. And basically what this model
3 does is it gives you certain fractions for liquid,
4 fractions for a pool, and fractions for the vapor.

5 Again, liquid deposited on the victims and
6 vapor were observed on the victims and on their
7 clothing.

8 And this also -- the end of that model was
9 used to go ahead and determine a concentration when
10 this explosive, this 50 gallon of TIC exploded or
11 this one to four liters of chemical warfare agent
12 exploded.

13 So this was, first of all, exploded. The
14 end of that model was used to generate the
15 concentration of the hazard. Then they are
16 eventually deposited onto the victim.

17 Then at the hospital, we also took this
18 into consideration. There are four different types
19 of scenarios.

20 A lot of people would say, Aw, geez, if
21 you go ahead and decon everybody, there is no --
22 they won't need any PPE. Or we are going to assume

1 that everybody who comes into the hospital has been
2 a hundred percent thoroughly decontaminated.

3 Well, some people -- some experts say,
4 yes, that may happen. But others say, you know,
5 there is still potential that people still can get
6 through the wire and get through the security system
7 and enter the hospital contaminated.

8 So we looked at these four scenarios here,
9 and we decided to go with Event Scenario No. 4
10 because it was the most severe, where mass
11 casualties would arrive at the hospital, no time for
12 decontamination. The hospital staff really had no
13 time to implement their decon protocols, or -- so
14 that's the case -- that's the scenario we went with.

15 And then, again, you have to model, with
16 the end of that model again. Because now the source
17 is not a 55-gallon drum blown up in the hot zone.
18 It's the incoming victims into the hospital.

19 So we, again, we used InDeVap in the ED
20 and the decontamination scenarios used were no
21 doffing at all, no doffing, no decon. Doffing with
22 10 percent, 25, 50, and 90 efficacy of the

1 decontamination at the emergency department.

2 So this kind of gives us a range when we
3 were running our models.

4 We also looked at the air changes per
5 hour. You know, power on, six to eight air changes
6 per hour. Power off is .3 air changes per hour.

7 Then we conducted surveys at five
8 different hospitals and did some research to find
9 out the average size individual treatment room and
10 the center console area.

11 And these volumes of the rooms, the 1,500
12 for the individual treatment room, was using the
13 modeling. So was the center console area at, you
14 know, 27,040 cubic feet. So all of these parameters
15 had to be established and be placed into the model.

16 These were the five hospitals visited, and
17 these hospitals also were surveyed. Their HVAC
18 systems were surveyed. Their operating procedures.
19 Their room sizes. So we did evaluate five different
20 hospitals.

21 This is just photos of some of the
22 hospitals' individual rooms. We have all seen them.

1 And then, now, the results determined the
2 following: The peak hazard concentrations for the
3 individual treatment room, the center console area,
4 the patient bubble in the individual treatment room,
5 the patient bubble in the console area.

6 And you probably want -- the patient
7 bubble was just the volume around an individual
8 victim and where this individual victim would be off
9 casting the TIC or CWA.

10 This is a typical decay chart of a victim,
11 the decayment into an ED after being exposed to 50
12 gallons of chlorine.

13 Under the different conditions, as you can
14 see, small room average, small room peak, large
15 room. For this particular case, there was no
16 reduction due to doffing or decon. Again, 50
17 gallons of chlorine exploded with a 5 to 1 burster
18 round.

19 But as you can see, it is a high
20 concentration. Then, as time progresses, it will --
21 it decays, as in all cases. But this -- a lot of it
22 depends on the vapor pressure, just different

1 conditions.

2 And from our hazard analysis, this is what
3 we, for the TIC estimated concentrations, we go up
4 to the highest of 41 under this condition, no
5 doffing, no decon. At 41.8 milligrams per meter
6 cubed.

7 Now, that's the peak concentrations. But,
8 again, as that chart, as I showed you before, it
9 will decay over time. And that was in the peak
10 patient bubble.

11 This is for the chemical warfare agent.
12 In the no-doff worst-case condition is in the
13 no-doffing no-decon scenario, and for GB at one
14 liter. And that was at .9 milligrams per meter
15 cubed.

16 And this concludes my presentation of
17 hazard assessment.

18 The biological -- this -- the first half,
19 we just hit all of the chemical, the TICs and the
20 CWAs. Next year, we are going to go and do one for
21 biological as well.

22 So at this time, I will take your

1 questions.

2 MR. PITTS: Sam Pitts, United States
3 Marine Corps ChemBio Incident Response Force.

4 Frank, just a technical comment. We might
5 steer you towards considering the wisdom of doing
6 decontamination perhaps outside of the hospital
7 facility.

8 For some of the more persistent agents, if
9 you get them in the interior of the hospital, they
10 could be extremely problematic, especially if you
11 consider some of the emerging threats that we are
12 looking as well as the some the more persistent
13 agents.

14 That's the comment.

15 Question. You didn't look at any
16 radiological contamination from either fallout,
17 rainout, or RDD isotopes of any kind?

18 MR. PALYA: No, sir. We were just
19 concentrating -- this, again, the first half dealt
20 with mainly the chemicals. And now, we are going to
21 go look at the biological.

22 But maybe it is worth mentioning, as we go

1 through the biological, being particulates,
2 versus -- we may want to look at that and see some
3 of these isotopes.

4 I'll talk to my partners on this, and
5 maybe we could, you know, look at it and see how we
6 would approach this.

7 I mean, we really never thought much of
8 it.

9 MR. PITTS: You might also suggest -- like
10 with the clean up after the anthrax in the Senate
11 office buildings, we had to actually remove like
12 carpeting, tile, ceiling tiles, furniture, to get
13 them down to background levels, safe background
14 levels.

15 If you bring it inside of a hospital, you
16 may compel the hospital staff to perform their
17 operations in an elevated PPE, which we would also
18 suggest is really not a cerebral approach to utilize
19 in a hospital, respectfully.

20 MR. PALYA: Yes.

21 Again, we looked at this because there
22 was -- a lot of the people felt that maybe PPE

1 wasn't used and needed in hospitals because all of
2 the decon was going to be performed outside.

3 Maybe, but maybe not.

4 The University of Maryland hospital down
5 in Baltimore relies on the Baltimore Fire Department
6 to go ahead and perform their decon. So they really
7 don't have a lot of decon set up in place, in the
8 area. We are going to have the fire department.

9 But by the time the fire department
10 deploys and gets set up, Lord only knows how much
11 time is going to elapse.

12 Now, for instance, Shadyside Hospital in
13 Pittsburgh, they have got a real decon, nice decon
14 system in place where they just lock down and direct
15 people to go.

16 What you think would be lights, if you
17 look up, as soon as you walk into Shadyside Hospital
18 are showerheads. And then they just shower
19 everybody, and that's their decon method.

20 So some hospitals are better than others
21 as far as decon, but it depends. We can't make that
22 assumption that everybody is going to be clean when

1 they enter through the emergency department.

2 MR. PITTS: I guess that's the point we
3 are trying to make. You need to keep the
4 contamination outside of the hospital facility to
5 the greatest extent possible.

6 Once it gets inside, you may shut that
7 facility down, and it would be combat noneffective
8 for your purposes.

9 MR. PALYA: Yes, sir. That's what the --
10 the priorities are protect the facility, protect the
11 clinical staff, and then save the patient.

12 So that's how they do it. But you're
13 right. Go ahead and keep the hospital clean because
14 if that's contaminated, the whole hospital is
15 ineffective. The same with the staff.

16 MR. PITTS: A question on the civil live
17 agent test facilities.

18 Are they -- are the facilities, the
19 chamber, the restricted are where they do their
20 testing, are they of equal or similar dimensions,
21 Frank, or are they vastly different?

22 Could we test a vehicle in one, or are we

1 talking about small items in testing live agents in
2 the civil facilities?

3 MR. PALYA: That would be just respirator
4 components, that type of thing.

5 MR. PITTS: Small PPE items?

6 MR. PALYA: Yeah, right, that would meet
7 NIOSH's needs.

8 MR. PITTS: Got you. Thank you.

9 MR. PALYA: All right. You're welcome.

10 Any other questions? Okay, thank you.

11 CBRN RESPIRATOR STANDARDS DEVELOPMENT

12 CLOSED-CIRCUIT SCBA

13 MR. REHAK: Okay, good afternoon. I'm
14 back again. My name is Tim Rehak, and I'm going to
15 talk about the benchmark testing for CBRN hardened
16 closed-circuit SCBAs.

17 Okay, previously, at past public meetings,
18 we talked about the benchmark testing that was done
19 prior, and that included the LRPL, the heat and
20 flame testing, the salt fog test, and the sand and
21 dust testing.

22 With the past heat and flame resistant

1 testing, just a quick review of that.

2 The procedures we followed were from
3 Section 8.11.5 of NFPA 1981. Here, the unit was
4 exposed to 95 degrees C for 15 minutes. Then it was
5 exposed to direct flame contact for ten seconds,
6 raised to 150 millimeters, and dropped freely.

7 And with this test, though, the only
8 exception from the NFPA standards that we did, live
9 oxygen cylinder wasn't used.

10 And the problems that we noted in these
11 tests were afterflame beyond 2.2 seconds at -- on
12 some of the hoses, the harnesses, the facepiece hose
13 connector.

14 And with one of our test units, the
15 backpack fell off of the mannequin.

16 Now, follow-up testing, what we plan to do
17 is basically follow the same procedures as before,
18 except this time, we got Intertek agree to do the
19 tests with a live oxygen cylinder.

20 Basically, the status where we are at
21 right now is modified flame resistant closed-circuit
22 SCBAs were obtained from two different

1 manufacturers, and we already processed the
2 requisitions for Intertek to do the testing for us.
3 And they also -- well, let me back up a little bit.

4 In order to do the testing, I guess their
5 safety director required the people doing the tests
6 that they have some kind for safety barrier up just
7 in case since we are using live oxygen cylinders.

8 So basically, we have a requisition in
9 place for them to design and build a safety barrier
10 so that they can conduct these tests for us.

11 And basically right now, the latest I
12 heard, they are in the process of buying their
13 safety barrier. So we hope to have this testing
14 done sometime we are projecting in the middle of
15 December or early in January.

16 Other testing, benchmark testing we did
17 was the vibration endurance.

18 The procedures we followed here was NFPA
19 1981 Section 8.3.5.3, the second edition.

20 The tests for this was conducted by the
21 U.S. Army Research Development and Engineering
22 Command. And for this, two units were tested, one

1 each from two different manufacturers.

2 The results that we obtained, both
3 closed-circuit SCBA showed signs of external wear.
4 And one of them, two latching mechanisms became
5 disconnected. And with one of them, one internal
6 fitting was fractured.

7 The conclusions that we reached from this
8 testing, one system passed the follow-up operational
9 test when run on the ABMS. And the other unit
10 required -- excuse me -- replacement of the
11 fractured fitting before passing the follow-up
12 operational tests.

13 We also did environmental temperature
14 operational tests.

15 First, we did a hot test at 71 degrees.
16 This was done with two units. And one thing I would
17 like to note is the closed-circuit SCBAs were not
18 rated for this requirement.

19 For this test, both units were hot soaked
20 for 12 hours at the 71 degrees C. Operational tests
21 were then conducted, and the testing was stopped
22 when the CO2 level rose above 4 percent.

1 The results: Unit A reached 191 minutes.
2 Unit B made it to 11 minutes.

3 Continuing on with the environmental
4 operational performance tests, we did cold tests at
5 minus 30 degrees C with two units, again, noting
6 that the units were not rated for this requirement.

7 Both units were cold soaked for 12 hours,
8 and the same operational tests were run with the
9 same limits for CO2 when we would stop the tests.

10 And for this, the results were Unit A
11 reached 7 minutes, while Unit B made it to 84
12 minutes.

13 The chemical agent permeation and
14 penetration resistance against HD and GB, the closed
15 system -- what we are planning on doing is the
16 closed-circuit SCBAs will be held to the same
17 performance requirements as the open-circuit units.

18 We are currently working to develop a
19 system that can simulate the CO2 and humidity so
20 that we could activate the closed-circuit SCBAs
21 without requiring us to use an ABMS.

22 This will help us to control test costs,

1 eliminate the need for a walk-in test hood, and to
2 minimize decon.exposure risks.

3 We are not -- we don't plan on doing
4 benchmark testing on accelerated corrosion
5 resistance.

6 The particulate resistance, the facepiece
7 lens haze, luminous transmission, and abrasion
8 resistance, or with the communication performance
9 requirement or vibration endurance.

10 This is because of the testing will be
11 conducted in accordance with NIOSH standard test
12 procedures that will be based on NFPA 1981 standard,
13 the 2002 edition. And our rationale for doing this
14 is that NIOSH STPs can be updated to reflect the
15 latest changes to the NFPA standard.

16 Remaining benchmark testing that we plan
17 to do, again, we are going to do the heat and flame
18 resistance with the live oxygen cylinder and the
19 chemical agent permeation and penetration
20 resistance.

21 Any questions? All right.

22 CBRN RESPIRATOR STANDARDS DEVELOPMENT

1 COMBINATION UNITS

2 MR. SZALAJDA: I think you're all either
3 too satisfied from having lunch or looking forward
4 to the break. So my comments and Bill's comments
5 are going to be brief with regard to the last two
6 items.

7 The recent -- or the latest notice that we
8 put out last week released the first concept paper
9 for the CBRN combination units.

10 And what we are doing -- and it's sort of
11 doing back to the same story you have heard from us
12 for the past several years regarding CBRN
13 respirators, is that everything is built on three
14 tiers of requirements: 42 CFR Part 84; consensus
15 standards, whether national or international
16 standards; and also special CBRN requirements.

17 Combination units are going to be no
18 different than the procedures that have been
19 followed in the past.

20 The comment has been made -- Bill Hoffman
21 had made a comment earlier today that going forward,
22 all of the standards are going to be done using --

1 the CBRN standards are going to be done using
2 rulemaking procedures.

3 I think in terms of our process for going
4 through the initial phases of the development, we
5 are still going to continue the use of concept paper
6 to share the information with you regarding what we
7 are currently thinking with regard to the
8 performance requirements for the system.

9 I think the one thing to note with how we
10 have developed the standards in the past with policy
11 in our regulatory authorities versus going through
12 the rulemaking is that essentially we have followed
13 the spirit of rulemaking in what we have done with
14 policy, that we have had a dialogue. We have had
15 comments, opened up the requirements for stakeholder
16 review.

17 And feedback, listened to that feedback,
18 and made decisions like would be done in rulemaking,
19 whether we agreed, you know, with comments that came
20 from the stakeholders, or if we disagreed, and at
21 least were able to rationalize why we chose to
22 disagree with the stakeholder comments.

1 I think when you see, as we go forward
2 with the closed-circuit SCBA, the combination units
3 and the supplied air respirators, that even though
4 we are going to be going into a formal review
5 process review, a review and comment process with
6 rulemaking, that the spirit of what we have done in
7 policy is still going to continue with regard to the
8 types of dialogue that we have had in the past with
9 stakeholders regarding CBRN.

10 With the development of the combination
11 units, a couple of things have come into mind. And
12 from my perspective, I'm probably wrong because I'm
13 wrong pretty often, at least my wife tells me so.

14 I think this is -- from a technical
15 standpoint, this is going to be one of the easier
16 standards that we develop. I think most of the
17 concerns and what we are going to be looking for
18 feedback going forward are going to be related to
19 operational types of scenarios.

20 When you think about closed -- how you
21 select a respirator and how it is used in the
22 workplace, you may make definition decisions on are

1 you in an IDLH environment. Are you not in an IDLH
2 environment. What types of protection
3 characteristics does the respirator need to provide,
4 you know, to the wearer in going into a certain
5 environment.

6 You know, in the past, NIOSH, in the
7 process of certifying respirators, if we were to get
8 a combination unit, the type of approval you get is
9 at the lowest level of protection. So if you did
10 have a combination SCBA PAPR, SCBA APR, you would
11 get a 14G approval for a gas mask.

12 I think in going forward, one of the
13 things that we need to consider and where we need to
14 get stakeholder feedback is how we approve -- or
15 your recommendations on how we consider these types
16 of systems in going forward as far as the approval
17 process.

18 I think in general, though, when you look
19 at the types of requirements that we are looking at,
20 some of the considerations are related to how we
21 test the units. And I think the types of things
22 that indicate, or at least we indicated so far, I

1 think -- or at least to us were readily apparent as
2 far as considerations for general requirements.

3 I think the one thing of note, when you
4 look at the PAPR, is we want to make sure that there
5 still is a degree of protection available for the
6 user. If you had a combination SCBA PAPR, that you
7 would still have a degree of protection if the PAPR
8 or the blower component were to stop working in
9 operation.

10 Some of the specific things that we have
11 thought about. One is having some sort of indicator
12 for SCBA versus air purifying types of operations.
13 And I know the question is going to come up, Well,
14 what kind of indicator?

15 Well, we are looking for you to tell us
16 that. I think some of the things that we thought
17 of, very simply, an indicator can be a switch that
18 is on the respirator which takes a device from a
19 supplied air mode to an air purifying mode.

20 That can be -- that could be the indicator
21 because the operator would have to manually make the
22 change from one side to another, or you could have

1 something more elegant, like a heads-up display or
2 some other type of indicator that could be
3 considered in the operation.

4 One thing to note as we go forward in our
5 considerations for testing is that we expect, when
6 you look at the SCBA combination with an air
7 purifying respirator, when we do a test, it is going
8 to be done in the most stringent testing or
9 conditioning applicable to either combination.

10 What that means -- I guess, for an example
11 that we kick around, is when you look at the SCBA,
12 the SCBA has a cold temperature requirement as part
13 of the process.

14 Well, your air purifying system is going
15 to have to meet that requirement as well because of
16 how the system is going to be evaluated.

17 As far as CBRN performance, you know, we
18 are looking at established criteria. We are really
19 not planning on inventing anything new at this
20 point. The requirements, performance requirements
21 will be based on what has already been identified
22 for either the SCBA, the APR, or the PAPR.

1 And we do have a special docket to collect
2 comments regarding combination units at 082.

3 I think one thing I did want to bring up
4 with regard to the combination units, you know, we
5 have taken a very focused approach with regard to
6 the developments for this type of respirator in
7 looking at open-circuit SCBAs plus an air purifying
8 type element.

9 And you could look and say, Well, there's
10 lots of other examples that could be done. You
11 could have a closed-circuit SCBAs with air
12 purifying. You could have, you know, lots of things
13 that we probably haven't even considered yet.

14 But at least as far as right now, trying
15 to respond to what we have seen in the industry and
16 what we have seen in the stakeholder communities,
17 that is there a focus on having the availability of
18 these types of respirators in the near term.

19 And the focus for the standard, for this
20 standard initially, is to look at that combination.

21 So with that, does anybody have any
22 questions?

1 MR. METZLER: Rich Metzler of the SEA
2 Group.

3 Did you intend to publish a schedule for
4 the modules that you are going to be working on?

5 MR. SZALAJDA: Yeah. The question was if
6 we intend on publishing a schedule and going
7 forward.

8 I think, at this point, one of the things
9 that we are doing is looking at the -- and Bill can
10 correct me if I'm speaking out of turn for the
11 branch.

12 But I think we are looking at prioritizing
13 the different modules that we are working between
14 things that -- or making changes in the near term to
15 Part 84 along with the CBRN type of activities going
16 forward.

17 I think that's one of the things, at least
18 as far as the branch will have to determine, you
19 know, the types of schedules because we are limited
20 with the resources, you know, that are available.
21 And depending on what the priorities are in the
22 organization, you know, other things will be

1 promoted quicker than others.

2 MR. METZLER: And last, I have a comment.

3 I agree with Dale Pfreim's comments, that
4 there seems to be little justification for having
5 differences in the environmental testing for
6 loose-fitting PAPR versus tight-fitting PAPRs.

7 In a formal rulemaking process, I would
8 expect you would have to provide a more detailed
9 rationale in why that decision was made.

10 Also, I have noticed in Tim's
11 presentation, you're not applying abrasion
12 resistance to the lenses on those closed-circuit
13 self-contained breathing apparatus, or at least it
14 appeared that way to me. And it is required in the
15 full facepiece CBRN APRs.

16 MR. PALYA: That would be under 1981 --

17 MR. SZALAJDA: Turn it on, Frank.

18 Well, while Frank is turning the
19 microphone on, I think, just to address the topic
20 that -- regarding loose-fitting versus tight-fitting
21 PAPRs.

22 At this point, you know, we made a

1 determination as part of the standards development
2 process for the PAPRs, at least as far as how to --
3 Step 1, how to expeditiously bring the standard to
4 bear.

5 One of the things that -- and it was a
6 very specific tightrope that we had to follow in
7 looking at the performance requirements for the
8 PAPRs, whether -- when you have the needs of the
9 emergency responder on one side where PAPRs could be
10 used in the same scenarios as air purifying
11 respirators as gas masks versus scenarios where
12 PAPRs are used in an emergency department or, you
13 know, medical type applications where their needs
14 may be different.

15 I think, as you may have seen, with -- or
16 picked up with Frank's presentation on the health
17 hazard assessment for the work that's being done by
18 OptiMetrics, the performance requirements for the
19 what the hospital workers need are going to be less
20 than what is expected for somebody actually working
21 at the site.

22 So we made a decision based on, you know,

1 that type of analysis to go ahead and look and make
2 a determination where we could go without doing the
3 conditioning for the loose-fitting PAPRs because we
4 do not see those types of systems being used where
5 the tight-fitting were.

6 MR. METZLER: You are going to have
7 cautions, limitations, and restrictions of use to
8 prevent the use of those loose-fitting PAPRs other
9 than for that specific application.

10 MR. SZALAJDA: I appreciate your comment.
11 I think that's part of what we tried to address.

12 And part of it is going to get into the
13 relationship between the manufacturer and the user
14 community, as least as far as how these types of
15 products are marketed.

16 And I think the one thing to keep in
17 mind -- and there is a caution and limitation in the
18 PAPR, the Step 1 PAPR standard, which says, you
19 know, you should not be using the loose-fitting
20 types of system where escape is possible.

21 I forget the actual number on the -- or
22 the letters on the cautions and limitation.

1 And again, it needs to get into, you know,
2 the types of -- the types of decisions that are made
3 by the users in buying these types of products.

4 I mean, you should not be wearing a
5 loose-fitting type of respirator if you're working
6 where you need to have an escape capability.

7 MR. PALYA: Okay, Rich. On that abrasion
8 resistance, there is an abrasion resistance
9 requirement on that closed-circuit. And that
10 goes -- a lot of those durability requirements go
11 back to 1981. So that's pulled from the 1981
12 standard.

13 MR. REHAK: We're not going to do the
14 benchmark testing on those units because we have
15 1981.

16 MR. SZALAJDA: We will take a couple more
17 questions, and then we will let Bill go ahead and
18 proceed.

19 MR. HEWITT: Don Hewitt. Just a quick
20 question with regard to the combination unit.

21 Since the intended use of this thing,
22 particularly for emergency responders, is this

1 notion of being able to conserve the supplied air,
2 you know, while using the PAPR, and the transition
3 is likely between IDLH and non-IDLH environments,
4 one of the questions I have heard from a number of
5 responders is, I know there is supposed to be a
6 switch so you could tell which mode it's in.

7 The question is, has any consideration
8 been given in the requirement to mandating some
9 warning in the device for the transition to IDLH,
10 some sensor, so that somebody can say, You're
11 running on the PAPR. And, gee, it has changed.

12 Because the fear is, of course, that the
13 person is going to wander into an IDLH environment
14 and may not have a handy sensor to look at.

15 Is there any consideration, or are they
16 just going to do a caution limitation and say don't
17 do that.

18 MR. SZALAJDA: That's a very good comment.
19 And I think that's somewhere -- you have touched on
20 an area where we are looking to get feedback back
21 from the community with regard to what that type of
22 requirement should be, you know.

1 Because, again, you know, it is sort of,
2 you know, with the system it's how complicated to
3 you want to make the design.

4 In one of the things that -- you know, at
5 least as far as the indicator, our initial cut in
6 looking at it was, Well, simply put, you can have a
7 indicator that says it is either, you know, supplied
8 air or it's air purified. You're in one or the
9 other mode.

10 When you start getting into details as far
11 as where you should be and in what mode, that's I
12 think where the toughest part of this standard is
13 going to be, is in that classification as far as
14 addressing, you know, the types of approvals that we
15 give -- we give to the respirator. Then, in turn,
16 how people actually use it.

17 MR. HEWITT: We will try to get you some
18 feedback from responders.

19 MR. SZALAJDA: That would be great. Thank
20 you.

21 MR. PITTS: Sam Pitts, United States
22 Marine Corps Chem/Bio Incident Response Force.

1 Jon, very similar to what Don said, we are
2 very intrigued by these combination units, but we
3 have some questions, like in the gating mechanism
4 that separates one tidal volume or plenum, you know,
5 from the other.

6 We are also a little curious about, if we
7 were to use the PAPR first on an entry and then go
8 in a, say, an enclosed space and utilized bottled
9 air. And then, say, we ran out of air, and we are
10 coming back through decontamination and want to go
11 back on the PAPR or be compelled to go back on the
12 PAPR, how are you going to determine the usable life
13 that's left on that canister, and has it reached
14 saturation?

15 And have you thought about the, even with
16 filters that are somewhat saturated, the tranquil
17 migration of the contaminant through the filter bed
18 in nonuse, how -- we are not smart enough to know
19 the answers, at the risk of exposing my Cro-Magnon
20 genetic material.

21 MR. SZALAJDA: On that question, Sam, I
22 don't think you have to apologize because we don't

1 have the short answer for you yet either.

2 I think that's part of the consideration
3 for us in looking at the requirements is, you know,
4 not knowing where the system may be going, what
5 happens.

6 And just a hypothetical, what happens if
7 you have a SCBA PAPR, and you go and use it in a
8 firefighting type operation, and you are on the
9 bottle there. What effect does the heat and the
10 products of combustion have on the filters?

11 We don't have that answer yet. And
12 hopefully, as the requirement develops over the next
13 several months, we will be able to start putting
14 some flesh to the performance requirements for those
15 type of considerations.

16 Any comments or suggestions of things that
17 you think are important, you know, with regard to
18 the performance, you know, just keep our dialogue
19 going, and we would be happy to --

20 MR. PITTS: Some of us were postulating
21 that perhaps we could start, you know, with the PAPR
22 and go up to bottled air, but not the other way as a

1 training or an operational concept of employment.

2 MR. SZALAJDA: That's a definite
3 possibility.

4 Again, I think it gets into -- with this
5 system, I think the big challenge for us is going to
6 be, not necessarily the performance. Because I
7 think between all of the standards that we have
8 developed, we will be able to come up with a good
9 cache of performance requirements, but operationally
10 how is it going to be used.

11 And I think that's the tougher question
12 that we are going to have to answer, you know, in
13 the time to come.

14 MR. PITTS: We are thinking along the same
15 lines, then. Thank you.

16 CBRN RESPIRATOR STANDARDS DEVELOPMENT

17 SUPPLIED-AIR RESPIRATOR

18 MR. HOFFMAN: Okay. The last one we are
19 going to talk about before the break is the
20 conceptual requirements for an airline respirator,
21 actually, a Type C or Type CE. And those terms may
22 now be obsolete since Type A and Type B, don't seem

1 to be much need or call for those anymore.

2 The initial concepts that we are
3 considering for a supplied air respirator would be
4 that we would use existing criteria from 42 CFR Part
5 84, consensus standards, and the CBRN statement of
6 standard.

7 And the supplied air respirator CBRN
8 standard, again, will be developed using a
9 rulemaking process, as would everything else from
10 this point forward.

11 At the present time, we are looking at a
12 supplied air respirator since it would be used for
13 CBRN type of environment to include a 15-minute
14 open-circuit escape cylinder. It's an airline
15 respirator that has an escape bottle in the event,
16 obviously, that if something happens to the air
17 supply.

18 Requirements from 42 CFR -- and, again,
19 this is in its very early stages.

20 We would look at the appropriate
21 requirements from Subpart J, which include also
22 Subparts A, B, C, D, E, F, and G, which are the

1 general requirements that we apply to all
2 respirators. Those are the things from Part 84.

3 Requirements from consensus standards, we
4 would look at some of the things that most people
5 are already familiar with from the CBRN standards,
6 durability, the low temperature, the lens materials,
7 and the things that you can see on the screen
8 picture here as well.

9 So, again, it's a compilation of things
10 that have been done to date.

11 The CBRN specific requirements, of course,
12 we are looking at an open-circuit SCBA, and we would
13 also be looking at the CBRN APR statements of
14 standards to pick up on things that we have already
15 done before.

16 So we are not looking at it so much as
17 anything brand new in the area of CBRN requirements,
18 but adopting what we have used in some of the other
19 ones in applying it to a supplied air respirator.
20 That's a very brief presentation. We have just
21 started on this.

22 Again, this has a different docket number

1 on the yellow handout sheet that's in your packet,
2 that you will find this listed. And it is Docket
3 No. 83.

4 I do want to comment that a couple of
5 questions we would expect to see, that we have been
6 asked many times, is would there be a provision for
7 the takeoff for the operation of a pneumatic tool.

8 If I'm going in with an airline respirator
9 into some type of an environment, the reason I'm not
10 doing that and not using an SCBA is I may be in
11 there for some period of time.

12 If I'm going in there for some period of
13 time, I have got a job to do. And it may be using a
14 cutoff tool, an air drill, or something like that.
15 Would we have provisions for that?

16 Also, would we consider changes for hose
17 lengths or hose length connections, what would they
18 would have to be, could you use a longer length than
19 we presently require. Could you use different
20 lengths, or how would they be adaptable, things that
21 we really haven't thought about yet, but things that
22 we would be looking for your input on, is there a

1 need for that.

2 I know I can think of one specific
3 example. Terry Cloonan, when we were at the World
4 Trade Center, people wanted to go in with airline
5 respirators with a 5 or 600 feet of hose so they
6 could go in there and spend a little bit of time and
7 look. And they wanted it -- they wished such a
8 system was available that was NIOSH approved, which,
9 of course, back then, it wasn't.

10 A very brief overview. Are there any
11 questions specific to the airline at this time?

12 Okay. What I would like to do is, if we
13 could, we are running a little bit behind schedule.
14 Take our break, but hold it to about ten minutes.
15 So if people could be back at about a quarter to 3,
16 that would be great, and we could try to catch back
17 up.

18 Thank you.

19 (A recess was taken.)

20 MR. BOORD: If we can take our seats, we
21 will continue with the program.

22 Okay. Before we -- before we begin with

1 the next discussions, I would like to request that
2 everybody look into their information packet. And
3 in your packet, you will find two different customer
4 satisfaction surveys.

5 And what I would ask you to do is if you
6 look at the bottom left-hand corner of the survey,
7 you will see the date.

8 One is for today's meeting, and one is for
9 tomorrow's. So October 12 and October 13.

10 The final presentation after we have the
11 discussions on the Total Inward Leakage and the
12 quality assurance provisions, the final presentation
13 we have today will be addressing our -- some of our
14 quality initiatives in our work with the National
15 Academies and our work with the OPM and the surveys
16 that we have been performing.

17 This survey that you have in your packet,
18 it is important to us to retrieve the information.

19 So I'm going to ask the next presenters to
20 wait two minutes. And I would hope that during that
21 next two minutes, you would look through the
22 customer satisfaction form dated October 12 and

1 share with us your opinions of the presentations and
2 the discussions that you have heard today.

3 Following the presentation -- Maryann,
4 will it be your presentation they will be collected,
5 or during?

6 MS. D'ALESSANDRO: During.

7 MR. BOORD: Okay. So during the last
8 presentation, we will come around to collect the
9 surveys.

10 So I would appreciate it if you could take
11 the next two minutes and fill that out.

12 Thank you.

13 (There was a pause in the proceedings while the
14 attendees filled out their surveys.)

15 MR. HOFFMAN: The last group of
16 presentations today will be the Total Inward Leakage
17 program that Bill Newcomb is going to present. The
18 Quality Assurance module, which Bill Newcomb along
19 with Dr. Doug Landsittel will present information.

20 And then what is called on the agenda the
21 administration module, but really which has evolved
22 into the certification fees module, which will be

1 presented by Heinz Ahlers.

2 So, Bill, if you want to step up.

3 TOTAL INWARD LEAKAGE PROGRAM

4 MR. NEWCOMB: Thank you.

5 The Total Inward Leakage program has been
6 around for a couple of years, but for those who may
7 not remember, I'll give you a little bit of
8 background.

9 When NIOSH was established, Schedule 21C
10 had an isoamyl acetate test. Prior to that,
11 Schedules 21A and 21B had coal dust tests for
12 fitting of respirators.

13 With the 21C, there were some
14 configuration issues in the fact that isoamyl
15 acetate fit testing needs an organic vapor removal
16 mechanism, and most particulate respirators do not
17 have that type of mechanism. So they had to be
18 altered in order to be tested.

19 When 42 CFR Part 84 was promulgated in
20 1995, the isoamyl acetate test was eliminated for
21 particulate respirators, although it still remained
22 as a qualitative fit test for other types of

1 respirators.

2 One of the impetus for not having a fit
3 test was the fact that OSHA still required an
4 individual fit test of a respirator before it would
5 be used.

6 So it was felt that, even though NIOSH did
7 not have a fitting test as part of certification,
8 that any respirators that did not fit well would be
9 not used in the marketplace because of the
10 requirement for individual fit testing.

11 In 2000 -- I believe it was 2003 it was
12 actually published, but the respirator usage in
13 private firms, 2001, suggested that 53 percent of
14 the respondents were actually doing fit testing.

15 And this number, I believe was greatly
16 exaggerated because of the fact that there seemed to
17 be some confusion in the answers between fit testing
18 and fit checking, or what is termed today user seal
19 check.

20 At the OSHA public hearings for the
21 changes to 1910 134, the -- when the table of
22 assigned protection factors was first introduced,

1 there was some concern over protection factors that
2 were given to some of the respirators.

3 And at that time, NIOSH committed to
4 putting -- to adding certification tests for fitting
5 of respirators.

6 So consistent with NIOSH's modular
7 approach, the standards to be developed would be for
8 half-mask respirators for particulates, including
9 filtering facepieces, and that would be done first.
10 Then the regulations would be modified to include
11 those tests.

12 After that, other types of respirators,
13 full facepieces, hoods, and helmets would be
14 addressed.

15 Again, one of the criteria that we set
16 upon for the TIL testing for the whole program is
17 that it would not be a substitute for the OSHA
18 mandated individual fit test. Because the only
19 method of assessing individual fit is a fit test.

20 Furthermore, no respirator can be
21 certified to fit. The respirators would be
22 quantified, or evaluated, to show that they could

1 give fit to a certain population.

2 The Total Inward Leakage program was
3 broken up into three phases. The first one was a
4 conceptual development phase. The second was to
5 establish a test facility, conduct the actual
6 benchmark testing, and establish the criteria
7 concepts.

8 Phase 3 was to finalize the requirements
9 and the implementation plan.

10 Now, the guidance for establishing the
11 certification criteria were set upon back in, I
12 believe, 2004. And they would not be based on the
13 OSHA APS. We did not want to be influenced by the
14 current regulations for fit testing. But they would
15 be based on actual fit test results. Also, that it
16 would be inappropriate to use previously obtained
17 data for several reasons.

18 We would conduct benchmark testing on
19 state-of-the-art respirators within the class, and
20 we would use the entire panel for TIL evaluation.

21 For the half-mask project, the following
22 test method characteristics were compared:

1 The ability to use -- to be measured,
2 regardless of the air purifying element; knowing
3 that they are all particulates, but some would be
4 N99. Some would be P100. Others might be N95s.

5 That it have the required sensitivity for
6 the desired results; the ability to give fairly
7 accurate and reproducible results; the ability to do
8 the test exercises without disturbing the fit of the
9 respirator; ease of duplication within the labs;
10 cost of the equipment; need for a test chamber; and
11 ease of preparation, clean up, et cetera.

12 We came up to the conclusion that the best
13 choice for measuring half-mask respirator Total
14 Inward Leakage would be the PortaCount Plus with a
15 companion in a direct reading mode.

16 And the most reproducible exercises were
17 those found in the OSHA fit test protocol with some
18 minor modifications.

19 NIOSH embarked on a project which you have
20 probably heard about several times to look at the
21 fit test panels that were in use. And at the time
22 that we started this program, there were two panels

1 from Los Alamos' national laboratory that went back
2 quite a ways. One was a half-mask panel that used
3 lip length and face length. And the other was a
4 full face panel that used face width and face
5 length.

6 It was determined that those panels did
7 not represent the public at large as the respirator
8 users of today. And, furthermore, when some of the
9 results of the tests of the studies were evaluated,
10 it was felt that lip length was not a good indicator
11 in fit of respirators.

12 So we came up with a further -- or so
13 should I say Dr. Zhuang came up a new bivariant fit
14 test panel with the face length and face width,
15 which essentially moved up and to the left of the
16 old panel.

17 It seems that the faces in the general
18 population seemed to be longer and wider than they
19 were in the -- from the anthropometrics that we used
20 to establish the Los Alamos panel.

21 The matrix is broken up into ten boxes
22 with 25 members in the boxes. And you can see that

1 Panel 4 has five members, and Panel 7 has four
2 members, and the rest of them have 2.

3 This is to replicate the approximate
4 percentages of the population of respirator wearers
5 that fall in those categories.

6 We conducted the benchmark testing over
7 the last year. We tested 57 filtering facepiece
8 respirators, 43 elastomeric half-mask respirators
9 and one quarter-mask respirator.

10 Again, 25 subjects across the board, three
11 donnings per subject, which gave a total of 8,250
12 data points.

13 To summarize where we are today, Phase 2
14 is complete. The study was designed to assess the
15 overall capabilities of individual respirators.

16 The benchmark data was derived by testing
17 across a complete panel regardless of respirator
18 size designation and, therefore, does not represent
19 actual field use.

20 One of the reasons we did this is that
21 there are respirators that appear to be one size, or
22 medium, that don't necessarily fit the people in the

1 center medium size of the panel.

2 The ones that are marked small don't
3 necessarily fit the best on the small. And the ones
4 that are marked large don't necessarily fit best on
5 the large.

6 And I think I this has to do with the fact
7 there is no standard for what a small is, or what a
8 medium is, or what a large is.

9 So we wanted to see the capability of the
10 respirators to fit a segment of the population, so
11 we tested across the whole panel with every
12 respirator, regardless of whether it was marked
13 small, medium, or large.

14 The data was being analyzed in several
15 ways, and no conclusions have been reached
16 concerning the proposed requirements for
17 certification.

18 There is a NIOSH docket -- it is the TIL
19 Docket 036, and you also have the standard NIOSH
20 disclaimer here.

21 Because we have a preponderance of data,
22 we have asked Dr. Doug Landsittel, who is a

1 statistician and senior fellow with NIOSH to look at
2 the data and try to make some sense out of it. I'm
3 glad he's got to do it instead of me.

4 And he is going to come up now and tell
5 you some of the areas that we are looking at to try
6 to come up with some criteria for certification.

7 TIL CRITERIA DEVELOPMENT

8 MR. LANDSITTEL: Thank you. Thanks, Bill.

9 So this is the outline here of what I was
10 going to discuss. The focus will be on
11 statistically related issues.

12 And the two main considerations I'll focus
13 on within that context are definition of a
14 performance criteria and strategy for subject
15 selection.

16 For each of the possible approaches as far
17 as subject selection, I will look at the strengths
18 and limitations.

19 And then Bill already talked a little bit
20 about the existing data collection. I'll mention
21 that again briefly, and that will lead into
22 different statistical considerations for different

1 performance criteria.

2 And then I will conclude by summarizing
3 our current progress and corresponding challenges
4 and also look at the subsequent impact of results in
5 terms of practical implementation of the eventual
6 criteria.

7 So, as far as definition of performance
8 criteria, there's two main approaches that we could
9 pursue. And I'll mostly focus on this first one
10 here, which is probably a bit more intuitive.

11 One is to require a fraction of the
12 subjects to meet a particular penetration cutoff.

13 So we have three unknowns in that
14 scenario: What the cutoff penetration would be that
15 is deemed acceptable; the fraction of subjects that
16 need to meet that cutoff; and what an adequate
17 sample size would be for making statistically
18 defensible statements in formulating a criteria.

19 The second type of approach would be
20 similar thing, but a little bit different called a
21 tolerance limit where we have a certain percentage
22 of subjects within an acceptable range, a percent

1 confidence that the actual population or percent is
2 within that range, and then an adequate sample size,
3 again, for having adequate statistical precision.

4 Now I'm going to go into a little bit more
5 detail as far as the strategies for subject
6 selection and just outline potential avenues here.

7 One potential avenue would be testing
8 every respirator on every subject, similar to the
9 existing data that Bill described.

10 The second approach might be specifying a
11 restricted range of face sizes for a given size
12 respirator.

13 And then third would be for models with
14 sizing of the same model, only require the subject
15 pass through one size, which I will go into a little
16 more detail to appropriately distinguish between
17 that second and third bullet.

18 As far as the idea of testing every
19 respirator on every subject, that would be where you
20 would randomly select a certain number of subjects
21 for each respirator. And then based on the NPPTL or
22 some other panel, select the specified number of

1 subjects, regardless of the respirator sizing.

2 As far as strengths and limitations,
3 obviously this would be the most straightforward
4 approach, but would be limiting for respirators that
5 were designed for specific face sizes.

6 So I mention this approach here for
7 completeness of the discussion and because it's our
8 existing data that is collected, but is not being
9 considered for the final criteria.

10 The second approach would be specifying a
11 restricted range of face sizes. So based on a
12 respirator size, then you would restrict a selection
13 of the sample to a certain subset of face sizes and
14 then randomly select that specified number of
15 subjects for a given respirator.

16 This requires a definition of how
17 respirator sizes specifically relate to, say, cells
18 of the NPPTL panel or some other categorization that
19 you might pick.

20 And in this case, it becomes pretty
21 complex because your choice of panel and how you
22 define what's a, say, small, medium, or large

1 becomes critical in formulating the final criteria.

2 In some ways, I think this is an intuitive
3 way to go about it, but actually in terms of
4 practical implementation becomes very complex with a
5 lot of statistical questions related to it.

6 So as far as current analysis ongoing, we
7 are currently working on assessing the relationship
8 between size of the respirator and face dimensions
9 and how they jointly relate to respirator fit.

10 Now, the third strategy requires a little
11 more explanation, is required given subject pass for
12 only one size.

13 So the approach here would be to consider
14 a family of respirators as a whole, say, small,
15 medium, and large, and then randomly select a given
16 number of subjects for each respirator, but then
17 have some more flexible approach to determine which
18 subject is assigned to a given respirator.

19 So rather than a priority, say, that sells
20 one, two, and three of the panel, or small, et
21 cetera, have some flexibility, whether it is on the
22 part of the manufacturer or some other approach, to

1 important to note that those 25 subjects are
2 actually sampled from a pool of 87 total used across
3 all of those tests.

4 And, again, there was a fixed number of
5 subjects per NPPTL panel as -- per panel cell, I
6 should say, as explained in the last talk meant to
7 be representative of the population but irrelevant
8 to the respirator size.

9 And so the point I want to get to as far
10 as the existing data collection is there are two
11 main concerns that we are working on addressing.

12 One is the criteria feasibility. So if
13 you pick a particular cutoff for acceptable
14 penetration, how feasible is that really going to be
15 in practice, and what is the relationship between
16 face dimensions and model size and how do they
17 jointly relate to the model fit.

18 You will be quizzed on this next slide
19 later.

20 This is just meant to be an illustration.
21 I don't want to dwell on this too much, but I didn't
22 really -- and here is where I have to get out the

1 pointer here.

2 I didn't really have room to put it, but
3 you have face width across the X-axis and face
4 length here. I'm going to hit Bill's head on the
5 way here. Length and width. I'm not nearly
6 coordinated enough to do it on that one. You are
7 going to have to look over there.

8 So we have -- what this represents here is
9 the cells are labeled for the NPPTL cells of the
10 tables described before, or panel.

11 That's at Cell 1, 2, 3, 4, et cetera. The
12 numbers below the cell right there, those numerical
13 values, as explained in the title, are mean
14 penetrations by NPPTL cell.

15 And I just took one example here of medium
16 size elastomeric models. And not all of them are
17 quite this complicated of a result, but this is
18 actually fairly similar.

19 So all I was doing is summarizing
20 collapsing over a number of different models that
21 fit into, say, medium size elastomeric models, how
22 does the average penetration look by different face

1 sizes.

2 And what the different colored rectangles
3 and circles represent here is areas of the facial
4 dimensions where there were no statistical
5 differences.

6 So, for instance, between Cells 6 and Cell
7 10, they are both in the black circle, so there is
8 no significant difference.

9 The largest rectangle is this red
10 rectangle, which is like a maze trying to follow it,
11 but there is no statistical difference between
12 those. On the other hand, so two is statistically
13 different from the ones not within the blue
14 rectangle.

15 So my point here is to underscore
16 something that Bill has said in the last discussion
17 was that it doesn't work out to a real clear
18 picture, at least at this point.

19 And we are in the process of kind of
20 reanalyzing this data in ways I will explain here in
21 a minute. But there is not a real clear picture of
22 well, here is where the medium size fits. Here is

1 where the small size fits, et cetera.

2 Okay. So what are the statistical
3 considerations that we are trying to take into
4 consideration?

5 Well, for a different option, I'm
6 referring to that first type of formulation that I
7 discussed where you require a certain fraction of
8 the subjects to be below a certain cutoff
9 penetration value.

10 We have to evaluate -- if we say that we
11 determine the penetration either a-priori from our
12 existing data, or we look at different options for a
13 specific penetration cutoff, once you specify a
14 penetration cutoff, then you have to decide, Well,
15 what percentage of the subjects do we need to meet
16 that penetration cutoff and what's the -- what's a
17 sufficient sample size.

18 So that's one issue. And I will talk
19 about that one a little bit more in a minute.

20 Another issue that I'm not really going to
21 talk about that we are still in the process of
22 getting into is the analysis across multiple

1 measurements.

2 The respirator is donned three times per
3 subject, and each of those, you have multiple tasks.

4 Currently, the penetration values as we are
5 analyzing them are just averages across those.

6 And one underlying factor or overriding
7 factor here I want to mention is that we are not
8 trying to look at the statistical issues in
9 isolation, but rather considering them jointly with
10 scientific considerations and feasibility
11 considerations.

12 So let me talk a little bit about
13 statistical properties at different criteria. So
14 again, we are saying we have a specific penetration
15 cutoff value, and we want to look at the first -- we
16 will forget sample size. We will say a required
17 percentage of subjects needing to meet that cutoff.

18 What do I mean by -- so what we are
19 looking at is we are looking at -- we want to look
20 at a choice that has, quote, good statistical
21 properties.

22 So what do I mean by good statistical

1 properties? Well, let me explain that via a couple
2 of illustrative examples.

3 In one scenario, let's say we have a model
4 that hypothetically we know to pass or meet that
5 penetration cutoff very high percentage -- for a
6 very high percentage of the population.

7 If we make that assumption, then we would
8 want to see a very high probability that it meets
9 that specified percentage of the given sample size
10 with high probability, or a high percentage of the
11 times.

12 On the other hand, if we specify a model
13 or look at one that only passes the cutoff for a low
14 percentage of the population, we would want to see a
15 high probability it fails to meet that specified
16 percent of the given sample size.

17 So let me get a little more specific in
18 terms of the data we have.

19 Here is one example. We looked at the
20 requirement of what would happen if we required 24
21 out of 25 to meet a given cutoff value. And this
22 tends to lead to less optimal statistical

1 properties.

2 And basically I think the explanation here
3 intuitively is we are just very close to a threshold
4 there of having to pass for every single person.

5 A respirator model truly meets the cutoff
6 for 96 percent of the population. And one of these
7 symbols got changed. That is actually supposed to
8 be an arrow there, but I think you can follow along.

9 Turns out that if you make the
10 assumption -- I'm not talking about an actual
11 respirator in practice, just doing calculations
12 where we make that assumption -- it turns out with
13 this cutoff of 24 out of 25, that, in fact, under
14 that assumption, the respirator that works for 96
15 percent of the population would fail that test over
16 25 percent of the time.

17 So that seemed like a less optimal result.

18 Let's take another example. If we require
19 only 15 out of 25, or 60 percent of the sample to
20 meet the cutoff, this also tends to lead to less
21 optimal statistical properties.

22 And in an example -- we did a lot of

1 calculations with this, but you take an example, the
2 model that truly meets the cutoff for 60 percent of
3 the population, in fact, it will fail this test on
4 average about 40 percent of the time, or over a
5 large number of trials, 40 percent of the time.

6 So that also did not seem optimal.

7 On the other hand, if we pick a cutoff for
8 a percentage of the pop -- a fraction of the sample
9 that's somewhere in between there, say 20 out of 25,
10 we get better statistical properties. A respirator
11 model that truly meets the cutoff over 90 percent of
12 the time will almost always pass that criteria. A
13 respirator that truly meets the cutoff less than 60
14 percent of the time will almost always fail that
15 test.

16 So what I hope to accomplish with this
17 slide is just to give you an illustration of some of
18 the specific statistics that we are looking into to
19 try to systematically judge a criteria.

20 What about sample size? Well, if we
21 increase it to 50 per test instead of 25, which I
22 used in the previous slide, that improved some

1 statistical properties, but not quite across the
2 board.

3 For instance, if you are given a
4 respirator that truly meets the penetration cutoff
5 over 90 percent of the time, using that requirement
6 of 20 out of 25, I say it would almost always pass.
7 It is around 97 percent of the time.

8 If we move the sample size up to 50, it
9 gets a little better. It is closer to a hundred
10 percent.

11 Given a respirator that truly meets the
12 penetration cutoff -- and I apologize. It got moved
13 down a little bit here.

14 The respirator truly meets that 96 percent
15 of the time, if we use this cutoff of 24 out of 25,
16 this respirator will pass -- this is the one I said
17 would fail over a quarter of the time. That
18 translates to pass over 73 percent of the time.

19 And the last one you probably can't read,
20 but if you have a requirement of 48 out of 50, it
21 gets a little worse with that sample size. The
22 respirator would only pass under 70 percent of the

1 tests.

2 So, again, just more considerations that
3 we have to systematically account for.

4 So let me start summarizing here and try
5 to bring it to conclusion. So we are looking at
6 statistical assessment of sample sizes and
7 percentage of the sample required to pass for the
8 given criteria. And we have completed some of these
9 analyses.

10 I briefly mentioned a few bullets, but we
11 have a lot more output than that for a couple of
12 selected sample sizes and a wide range of required
13 percentages needed to meet that cutoff.

14 So currently what we need to do is assess
15 other variations on this and also look at where I
16 described the tolerance limit approach, which may
17 have some drawbacks or benefits, but also address
18 that type of approach in the same way.

19 As far as determining the appropriate
20 penetration cutoff -- and I haven't really shown any
21 results here because they are still ongoing, but we
22 have completed some analyses to assess feasibility

1 across different types of respirators and model
2 sizes for different face dimensions.

3 But we are currently reanalyzing
4 respirator fit relative to the face size and
5 respirator size. And considering the issue of what
6 I'm calling finite sampling -- in other words, you
7 will recall I said for this data we currently have,
8 it was 25 subjects testing on each respirator.

9 But that's only 25 each time selected out
10 of 87, so it brings up some intricate statistical
11 issues for which we are using a model called
12 repeated measure analysis model to look at that data
13 currently.

14 As far as analysis of individual versus
15 average penetration values, as I mentioned, we have
16 donning-to-donning and task-to-task variability. We
17 have not gone very far in terms of addressing that
18 issue. But that's another issue that we have to
19 take into consideration.

20 Determination of an optimal strategy for
21 subject selection and testing, this actually turns
22 out to be a very complex and integral part of the

1 criteria, as I hope I have tried to at least
2 illustrate to some degree.

3 And just to remind you, we have those
4 three possible approaches, looking at every subject,
5 every size. Which, again, we are not -- I mentioned
6 for sake of completeness of discussion, but not
7 concerned for the criteria.

8 Second option, where you define sizing
9 a-priori with a set panel and size definition. And
10 thirdly, considering size with more a flexible
11 approach.

12 So we are currently doing analyses to
13 address each of those two considerations.

14 So finally, I'm going to conclude by
15 saying a few statements about the impact that
16 subsequent results might have.

17 Certainly, each model and size is to be
18 tested on -- that should say at least 25 subjects.
19 We are still looking at the appropriate number of
20 subjects and the statistical approach for specifying
21 the criteria. Those are still under analysis.

22 The strategy for subject selection and

1 testing, this is unlikely really to affect the total
2 number of subjects being tested, but rather how
3 those subjects might be divided between different
4 sizes when you have different sizes of a given
5 model.

6 And then as far as complexity of the
7 analysis and any timeline issues in criteria
8 development, that's highly dependent on the subject
9 selection where that second approach is the most
10 complex approach.

11 And as I just hit the final thank you
12 slide here, I want to say that what I hope to kind
13 of clarify through this discussion is that we are
14 trying to comprehensively look at both statistical
15 issues intertwined with feasibility and scientific
16 considerations in a very systematic manner moving
17 toward formulating the final criteria.

18 So I will be happy to take and/or defer
19 any questions you might have.

20 MR. NEWCOMB: Before we get to questions,
21 there's one thing I would like to say that I didn't
22 in my presentation.

1 The last time we had this discussion, I
2 told the manufacturers that they would be able to
3 see the data after the public meeting. And we will
4 be making individual manufacturer's raw data
5 available to any manufacturer that would like to see
6 how his respirator did in the benchmark testing,
7 knowing that there's really no criteria yet, but at
8 least you can see the numbers that we got.

9 And, unfortunately, I'm going out of town
10 for almost a month, and I won't be available until
11 December. But any manufacturer that does want to
12 come in and review his data is welcome to do so at
13 this point. Thank you.

14 MR. SAVARIN: Mike Savarin, Bullard
15 Company.

16 It seems a lot of effort is being expended
17 in trying to statistically analyze fit to data, come
18 up with models, kind of play around with the whole
19 thing. And I think that was a -- I think it is a
20 valiant effort to see -- get an insight into some of
21 the complexities surrounding what on the face of it
22 looks a relatively simple thing to do, come up with

1 a map on how to award pass and fail criteria.

2 Some time ago, a detailed study was
3 performed by an Asian gentleman at NIOSH, whose name
4 escapes me. It wasn't Ziqing, was it, yeah, Ziqing
5 Zhuang, who looked at the face panels in great
6 detail looking at modernizing today.

7 It has been a great deal of time since we
8 have sort of seen the full outcome of this. I
9 understand it was supposed to be under peer review.

10 Assuming that that study is relevant, it
11 would appear to me that the best thing to do would
12 be to somehow break that study up statistically
13 divided by the demographics and try and assign face
14 sizes in accordance with that panel.

15 That seems to me much more straightforward
16 than trying to fit this thing that you are doing
17 right now.

18 MR. LANDSITTEL: Well, let me make a few
19 comments. I think you are referring to the PCA
20 panel with the principal components, and that is
21 nearing completion of review.

22 There was some switching of the National

1 Acadamies' review, so it got pushed back a little
2 out of our control. But that is nearing completion
3 of review. The review has not been finished.

4 So certainly comments that we get back or
5 a review of that would be relevant, but it
6 doesn't -- I don't think that -- that's one issue
7 related to the criteria development, but I don't
8 think that -- and I'm not sure, to be honest, how to
9 provide a concise answer to that. But I don't think
10 that that just answers the question.

11 It provides an interesting look at the
12 these joint relationships between different ways to
13 categorize face dimension and the fit, but there are
14 still other, you know, other issues in relation to
15 how you formulate the criteria. And it's not clear
16 that you necessarily want to have everything hinging
17 on one panel, although it is certainly useful to,
18 you know, have the panels to evaluate the question.

19 MR. BOORD: Mike, I think if you're asking
20 if the analysis that we are doing is utilizing the
21 latest NIOSH research for an anthropometric panel,
22 the answer is yes.

1 So the data and the analysis that is being
2 applied that Doug is using for his statistical
3 approach is indeed that panel.

4 One of the questions that we are
5 confronted with going forward is whether that
6 becomes the bivariate panel that Dr. Ziqing Zhuang
7 had developed, or do we go down a different road,
8 which is to use the PCA panel.

9 So the bottom line, though, is it's the
10 latest anthropometrics.

11 MR. SAVARIN: Okay. I'm trying to --
12 after what we saw, I wasn't clear that the new
13 assessment or conceptual analysis was going to
14 generate anything better, actually.

15 MR. BOORD: Well, we are using the most
16 current anthropometric data.

17 MR. METZLER: Rich Metzler of the SEA
18 Group.

19 I was wondering, you didn't mention this
20 in your analysis, but are you looking at the data to
21 determine whether there is a difference in the
22 fitting characteristics of elastomeric half-mask and

1 filtering facepiece mask?

2 MR. LANDSITTEL: Yeah. Certainly almost
3 all of the analyses we do is stratified by that
4 factor. And it's not -- we are not just kind of
5 lumping those in together.

6 I don't think the focus has really been to
7 try to differentiate between the fit of those, but
8 that's certainly, you know, part of the analysis.

9 MR. METZLER: I wonder will you eventually
10 draft and produce a report on this, and will that
11 work be peer reviewed?

12 MR. BOORD: Absolutely.

13 MR. METZLER: Because everyone is wanting
14 that data, all of the data, not just the small
15 subsets of the individual manufacturers.

16 Do you plan to implement this through
17 policy, or is this going to be another module that
18 will go through formal rulemaking?

19 MR. BOORD: The plan will be to implement
20 the entire program through rulemaking.

21 MR. METZLER: Thank you.

22 MR. PFRIEM: Dale Pfriem, ICS

1 Laboratories. Question for Bill.

2 Bill, when this work was originally
3 presented a few years back by Dr. Z, there was some
4 lively discussion, if we should have stable
5 concentrations in a test chamber, et cetera. You
6 know, I think you remember those.

7 In your latest data sets, what was the
8 challenge concentration? Was it controlled?

9 MR. NEWCOMB: We had, I believe, four
10 sodium chloride generators in the lab space, and we
11 did have a minimum background concentration.

12 I don't remember exactly what it was right
13 now. We didn't control the upper limit, but we did
14 control the minimal -- minimum concentration of
15 background.

16 MR. PFRIEM: And then, that said, going
17 forward, what are your thoughts about upper and
18 lower bounds and uses of a chamber under controlled
19 environmental circumstances?

20 MR. NEWCOMB: I don't think that -- at
21 least I haven't seen that a higher concentration
22 because of the protection factors are so low is

1 going to make much difference, but we do need a
2 minimal concentration.

3 MR. PFRIEM: So you guys will at least
4 establish a minimum?

5 MR. NEWCOMB: Yes.

6 MR. PFRIEM: Will you specify a chamber
7 and ambient temperature and humidity concerns?

8 MR. NEWCOMB: Most likely.

9 MR. PFRIEM: Thank you.

10 QUALITY ASSURANCE MODULE

11 MR. NEWCOMB: I told you I was glad that I
12 wasn't doing the statistics. Now you know why.

13 Quality assurance module. Something you
14 probably haven't heard about in a while. It hasn't
15 been forgotten. A little history on it.

16 A relatively new project. It has been
17 under discussion since 1995. There was a
18 manufacturers meeting in 2000, two public meetings
19 in 2000, and two public meetings in 2003 where it
20 was discussed.

21 The difference between today's discussion
22 and those discussions is that at the time we first

1 started talking about this, it was a combination
2 administrative module and quality assurance module.

3 And the administrative module has things
4 like fees involved in it. And all manufacturers
5 around the table, around the room know that we are
6 still working with 1970 fees in the testing that is
7 done at NIOSH.

8 It's actually the best buy there is in the
9 United States, I believe, right now for test time.

10 And the administrative module we are going
11 forward with as well, but we felt it was better to
12 separate the administrative and the quality
13 assurance provisions.

14 The status of the quality assurance module
15 at this point in time is that the concept of the
16 proposed modifications to 42 CFR Part 84 have been
17 written and the preamble that is necessary to go
18 forward with a notice of proposal also had been
19 written, and it's ready for internal review.

20 What's in the concept?

21 Well, the first thing is it's a paradigm
22 shift from manufacturers' benefit to consumers'

1 benefit.

2 What I mean by this is the original way
3 that 42 CFR 84 was written, it was based upon the
4 manufacturer not making bad product.

5 What we, and what the consumers, want is
6 something that looks at the consumer's chance of
7 getting a bad product, putting the emphasis on the
8 consumer's benefit rather than manufacturer's
9 benefit.

10 There is a mandatory quality management
11 system requirement, a clarification of the audit
12 procedures. As most of you know, there have been
13 some policy letters and so forth on the audit
14 procedures and how they pertain to the manufacturer
15 and to manufacturing entities that are controlled by
16 the manufacturer, and also the method of getting
17 product for auditing.

18 There are some modifications to the
19 application procedure, and there will be a codified
20 procedure for the use of external auditors. Right
21 now, again, under policy, NIOSH is using external
22 auditors, but this will be written into the code.

1 One of the major changes is quality
2 assurance requirements rather than quality control
3 procedures. Back in 1970, when this was first
4 written, people didn't talk about quality assurance.
5 They talked about quality control. And for those of
6 you that worked with it, there is a difference.

7 There is also a procedure for revocation
8 of approval for QA deficiencies, clarification
9 wording on that. Also a clarification of the
10 procedures for changing ownership.

11 Back when the regulation was written,
12 there wasn't a lot of larger companies gobbling up
13 smaller companies. And there has been an awful lot
14 of consolidation in the respirator manufacturing
15 business over the last few years, and there is not
16 always the best notification to NIOSH of the change
17 in ownership, the change in quality assurance plans,
18 and the change in management philosophies. So we
19 want to make the code clearer in that respect.

20 There is also modifications to the quality
21 control plan content that's required to be given to
22 NIOSH in the application. Further, there is

1 replacing of the classification of defects with a
2 critical-to-quality characteristics concept.

3 We don't like to see defects, so why
4 classify them. So we are looking at, again,
5 changing the way we look at that.

6 Replacing mandatory sampling plans. If
7 any of you are involved in that today, you know that
8 there are certain AQLs that are called out for
9 different characteristics, and you have to go to a
10 military handbook and see how many products have to
11 be sampled.

12 What we are going to do is allow flexible
13 plans suited to manufacturing entities. If you have
14 statistical process control, you will probably have
15 to do less sampling. There will be rewards for
16 having good programs.

17 If you have a poor program, you will
18 probably find that you have to do a lot more
19 sampling with the new requirements than was done
20 with the old program and, thus, an impetus to
21 improve the quality procedures.

22 There is also clarification of a procedure

1 for reporting consumer and user complaints.

2 Right now, if you have ISO 9000, there's a
3 requirement in there that you have a procedure, but
4 obviously there is nothing in that requirement that
5 says you have to notify NIOSH and that you have
6 correspond with NIOSH about the way you are handling
7 that procedure.

8 Again, this will be added to the proposed
9 requirements.

10 Also one of the issues that some of our
11 auditors have come across -- and I won't say it is
12 in all manufacturing facilities, but some -- where
13 they look for records, and they find that the
14 records have -- are no longer available.

15 We have put into this a requirement that
16 the records be kept for -- the quality records be
17 kept as long as the expected life of the product.

18 What's next? Well, the first thing we
19 have to do is a NIOSH NPPTL internal review, which
20 has been quasi underway, a complete NIOSH review.

21 The NIOSH OD has given us a hand in
22 preparing this, so I don't foresee any big issues

1 there.

2 Obviously then CDC has to review it, HHS
3 has to review it. OMP has to review it, and then
4 finally it has to be published as a notice of
5 proposed rule in the Federal Register.

6 We are looking at a timeline which
7 would -- some of my font has changed. The Federal
8 Register notice in the old system, before I got this
9 elongated screen, said it was going to be
10 approximately last May -- next May, rather.

11 So that May that you see over there on the
12 far right, it should be above the Federal Register
13 notice.

14 That gives approximately a month for the
15 approvals. Some of them may take less time than
16 that. Some of them may take more time than that.
17 Hopefully there won't be a lot of changes in it, and
18 we will see a proposed rule on the street by the
19 middle of next year.

20 Thank you very much. I would like to
21 entertain any questions.

22 Must have been a quality presentation.

1 Thank you.

2 ADMINISTRATIVE MODULE

3 MR. AHLERS: This was supposed to be one
4 slide. Here we go. We don't need those. We will
5 go through it quickly to talk about money.

6 Okay, very simple slide.

7 As Bill mentioned, the NIOSH fees have
8 been in place since approximately 1970. The only
9 changes that have taken place to date have involved
10 the CBRN testing.

11 NIOSH desperately needs to update our fees
12 because of the cost of running the laboratory and
13 the costs that we are incurring in having a certain
14 number of tests done on site by contractors.

15 And every time you pay us for a test that
16 we have to have the contractors do, we lose a great
17 deal of money.

18 And I'm sure that that troubles you all
19 greatly, but it does trouble my boss, and it is part
20 of my performance plan. So we have to do something
21 about the approval fees.

22 You have this yellow sheet of the

1 certification dockets that have been opened, and you
2 can add on to there, there is a new docket, No. 092,
3 on certification fees.

4 And we are very much interested in your
5 comments on certification fees because we are busily
6 putting together how much it costs us to operate the
7 tests.

8 You know, we can do that. We can break it
9 into what it costs us to pay the contractors, what
10 it costs us to run the labs, what it costs to run
11 our own people. But what we don't know about is
12 what the impact of our fee increases have on you.

13 And we are very interested in knowing that
14 because it is probably highly unlikely that at any
15 point in time we are going to pass on all of costs
16 that there are associated with the tests to the
17 manufacturers. Unless you sit back and don't offer
18 any comments whatsoever on the fee schedule, we
19 would assume that maybe you would like to see that
20 happen.

21 So we are very open because, you know, we
22 realize with the cost of development of different

1 kinds of respirators, the testing fees can become,
2 you know, very prohibitive when you have a customer
3 base of a thousand or two thousand people for a
4 given type of respirator.

5 So we are interested in that type of
6 information and what you see as things you can
7 tolerate in those kinds of areas, and we would be
8 very happy to entertain those in that docket.

9 So, again, it is 092, and it's
10 certification fees.

11 We will be moving forward with gathering
12 our data, and we will hopefully be able to have that
13 available to put up on the web. It's something like
14 an ANPR (phonetic) sometime in the next 60 days we
15 are guessing, in a draft kind of format.

16 This would be precede as a formal
17 rulemaking. Actually, it's an informal rulemaking,
18 but it would go through all of the rulemaking steps,
19 so there would be the same things.

20 Why it is split off in the QA module is
21 hopefully this will would move forward somewhat more
22 swiftly because all of those steps and through CDC

1 and the rest of the federal government tend to be a
2 little quicker when it looks like money coming into
3 the federal government.

4 So if you have any questions, I would be
5 glad to try and answer them at this point.
6 Otherwise I would encourage you to get your comments
7 in.

8 Thank you.

9 And then Les Boord, save Bill jumping up.

10 MR. BOORD: Okay. For our final
11 discussion today, I would like to talk about some of
12 the quality initiatives that we have in the
13 laboratory.

14 And that discussion will be led by our
15 associate director for science, Dr. D'Alessandro.
16 So Maryann.

17 SCIENTIFIC EXCELLENCE FOCUS

18 MS. D'ALESSANDRO: You can start finishing
19 your surveys while I get my presentation up.

20 Just saw the whole thing, so...

21 Thanks, Les.

22 I'm going to focus on the scientific

1 excellence focus at NPPTL, which primarily focuses
2 on quality performance initiatives which are
3 described in three categories, evaluations, customer
4 and market knowledge, and customer relationships and
5 satisfaction.

6 Under evaluations, one key component of
7 evaluations which helps us to emphasize our quality,
8 relevance, and impact of everything we are doing in
9 NPPTL is our National Academies involvement in
10 NPPTL, and I will get into that on the next slide.

11 Another area is the scientific information
12 product review.

13 We have a very rigorous process for
14 evaluating all of our activities to include project
15 proposals, protocols, specific investigations that
16 are conducted in the lab, manuscript reviews, as
17 well as scientific information products such as
18 those that Frank Palya discussed, and other
19 information products that are being developed in the
20 lab.

21 The logos that you see on the right are
22 those specific organizations who have a regular

1 involvement in our peer review processes.

2 The National Academies in the highest
3 level reviews that we have, the AIHA, ISEA, and OSHA
4 are always solicited to participate in our reviews,
5 and then those -- that text across the bottom are
6 the various agencies that we do solicit depending on
7 what the review is and what expertise is needed in
8 the review.

9 NIOSH has required peer review in all of
10 the activities that are conducted. And what we are
11 transitioning to is all of our research activities
12 being peer reviewed, and then those research
13 activities feeding into our standards and
14 certification activities.

15 We are beginning to benchmark with other
16 agencies, and I won't get into that today, but
17 that's a process we are just initiating at this
18 time.

19 In the customer and market knowledge and
20 customer relationships and satisfaction area, the
21 bottom logo there, the Office of Personnel
22 Management is the agency who is assisting us with

1 those activities.

2 And OPM was the agency selected because
3 they have a very high level of expertise in
4 organizational psychology in their agency. They
5 have developed surveys that are used government
6 wide.

7 And that was the reason that we selected
8 that, so we could also benchmark ourselves with
9 other government agencies who take their surveys and
10 also use them with their organizational psychology
11 expertise.

12 The public meetings and feedback, the
13 surveys that you are preparing for us today
14 determine how well we did with these type of events.

15 Customer satisfaction groups, I'll get
16 into that. And then with customer relationships and
17 satisfaction, customer satisfaction surveys, I will
18 discuss. And then direct customer involvement is
19 something that NIOSH has done for a long time, and
20 we continue to do.

21 With the National Academies involvement in
22 NPPTL, one activity is -- I will start with the

1 fourth bullet there, the fourth dash, and that's
2 what Frank Hearl from NIOSH OD discussed today.

3 That's the National Academies evaluation
4 of various activities. And that's something that we
5 at NPPTL did not initiate. That's something that
6 was initiated NIOSH wide to evaluate all activities
7 in the various sector groups in NIOSH and also
8 cross-sectors for which PPT is one of those
9 cross-sectors and will be evaluated next June.

10 And our evidence package will go in for
11 evaluation in Spring 2007.

12 We are currently submitting names to the
13 National Academies to participate in that review.
14 And if any of you do have names for consideration,
15 we welcome you to provide those names to us to
16 forward on to the National Academies.

17 Now back to the first three bullets.
18 Those three dashes are initiatives that NPPTL has
19 proactively initiated in order to improve upon what
20 we are doing in the lab.

21 The first is the committee on PPE for the
22 work force. That activity was initiated

1 approximately two years ago, and the contract was
2 finalized with the National Academies a year ago.

3 And the committee formed, and we had three
4 open meetings in Fiscal Year '06. And the next
5 meeting is scheduled for October 23 and 24th in
6 Washington DC at the National Academies.

7 That committee is comprised of a number of
8 experts in PPT, in standards development
9 organizations, academia, various government
10 agencies, and also some experts who are outside of
11 the PPE and PPT field in order to have a fresh
12 perspective and perhaps provide us information on
13 what the PPE needs are in the nation from those who
14 have not been involved.

15 And something, the first two meetings were
16 really -- we really got them up to speed with what
17 we were doing in the lab and what NIOSH is doing and
18 where we are heading and what our strategic planning
19 process is.

20 And then by the third meeting, they were
21 really able to provide us some advice. And the main
22 advice that came out of that committee this past

1 year was that there a need to really understand what
2 the PPE needs are if there were an influenza
3 pandemic, not only for the work force, but also for
4 PPE for the general public.

5 So we are going to be conducting a
6 workshop through them around February 2007 time
7 frame. And the focus will be PPE during an
8 influenza pandemic focusing on research standards,
9 certification, and testing directions in those
10 areas.

11 The FDA will be involved in this. OSHA
12 will be involved. NIOSH. Perhaps EPA. A lot of
13 government agencies and as many standards
14 development organizations as will participate as
15 well, and other government agencies.

16 The second and the third bullets are two
17 other activities that we initiated in NPPTL. And
18 those activities, the first one is what one of the
19 members, Mike Savarin, brought up earlier, and that
20 was the anthropometric survey of respirator panel
21 modification.

22 These two, the second and the third bullet

1 are two activities in NPPTL we thought warranted the
2 highest level of scientific review because of the
3 impact they are going to have, not only on all of
4 the activities we are doing in NPPTL, but on the
5 manufacturers and on the users of PPE as well.

6 So the National Academies is in the
7 process of reviewing, or has completed the review of
8 that survey of the results that came out of that
9 survey, the conclusions that were drawn, and how
10 that data is planning to be used in the future.

11 The report was actually due to us in June,
12 but that committee was hijacked by the Department of
13 Health and Human Services.

14 And that report that you see there in
15 green is what came out of that, and that was the
16 committee on the development of reusable face masks
17 for use during an influenza pandemic.

18 That came out in March, or April time
19 frame, and our researchers are actually using the
20 results from that committee report in the future
21 activities, as is shown in one of the posters and
22 the discussion this morning.

1 So that report is now is due this month,
2 but it may be delayed. It is currently in the
3 review process.

4 National Academies also has their own
5 review process as well.

6 It also important to note with this
7 committee, that there is some very -- some names you
8 will probably recognize on that committee. Alan
9 Hack (phonetic), for one, who was involved in the
10 development of the LANL panel was on that committee.
11 Lisa Bruso (phonetic), who is a leading researcher
12 at the University of Minnesota. Howard Cohen, who
13 has been involved in standards development for
14 respiratory protection for a long time.

15 So there are some very key personnel
16 involved who are assisting us in making these
17 decisions and will help us move forward with where
18 we should be going in those activities and will also
19 lead into the future standards and certification as
20 well.

21 The review of the BLS survey for
22 respirator use in private sector firms, we also had

1 them evaluate. And the reason for this is because
2 our surveillance information is what we use --
3 another part of what we use to determine what we
4 should be doing in research areas, standards areas,
5 and certification.

6 And that study was formulated internally
7 with NIOSH personnel and Bureau of Labor Statistics
8 Personnel.

9 I'm not sure how much of the outside use
10 there was in developing that survey. So we thought
11 it warranted a National Academies review to help us
12 in formulating future surveillance initiatives in
13 helping us see how we should conduct our activities
14 in the future.

15 There were three open meetings conducted
16 for that activity in 2006, and that report is due
17 this month as well.

18 The next area of our quality initiatives
19 is in our customer satisfaction surveys. Again, we
20 have an interagency agreement with Office of
21 Personnel Management to assist us in developing the
22 survey.

1 And also we have a customer and market
2 focus team within NPPTL that consists of members of
3 the Office of the Director and each of the various
4 branches who has put together various NPPTL specific
5 questions in addition to the OPM core customer
6 satisfaction items that they use for all of their
7 surveys that are administered.

8 The survey was pilot tested in October
9 2005, obtained OMB approval for distribution in
10 December 2005. And we administered it online in
11 December 2005.

12 The customer base that we use, we
13 separated our customers into two groups,
14 manufacturers and users of PPE. And users also were
15 a little bit broader than just users of PPE. We
16 also included academia in there and others who have
17 signed up for our list serve.

18 We began analyzing the results from that,
19 the survey in -- from January to April time frame,
20 began acting on the results in April. We are
21 continuing to do that in monitoring and evaluating
22 our progress.

1 The survey that was conducted utilizes
2 nine service dimensions that you see listed here on
3 the left in the yellow rectangles.

4 And the results from the survey are posted
5 on our website. And to get specific details on what
6 exactly those dimensions mean, you can go to the
7 website. And they are all defined on there on the
8 final report of the results.

9 These nine dimensions are the nine core
10 dimensions that OPM uses in their surveys. And,
11 again, the reason we used those is so we can
12 benchmark with other agencies.

13 In addition, we had NPPTL specific items
14 that we put within each of those dimensions that
15 were not OPM specific questions. And our hope is
16 that, again, there is a -- should be a circle there.

17 That has disappeared in the middle. And
18 what that says is customer satisfaction is what we
19 are hoping to obtain, and then the outcomes would be
20 the rectangles that you have on the right.

21 This is a summary of the results. We had
22 a 30 percent return rate for both the users and the

1 manufacturer's surveys, responses from 185 users and
2 75 manufacturers.

3 While OPM did indicate that this is a
4 reasonable number, there is definitely room for
5 improvement. And we are hoping the next time the
6 survey is conducted, that we can get a better return
7 rate.

8 Now I'm just going to summarize some of
9 the results from both the manufacturer and the user
10 survey. And the results are color coded with blue,
11 green, yellow, and red codes.

12 I'm happy to report you will not see any
13 red. We did not have anything in the critical range
14 when it came to the results, but we did have some
15 marginals. And the marginals are where we have
16 begun to focus.

17 In the user survey, the marginal results
18 were in the recovery area. And so that is where we
19 decided to focus. And most of the other results
20 were pretty good.

21 Quality and tangibles. Quality, the users
22 said that the quality of our products was very good,

1 and I think that's a reflection on our certification
2 activities and the products that manufacturers
3 develop.

4 The other areas in green are areas we
5 could work on for the users, but we are focusing on
6 the recovery area. And that is how we respond to
7 issues that users raise and how we address the
8 concerns that they have in what we are doing.

9 This is the benchmark data provided from
10 OPM, and it shows -- it is -- I misspoke yesterday.
11 I said it was 1,200 surveys the government
12 conducted. It is actually a hundred surveys that
13 OPM -- approximately a hundred surveys OPM has
14 conducted.

15 And it is important to note that other
16 government agencies who have used this survey have
17 used other government customers. We are the first
18 ones to take this outside of government personnel to
19 our customers. You are not government employees or
20 other government representatives. This is the first
21 time that has been done.

22 As you see, the blue is the high benchmark

1 area, and the red is the low. And the green circles
2 in the center are where we fell for each of those
3 areas. And you can see that we are above average in
4 all of them. And, again, the recovery is where we
5 are the lowest.

6 For the manufacturers, the issues were in
7 recovery, timeliness, quality, and choice that
8 needed the most help.

9 Choice, there isn't much we can do about
10 that. There is nowhere else that manufacturers can
11 go. But we can focus on the quality, timeliness,
12 and recovery. And that is where we are focusing our
13 activities.

14 Again, looking at the benchmark data,
15 though, it is nice to note that we are above average
16 in all of those areas as well. But, again, the
17 recovery, timeliness, and quality are low, and
18 choice.

19 This dimension profile shows you a
20 comparison between the manufacturers and the user
21 data. And you can see most of them track closely
22 together, but there are some, like quality.

1 Manufacturers rated us low in quality. And the
2 users rated us high.

3 And, of course, the manufacturers had
4 different products. There were different reasons
5 for their ratings than the users.

6 And also in the -- the other difference is
7 in the timeliness area. The users rated us higher
8 there than the manufacturers did.

9 So now that we have the survey results,
10 where do we go from here?

11 Now, I guess there are three particular
12 benefits to us in having these survey results.

13 One is that they will validate that what
14 we are doing are the correct things that we should
15 be doing. And, secondly, it will resolve other --
16 the areas, perhaps where we thought we should be
17 working, but really the surveys and customer
18 satisfaction groups are showing that we should not
19 be working in those areas. So we can resolve those
20 issues.

21 And another way it helps us is in helping
22 us when we have these, the second bullet, the

1 customer satisfaction groups.

2 At these customer satisfaction groups,
3 something that has come out of those is something
4 that in some cases did not come up in the survey and
5 something we weren't working on in the first place.

6 So there are three ways that these
7 activities are helping us.

8 What we are doing now in response to the
9 survey is the next step is we are working on the low
10 hanging fruit in most of the branch activities, to
11 address those issues that came up in the surveys.

12 And, secondly, we are creating customer satisfaction
13 groups.

14 And in the customer satisfaction groups,
15 it will benefit our customers by keeping them
16 satisfied on an ongoing basis and providing them an
17 easy way to voice complaints and concerns and seek
18 more information.

19 For us, it will provide a resource for
20 direct customer contact and give us direct feedback
21 into what we are doing and allow us to have regular
22 input in keeping up with the changing PPE market.

1 Today we have conducted two customer
2 satisfaction groups. The first group was conducted
3 in April 2006 with manufacturers.

4 And it is important to note that we do not
5 solicit manufacturers. We solicit organizations.
6 And those logos to the right there are the
7 organizations we solicited.

8 For the manufacturers, we solicited ISEA,
9 SEDA, and a Canadian group. And then for our second
10 group, the fire services, we were focusing -- in the
11 customer groups for users, we are focusing on the
12 fire services first since that's most of our
13 research activities, certification, and standards
14 activities has focused in that area of late. So
15 that's where we decided to focus first.

16 We had one fire services group in
17 September, and we solicited Pennsylvania Region 13
18 for that group. The next group is scheduled for
19 this month in Arlington, and we have solicited IFF
20 and International Association of Fire Chiefs for
21 that group.

22 We have three meetings that will be

1 scheduled in 2007.

2 We will have another meeting with the
3 manufacturers, since that is something we always
4 have to continue to improve in the certification and
5 evaluation and standards activities and research.

6 And we also have one with health care
7 because of the emerging needs, especially in the
8 pandemic influenza areas.

9 And then in manufacturing as well because
10 of the respiratory protection issues in
11 manufacturing, and the needs there. And we are
12 still soliciting organizations for those three
13 groups.

14 The actions that we are addressing to
15 address the user issues focus on recovery,
16 reliability, access, and on research updates.

17 Recovery is focusing on -- we are holding
18 the focus groups to see exactly what are the issues
19 that the users have with the recovery issues that
20 came out of the survey.

21 It wasn't clear to us exactly what those
22 issues are, so the focus groups are the next step to

1 improve upon the issues that came up there.

2 And we are beginning to develop another
3 approach for improving the methods for handling
4 requests for additional information.

5 And reliability, we are improving on our
6 review processes, as I mentioned earlier, primarily
7 our peer review processes and getting the National
8 Academies involved in what we are doing.

9 And we are involving stakeholders up front
10 in our research activities, standards and
11 certification evaluation activities as well.

12 With access, we are exploring other
13 potential avenues for disseminating our information.
14 We are trying to post all of the contractor reports
15 that we have coming through the lab. We are
16 videotaping this public meeting today and seeing if
17 there is anything we can do with that videotape,
18 perhaps somehow put some of that on our website.

19 And also we are trying to disseminate our
20 findings as quickly as possible.

21 Something that came out of the survey is
22 the need to provide research updates. That's one

1 reason why the activities were presented today and
2 the posters presented as well.

3 And also we are focusing on one research
4 activity monthly and providing updates on our list
5 serve in e-news as well. And there are e-news --
6 e-news is the NIOSH tool for providing information
7 on what NIOSH doing.

8 And there are sign-up forms on the side of
9 the room and at the registration table at the --
10 outside the room to sign up for e-news.

11 And, again, updating research activities
12 at public meetings.

13 The manufacturers heard yesterday all of
14 the quality, timeliness, and recovery issues that
15 are being focused on in the certification and
16 evaluation activities.

17 And our next steps are to continue to act
18 on the results, monitor and evaluate our progress.
19 And we intend to conduct our second NPPTL customer
20 satisfaction survey for both manufacturers and PPE
21 users at around the March time frame next year.

22 At this time, I'll entertain any

1 questions.

2 Thank you. And if you could please just
3 pass your surveys to the center of the room before
4 you leave, we would awe appreciate that.

5 Do you have any closing remarks?

6 MR. BOORD: Okay. Thank you Maryann.

7 I thank all of you for your attention
8 today and for participating in our public meeting.

9 I hope that, as a result of the
10 discussions that we have had today, that you have a
11 greater appreciation and understanding of some of
12 the activities of the laboratory, some of the
13 programs that we have in our policy and standards
14 branch, the research activities of the research
15 branch, and certainly the certification activities.

16 For tomorrow's meeting, we will follow the
17 agenda that you have in your information packets.

18 So the meeting will start at 8:30, and we should
19 finish and adjourn the meeting by 11:30.

20 I would request that you be here promptly
21 so we can start at 8:30.

22 Again, thank you for your attention. And

1 if there is any questions or discussions that any of
2 you want to have on a continuing basis with any of
3 presenters, we are certainly available to do that.

4 Thank you.

5 (Whereupon, the proceedings in the above
6 matter were concluded at 4:18 p.m.)

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22


CERTIFICATE OF REPORTER

1
2 I, Joseph A. Inabnet, do hereby certify
3 that the transcript of the foregoing proceedings was
4 taken by me in Stenotype and thereafter reduced to
5 typewriting under my supervision; that said
6 transcript is a true record of the proceedings; that
7 I am neither counsel for, related to, nor employed
8 by any of the parties to the action in which these
9 proceedings were taken; and further, that I am not a
10 relative or employee of any attorney or counsel
11 employed by the parties thereto, nor financially or
12 otherwise interested in the outcome of the action.

13

14

15



Joseph A. Inabnet

Court Reporter

16

17

18

19

20

21

22